A Randomized, Parallel-group, Double-blind and Open-label Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids
Phase: PHASE3
Conditions: Uterine Fibroids
Sponsor: Bayer

 
Document Type: 
Study Protocol 
Official Title: 
A randomized, parallel-group, double-blind and open-label 
placebo-controlled, multicenter study to assess the efficacy and 
safety of vilaprisan in subjects with uterine fibroids 
NCT Number: 
NCT03400943 
Document Date: 
17 FEB 2020 
 
 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  1 of 113
Cover page of the integrated protocol
A randomized, parallel-group, double-blind and open-label, placebo-controlled, 
multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine 
fibroids
This protocol version is an integration of the following documents / sections:

Original protocol, Version 1.0, dated 01 SEP 2017

Amendment 02 (global amendment described in Section 15.1)
forming integrated protocol Version 2.0, dated 15 NOV 2017

Amendment 03 (global amendment described in Section 15.2)
forming integrated protocol Version 3.0, dated 04 JUL 2018

Amendment 04 (global stand-alone amendment described in Section 15.3)
forming global protocol Version 4.0, dated 11 DEC 2018

Amendment 05 (global amendment described in Section 15.4)
forming integrated protocol Version 5.0, dated 21 NOV 2019

Amendment 06 (global amendment described in Section 15.5)
forming integrated protocol Version 6.0, dated 17 FEB 2020
Local amendments not forming part of this integrated global protocol:

Amendment 01 (dated 25 SEP 2017)
(local amendment, valid for South Africa only)

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  2 of 113
1.
Title page
A randomized, parallel-group, double-blind and open-label, placebo-controlled, 
multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine 
fibroids
Short title:  Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine Fibroids 
Acronym:   ASTEROID 3 
Test drug:
BAY 1002670 / Vilaprisan
Clinical study phase:
3
Date:
17 FEB 2020
Registration:
EudraCT: 2017-002997-38
Version no.:
6.0
Sponsor’s study no.:
15787
Sponsor:
Non-US territory: Bayer AG, D-51368 Leverkusen, Germany
US territory:  Bayer HealthCare Pharmaceuticals, Inc.
100 Bayer Boulevard, PO Box 915, Whippany, NJ 07981-0915, 
US
Sponsor’s medical 
expert:
Bayer U.S. LLC Pharmaceuticals
Study Medical Experts Women’s Health
11 Waterview Blvd
Parsippany, NJ 07054, USA
Tel: 
Email: 
The study will be conducted in compliance with the protocol, ICH-GCP and any applicable 
regulatory requirements.
Confidential
The information provided in this document is strictly confidential and is intended solely for 
the guidance of the clinical investigation.  Reproduction or disclosure of this 
document - whether in part or in full - to parties not associated with the clinical 
investigation or its use for any other purpose without the prior written consent of the 
sponsor is not permitted.
Throughout this document, symbols indicating proprietary names (, TM) may not be displayed.  
Hence, the appearance of product names without these symbols does not imply that these names are not 
protected.
PPD
PPD
PPD

PPD
PPD

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  4 of 113
Signature of principal investigator
The signatory agrees to the content of the final clinical study protocol as presented.
Name:
Affiliation:
Date:
Signature:
Signed copies of this signature page are stored in the sponsor’s study file and in the respective 
center’s investigator site file.
In the protocol document, this page may remain unsigned.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  5 of 113
2.
Synopsis
This section was changed in Amendment 2, see Section 15.1.1
Title
A randomized, parallel-group, double-blind and open-label placebo-
controlled, multicenter study to assess the efficacy and safety of vilaprisan 
in subjects with uterine fibroids
Short title
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine Fibroids 
Acronym
ASTEROID 3
Clinical study phase
3 
Study objective(s)
The primary objective of this study is to show superiority of vilaprisan in the 
treatment of heavy menstrual bleeding (HMB) in subjects with uterine 
fibroids compared to placebo. 
The secondary objectives of this study are to additionally evaluate the 
efficacy and safety of vilaprisan in subjects with uterine fibroids. With the 
implementation of protocol amendment 5 (version 5.0), additional focus will 
be put on safety evaluations of the endometrium, adrenal glands and skin.
The other objectives of this study are to evaluate the variability in exposure 
in relation to the efficacy and safety for vilaprisan and to collect patient-
reported outcome (PRO) and clinician-reported outcome (ClinRO) data.
Test drug
Not any longer applicable due to the closing of the clinical study. With 
the implementation of protocol amendment 5 (version 5.0) and aligned 
with the previous temporary pause measures, no new subjects will be 
recruited and no study medication will be given to the subjects who 
have been enrolled in the study. Originally, the information and 
instructions related to the test drug were the following:
Vilaprisan (BAY 1002670) 
Name of active ingredient Vilaprisan (BAY 1002670) 
Dose 2 mg, once daily 
Route of administration Oral 
Duration of treatment Treatment Group A1: vilaprisan, 2 treatment periods of 12 weeks, separated 
by 1 bleeding episode
Treatment Group A2: vilaprisan, 2 treatment periods of 12 weeks without a 
break
Treatment Group B1: placebo, 1 treatment period of 12 weeks and 
vilaprisan, 1 treatment period of 12 weeks, separated by 1 bleeding episode
Treatment Group B2: vilaprisan, 1 treatment period of 12 weeks and 
placebo, 1 treatment period of 12 weeks, separated by 1 bleeding episode

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  6 of 113
Reference drug
Not any longer applicable due to the closing of the clinical study. With 
the implementation of protocol amendment 5 (version 5.0) and aligned 
with the previous temporary pause measures, no new subjects will be
recruited and no study medication will be given to the subjects who 
have been enrolled in the study. Originally, the information and 
instructions related to the reference drug were the following:
Placebo 
Name of active ingredient Not applicable 
Dose Dose not applicable, once daily 
Route of administration Oral 
Duration of treatment See Treatment Groups B1 and B2 above 
Indication
Uterine fibroids 
Diagnosis and main criteria for 
inclusion /exclusion
With the implementation of protocol amendment 5 (version 5.0) and 
aligned with the previous temporary pause measures, no new subjects 
will be enrolled in the study.
Originally, the study population had to fulfill the following criteria:
Women, 18 years or older, with at least 1 uterine fibroid documented by 
ultrasound at screening with largest diameter 30 mm and <120 mm and 
HMB in at least 2 bleeding periods during the screening period each with 
blood loss volume > 80.00 mL, documented by the alkaline hematin (AH) 
method, will be eligible for enrollment in the study.  Women who are 
pregnant, lactating, or have any condition requiring immediate blood 
transfusion are not eligible. 
Study design
This is a randomized, parallel-group, double-blind and open-label, placebo-
controlled, multicenter study. 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  7 of 113
Methodology
With the implementation of protocol amendment 5 (version 5.0) no new 
subjects will be recruited and no study medication will be given to the 
subjects who have been enrolled in the study.
Subjects are not any longer required to document anything in the 
electronic diary (eDiary).
Any subjects who have taken at least one dose of study medication 
(including the subjects who completed the study or were prematurely 
terminated) will be asked to undergo the safety evaluation procedures 
described in this document.
Prior to the temporary pause subjects were asked to document the intensity 
of their daily menstrual bleeding in the Uterine Fibroid Daily Bleeding 
Diary (UF-DBD) and assess the intensity of their menstrual blood loss daily 
using a visual scoring system (Menstrual Pictogram [MP]) in an electronic 
diary (eDiary).  Subjects were to collect the sanitary products used during 
the study to analyze the volume of blood loss using the AH method.
Uterine fibroids were assessed during the study through ultrasound.
Patient-reported outcome (PRO) data were collected using the Uterine 
Fibroid Daily Symptom Diary (UF-DSD), the Uterine Fibroid Symptom and 
Quality of Life questionnaire (UFS-QoL), the Patient Global Impression of 
Severity and Change (PGI-S; PGI-C), the Short Form 36 Health Survey 
Version 2 (SF-36v2), and the Treatment Satisfaction Questionnaire for 
Medication (TSQM-9). Clinician-reported outcome (ClinRO) data were
collected using the Clinical Global Impression Investigator (CGI_I). Safety 
is assessed by the evaluation of adverse events (AEs), laboratory parameters, 
endometrial biopsies, cervical smears, physical and gynecological 
examinations including ultrasound, and vital signs. In addition, liver 
parameters were monitored on a monthly basis during treatment.
The (population) pharmacokinetics (PK) and the effect of intrinsic and 
extrinsic factors on the variability in exposure were assessed by population 
PK analysis using sparse vilaprisan concentration samples.
Type of control
Not any longer applicable as with the implementation of protocol 
amendment 5 (version 5.0) no new subjects will be recruited and no 
study medication will be given to the subjects who have been enrolled in 
the study.
Placebo 
Number of subjects
With the implementation of protocol amendment 5 (version 5.0) no new 
subjects will be enrolled in the study and no subjects will be treated.
Any subjects who have taken at least one dose of study medication 
(including the subjects who completed the study or were prematurely 
terminated) will be asked to undergo the safety monitoring procedures 
described in this document.
Based upon the anticipated screen failures rates (60% in the US and 50% in 
China and the other countries), about 585 subjects were planned to be 
enrolled to achieve the planned number of randomized subjects. A total of 
260 subjects were planned to be randomized (65 subjects in each treatment 
group). 
Primary variable
Amenorrhea (yes/no), defined as menstrual blood loss (MBL) <2 mL during 
the last 28 days of treatment

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  8 of 113
Time point/frame of 
measurement for primary 
variable
Presence of amenorrhea after 12 weeks of treatment in Treatment Period 1 
Plan for statistical analysis
The primary efficacy will be assessed by testing the amenorrhea rates of 
vilaprisan after 12 weeks of treatment in Treatment Period 1 versus placebo 
after 12 weeks of treatment using two-sided Cochran-Mantel-Haenszel test 
at a 0.05 significance level.  A hierarchical (fixed sequence) testing 
procedure will be used, involving the primary efficacy variable amenorrhea 
and key secondary efficacy variables HMB response, time to onset of 
amenorrhea and time to onset of controlled bleeding.
In addition, efficacy and safety variables will be summarized by descriptive
statistics.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  9 of 113
Protocol Amendment Summary of Changes Table
Amendment 6 (17 FEB 2020)
Overall Rationale for the Amendment:
Bayer has decided to close all clinical studies with vilaprisan, which were put on temporary 
pause in December 2018 (protocol amendment 4, version 4.0) while pre-clinical toxicology 
findings and their relevance to humans were being further investigated. Although the outcome 
of Bayer’s investigation revealed that the observed pre-clinical findings are regarded to be of 
limited relevance to the human situation (refer to vilaprisan Investigator’s Brochure [IB]
version 11.0 including associated amendment and Introduction section), a comprehensive 
safety follow up will be conducted to provide additional confirmatory evidence. The
amendment (protocol amendment 5, version 5.0) introduced measures and processes to 
prepare this study for an orderly closure, including safety follow up measures in all study 
participants who received at least one dose of study drug vilaprisan.
Recently Bayer received comments from FDA regarding details of the safety follow-up 
measures introduced in the protocol amendment 5 (version 5.0). The current amendment 
(protocol amendment 6, version 6.0) implements these FDA recommendations.
Section # and 
Name
Description of Major Changes
Brief Rationale
Short summary 
for sites
Described how subjects will be counseled when test results 
(e.g., hormone, liver, physical examination) are abnormal 
but still below the thresholds to trigger outside evaluation 
in the context of the study. 
To address FDA 
requests
9 Procedures and 
variables; 9.6.3.4 
Physical and gyn. 
examination
Added text and deleted footnote to Physical examination as 
this needs to be performed in all subjects.
To address FDA 
requests
9.6.3.1
Laboratory 
evaluations
Revised the interval for blood sampling after intake of high 
doses of biotin from 8 to 72 hours.
To address FDA 
requests
Added glycosylated hemoglobin (HbA1c) to the parameters 
measured for adrenal monitoring also in subjects who have 
completed or discontinued the study before or during the 
temporary pause.
To address FDA 
requests
9.6.3.2.7 Heavy 
menstrual 
bleeding / 
suspicious 
bleeding pattern
Described that, for comparison of subject’s subjective 
report with documented bleeding pattern and amount of 
blood loss, bleeding data of UF-DBD, MP, and/or AH 
method, if available, from the months preceding the safety 
closeout visit will be used.
To address FDA 
requests
10.2 Analysis sets
Added clarification that all randomized subjects belong to 
the FAS, excluding randomized subjects who did not start 
Treatment Period 1 due to the study being temporarily 
on hold.
To address FDA 
requests

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  10 of 113
Short summary for sites:
With the implementation of protocol amendment 5 (version 5.0) no new subjects will be 
enrolled in the study and no subjects will re-start treatment. All subjects who were 
randomized and started treatment before the temporary pause will be asked to have the 
comprehensive safety evaluation (with particular focus on endometrial, adrenal and skin
safety) performed. This also applies to subjects who have completed or discontinued the study 
before or during the temporary pause, provided they have taken at least one dose of study 
medication.1
All these subjects are asked to come to the site for the “Safety closeout visit” which is 
implemented with amendment 5 (version 5.0). In most cases the procedures scheduled for this 
safety closeout visit will not take place on the same day. The second scheduled visit, the 
“Safety result reporting visit” can be done as a telephone visit.
The following procedures are to be performed in the context of the Safety closeout visit; for 
details please refer to Sections 9.1 and 0:

Reconsenting the subject 

Documentation of concomitant medication and AEs

Check for adrenal disorder signs and symptoms, incl. vital signs and body weight

MRI of adrenal glands

Dispensation and collection of saliva test tubes

Referral to dermatology expert

Physical examination

Gynecological/breast exam

Cervical smear

Urine pregnancy test

Ultrasound examination 

Endometrial biopsy

Laboratory (blood sampling)

Collection of unused study drug and empty drug packs/drug accountability, if 
applicable

Collection of eDiary devices and review of bleeding data for unusual bleeding pattern 
(see Section 9.6.3.2.7)

Deactivation of the subject on the tablet computer without selecting a particular visit
At the second scheduled visit (“Safety result reporting visit”), the investigator is asked to 
communicate the results from the safety evaluations to the subject. This can be done as a 
telephone visit.
Details regarding the safety evaluation procedures and algorithms for identified abnormalities 
can be found in the respective chapters of this amendment. Test results (e.g., hormone, liver, 
physical examination) may be abnormal but still below the thresholds to trigger outside 
                                                
1 In subjects with exceptional circumstances, e.g., pregnancy, timing of the safety evaluations should be decided 
case by case.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  11 of 113
evaluation in the context of the study. In these cases subjects should at least be counselled 
about medical follow up according to local practice.
Before a subject is deemed lost to follow up, the investigator or designee must make every 
effort to regain contact with the subject (where possible, 3 telephone calls and, if necessary, a 
certified letter to the subject last known mailing address or local equivalent methods). These 
contact attempts should be documented in the subject’s source document.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  12 of 113
Table of contents
Cover page of the integrated protocol.................................................................................... 1
1.
Title page............................................................................................................................ 2
Signature of the sponsor’s medically responsible person..................................................... 3
Signature of principal investigator......................................................................................... 4
2.
Synopsis.............................................................................................................................. 5
Protocol Amendment Summary of Changes Table............................................................... 9
Table of contents..................................................................................................................... 12
Table of tables......................................................................................................................... 15
Table of figures....................................................................................................................... 15
List of abbreviations............................................................................................................... 16
Definition of terms.................................................................................................................. 19
3.
Introduction..................................................................................................................... 20
4.
Study objectives............................................................................................................... 23
5.
Study design..................................................................................................................... 23
6.
Study population ............................................................................................................. 27
Inclusion criteria ............................................................................................................ 27
6.1
Exclusion criteria ........................................................................................................... 28
6.2
Justification of selection criteria.................................................................................... 30
6.3
Withdrawal of subjects from study................................................................................ 30
6.4
6.4.1
Withdrawal ................................................................................................................. 30
6.4.2
Replacement ............................................................................................................... 31
Subject identification ..................................................................................................... 32
6.5
7.
Treatments....................................................................................................................... 32
Treatments to be administered....................................................................................... 32
7.1
Identity of study treatment............................................................................................. 33
7.2
Treatment assignment.................................................................................................... 34
7.3
Dosage and administration............................................................................................. 35
7.4
Blinding ......................................................................................................................... 35
7.5
7.5.1
Blinding measures ...................................................................................................... 35
7.5.2
Unblinding.................................................................................................................. 35
7.5.3
Emergency unblinding by the investigator................................................................. 35
Drug logistics and accountability................................................................................... 35
7.6
Treatment compliance.................................................................................................... 36
7.7
8.
Non-study therapy........................................................................................................... 36
Prior and concomitant therapy....................................................................................... 36
8.1
8.1.1
Iron supplementation.................................................................................................. 36
8.1.2
Progestin therapy for induction of bleeding ............................................................... 37
Post-study therapy.......................................................................................................... 37
8.2

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  13 of 113
9.
Procedures and variables ............................................................................................... 37
Tabular schedule of evaluations .................................................................................... 37
9.1
Visit description............................................................................................................. 39
9.2
9.2.1
Unscheduled visits...................................................................................................... 39
9.2.2
Optional pre-screening phone contact........................................................................ 39
9.2.3
Scheduled visits.......................................................................................................... 39
Population characteristics .............................................................................................. 39
9.3
9.3.1
Demographic .............................................................................................................. 39
9.3.2
Medical history........................................................................................................... 39
9.3.3
Reproductive, menstrual, and fibroids history............................................................ 40
9.3.4
Heavy menstrual bleeding questions.......................................................................... 40
Efficacy.......................................................................................................................... 40
9.4
9.4.1
Alkaline hematin method to assess HMB................................................................... 40
9.4.2
Ultrasound (efficacy) to assess uterine fibroids ......................................................... 40
Pharmacokinetics / pharmacodynamics......................................................................... 41
9.5
9.5.1
Drug measurements.................................................................................................... 41
9.5.2
Population pharmacokinetic analysis of vilaprisan .................................................... 42
9.5.3
Pharmacokinetic/pharmacodynamic relationship of vilaprisan.................................. 42
Safety ............................................................................................................................. 43
9.6
9.6.1
Adverse events............................................................................................................ 43
Definitions............................................................................................................... 43
9.6.1.1
Classifications for AE assessment........................................................................... 45
9.6.1.2
Assessments and documentation of AEs................................................................. 47
9.6.1.3
Reporting of SAEs................................................................................................... 48
9.6.1.4
Expected AEs.......................................................................................................... 48
9.6.1.5
Adverse events of special safety interest................................................................. 49
9.6.1.6
9.6.2
Pregnancies................................................................................................................. 50
9.6.3
Further safety.............................................................................................................. 51
Laboratory evaluations............................................................................................ 51
9.6.3.1
Endometrial biopsies............................................................................................... 53
9.6.3.2
Cervical smear......................................................................................................... 58
9.6.3.3
Physical and gynecological examinations............................................................... 58
9.6.3.4
Vital signs, weight, and height................................................................................ 59
9.6.3.5
Ultrasound (safety).................................................................................................. 59
9.6.3.6
Contraception and pregnancy test ........................................................................... 59
9.6.3.7
Adrenal monitoring ................................................................................................. 59
9.6.3.8
Liver symptom inquiry............................................................................................ 63
9.6.3.9
Liver monitoring ..................................................................................................... 63
9.6.3.10
Skin monitoring....................................................................................................... 64
9.6.3.11
Other procedures and variables...................................................................................... 65
9.7
9.7.1
Iron supplementation.................................................................................................. 65
9.7.2
Algorithm for monitoring of endometrial safety........................................................ 65
9.7.3
Heavy menstrual bleeding / suspicious bleeding pattern ........................................... 65
9.7.4
Unscheduled endometrial biopsy ............................................................................... 65
9.7.5
Monitoring of ovarian cysts........................................................................................ 65
Appropriateness of procedures / measurements ............................................................ 65
9.8
10. Statistical methods and determination of sample size ................................................. 65
General considerations................................................................................................... 65
10.1

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  14 of 113
Analysis sets .................................................................................................................. 66
10.2
Variables and planned statistical analyses..................................................................... 66
10.3
10.3.1
Variables..................................................................................................................... 66
Primary efficacy variable ........................................................................................ 66
10.3.1.1
Secondary efficacy variables................................................................................... 67
10.3.1.2
Other efficacy variables .......................................................................................... 67
10.3.1.3
Pharmacokinetics (PK)............................................................................................ 68
10.3.1.4
Secondary safety variables...................................................................................... 68
10.3.1.5
Other safety variables.............................................................................................. 68
10.3.1.6
10.3.2
Statistical and analytical plans.................................................................................... 69
Demographic and other baseline characteristics ..................................................... 69
10.3.2.1
Efficacy analysis ..................................................................................................... 69
10.3.2.2
Pharmacokinetic analysis ........................................................................................ 70
10.3.2.3
Safety analysis......................................................................................................... 70
10.3.2.4
Subgroup analysis ................................................................................................... 70
10.3.2.5
10.3.3
Missing data/drop outs ............................................................................................... 71
Determination of sample size......................................................................................... 72
10.4
Planned interim analyses ............................................................................................... 73
10.5
11. Data handling and quality assurance............................................................................ 73
Data recording................................................................................................................ 73
11.1
Monitoring ..................................................................................................................... 74
11.2
Data processing.............................................................................................................. 75
11.3
Missing data................................................................................................................... 75
11.4
Audit and inspection ...................................................................................................... 75
11.5
Archiving ....................................................................................................................... 75
11.6
12. Premature termination of the study .............................................................................. 76
13. Ethical and legal aspects................................................................................................. 76
Investigators and other study personnel......................................................................... 76
13.1
Funding and financial disclosure ................................................................................... 77
13.2
Ethical and legal conduct of the study........................................................................... 77
13.3
Subject information and consent.................................................................................... 78
13.4
Publication policy and use of data ................................................................................. 79
13.5
Compensation for health damage of subjects / insurance.............................................. 79
13.6
Confidentiality ............................................................................................................... 79
13.7
14. Reference list.................................................................................................................... 80
15. Protocol amendments...................................................................................................... 80
Amendment 2 – Dated 15 NOV 2017 ........................................................................... 80
15.1
15.1.1
Overview of the changes to the study......................................................................... 80
Change 1: Modification of the collection periods of sanitary products .................. 80
15.1.1.1
Change 2: Changes in the statistical analysis.......................................................... 81
15.1.1.2
Change 3: Modifications of the tabular schedule of evaluations ............................ 81
15.1.1.3
Change 4: Minor clarifications for consistency ...................................................... 81
15.1.1.4
15.1.2
Changes to the protocol text....................................................................................... 82
Section 2 Synopsis .................................................................................................. 82
15.1.2.1
Section 5 Study design ............................................................................................ 83
15.1.2.2
Section 6.2 Exclusion criteria.................................................................................. 85
15.1.2.3

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  15 of 113
Section 9.1 Tabular schedule of evaluations........................................................... 85
15.1.2.4
Section 9.2.2 Optional pre-screening phone contact............................................... 89
15.1.2.5
Section 9.2.3 Scheduled visits................................................................................. 90
15.1.2.6
Section 9.2.3.1 Visit 1 Screening............................................................................ 90
15.1.2.7
Section 9.2.3.2 Visit 2 Screening............................................................................ 91
15.1.2.8
Section 9.2.3.3 Visit 3 Randomization.................................................................... 91
15.1.2.9
Section 9.2.3.4 Visits 4, 5, and 6............................................................................. 92
15.1.2.10
Section 9.2.3.5 EoT visit......................................................................................... 93
15.1.2.11
Section 9.4.3 Alkaline hematin method to assess HMB ......................................... 94
15.1.2.12
Section 9.4.4 Ultrasound (efficacy) to assess uterine fibroids ................................ 94
15.1.2.13
Section 9.6.1.1 Definitions...................................................................................... 95
15.1.2.14
Section 9.6.3.1 Laboratory evaluations................................................................... 95
15.1.2.15
Section 9.6.3.3 Cervical smear................................................................................ 95
15.1.2.16
Section 9.7.1 Iron supplementation......................................................................... 96
15.1.2.17
Section 9.7.3 Heavy menstrual bleeding / suspicious bleeding pattern .................. 96
15.1.2.18
Section 10.3.1 Variables.......................................................................................... 97
15.1.2.19
Section 10.3.1.1 Primary efficacy variable ............................................................. 97
15.1.2.20
Section 10.3.1.2 Secondary efficacy variables........................................................ 97
15.1.2.21
Section 10.3.1.3 Other efficacy variables ............................................................... 98
15.1.2.22
Section 10.3.1.6 Other safety variables................................................................. 100
15.1.2.23
Section 10.3.2.2 Efficacy analysis, Section 10.3.2.3 Secondary efficacy analysis 
15.1.2.24
and Section 10.3.2.4 other efficacy....................................................................... 100
Section 10.3.2.5 Subgroup analysis ...................................................................... 103
15.1.2.25
Section 10.3.3 Missing data/drop-outs.................................................................. 103
15.1.2.26
Section 10.4 Determination of sample size........................................................... 105
15.1.2.27
Amendment 3............................................................................................................... 106
15.2
Amendment 4............................................................................................................... 109
15.3
Amendment 5............................................................................................................... 109
15.4
Amendment 6............................................................................................................... 112
15.5
16. Appendices..................................................................................................................... 113
Strong CYP3A4 inhibitors........................................................................................... 113
16.1
Strong CYP3A4 inducers............................................................................................. 113
16.2
Table of tables
Table 7—1:  Identity of test drug/vilaprisan tablets and matching placebo............................. 34
Table 9–1: Schedule of procedures .......................................................................................... 38
Table 16—1:  Strong CYP3A4 inhibitors.............................................................................. 113
Table 16—2:  Strong CYP3A4 inducers................................................................................ 113
Table of figures
Figure 5-1  Design overview - amended .................................................................................. 24
Figure 9–1: Overview of the endometrial safety monitoring algorithm .................................. 53
Figure 9–2: Adrenal monitoring algorithm .............................................................................. 61

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  16 of 113
List of abbreviations
ACTH
adrenocorticotropic hormone
AE
adverse event
AESI
adverse event of special safety interest
AG
Aktiengesellschaft, incorporated company
AH
alkaline hematin
ALT
alanine aminotransferase (also known as GPT)
AP
alkaline phosphate
aPTT
activated partial thromboplastin time
ASCUS
atypical squamous cells of undetermined significance
AST
aspartate aminotransferase (also known as GOT)
ATC
Anatomical Therapeutic Chemical
-HCG
beta human chorionic gonadotropin
BMI
body mass index
CD
Compact disk
CDISC
Clinical Data Interchange Standards Consortium
CGI_I
Clinical Global Impression Investigator 
ClinRO
clinician-reported outcome
CRA
Clinical research associate
CRF
case report form
CRO
contract research organization
CYP3A4
cytochrome P450 isoenzyme 3A4
DHEA-S
Dehydroepiandrosterone sulfate
dL
deciliter
E2
estradiol
EA
endometrial ablation
eCRF
electronic case report form
EDC
electronic data capture
eDiary
electronic Diary
eg
exempli gratia, for example
EIN
endometrial intraepithelial neoplasia
EoT
end of treatment
ePRO
electronic patient-reported outcomes
EU
European Union
FAS
full analysis set
FDA
Food and Drug Administration
FSH
follicle-stimulating hormone
FUP
follow-up 
g
gram
GCP
Good Clinical Practice

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  17 of 113
GMP
Good Manufacturing Practice
GnRH(a)
gonadotropin-releasing hormone (agonist)
GOT
glutamic oxaloacetic transaminase (also known as AST)
GPT
glutamic pyruvic transaminase (also known as ALT)
Hb
hemoglobin
HbA1c
glycosylated hemoglobin
HDL
high density lipoprotein
HMB
heavy menstrual bleeding
HPV
human papilloma virus
HRQoL
Health-related quality of life
IB
investigator’s brochure
ICH
International Council on Harmonisation
ie
id est, that is
IEC
Independent Ethics Committee
INN
international nonproprietary names
INR
international normalized ratio
IRB
Institutional Review Board
IVRS/IWRS
interactive voice/web response system
LC-MS/MS
liquid chromatography-tandem mass spectrometry
LDL
low density lipoprotein
LH
luteinizing hormone
MBL
menstrual blood loss
MCH
mean corpuscular hemoglobin
MCV
mean corpuscular volume
MD
doctor of medicine
MedDRA
Medical Dictionary for Regulatory Activities
mg
milligram
mL
milliliter
MP
menstrual pictogram
MRI
magnetic resonance imaging
M&S
Modeling and Simulation
P
progesterone
PAEC
progesterone receptor modulator-associated endometrial changes
PASS
Power analysis and sample size
PD
pharmacodynamic(s)
PGI-C
Patient Global Impression of Change
PGI-S
Patient Global Impression of Severity
pH
negative logarithm of proton concentration
PK
pharmacokinetic(s)
PPS
per protocol set
PRAC
Pharmacovigilance Risk Assessment Committee
PRM
progesterone receptor modulator

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  18 of 113
PROs
patient-reported outcomes
QA
quality assurance
QC
quality control
QoL
quality of life
QS
questionnaire
QSEVAL
Evaluator
RAVE
electronic data capturing system
RND
randomization 
SAE
serious adverse event
SAF
safety analysis set
SAP
Statistical Analysis Plan
SAS
Statistical Analysis Software
SD
standard deviation
SDTM
Standard Data Tabulation Model
SESAC
Site Electronic Source Assessment Checklist
SF-36v2
Short Form 36 Health Survey Version 2
SID
subject identification
SS
Symptom Severity
SUSAR
suspected, unexpected serious adverse reaction
TEAE
Treatment emergent adverse event
THIN
The Health Improvement Network
TP
treatment period
TSH
thyroid-stimulating hormone
TSQM-9  
Treatment Satisfaction Questionnaire for Medication 
tT
total testosterone
TVU
transvaginal ultrasound
UAE
uterine artery embolization
UF-DBD
Uterine Fibroid Daily Bleeding Diary
UF-DSD
Uterine Fibroid Daily Symptom Diary
UFS-QoL
Uterine Fibroid Symptom and Quality of Life questionnaire
ULN
upper limit of normal
UPA
ulipristal acetate
UPP
uterus-preserving procedures
US/USA
United States (of America)
WHO
World Health Organization
WHO-DD
World Health Organization Drug Dictionary
wk
week

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  19 of 113
Definition of terms
3/1 regimen
3 months (ie, 3 x 28 days) of treatment with 1 bleeding episode between 
treatment periods
6/2 regimen
6 months (ie, 6 x 28 days) of treatment followed by 2 bleeding episodes 
month
equals 28 days when referring to treatment (ie, 28 tablets per drug pack); 
equals 30 days when referring to the number of days in a month

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  20 of 113
3.
Introduction
With the implementation of protocol amendment 5 (version 5.0) no new subjects will be 
enrolled in the study and no subjects will receive any further study drug treatment. Any 
subjects who have taken at least one dose of study medication (including the subjects who 
completed the study or were prematurely terminated) will be asked to undergo the safety 
monitoring procedures described in this document.
Based on findings in preclinical carcinogenicity studies in rats and mice all vilaprisan clinical 
studies were temporarily paused since December 2018. In those carcinogenicity studies, 
adenocarcinomas of the endometrium and tumors of the adrenal cortex (benign and 
malignant) were seen in female rats and mice. Furthermore, skin sarcomas were found in 
female mice at a high exposure, representing 100 times the human therapeutic dose of 2 mg. 
Bayer has decided to close all clinical studies with vilaprisan, which were put on temporary 
pause in December 2018 (protocol amendment 4, version 4.0) while pre-clinical toxicology 
findings and their relevance to humans were being further investigated. Although the outcome 
of this investigation revealed that the observed pre-clinical findings are regarded to be of 
limited relevance to the human situation (IB version 11.0 including the associated amendment
and Introduction section), Bayer will conduct a comprehensive safety follow up to confirm 
this. Amendment 5 (version 5.0) introduced measures and processes to prepare this study for 
an orderly closure, including safety follow up measures in all study subjects who received at 
least one dose of study drug.
Amendment 5 (version 5.0) introduced endometrial, adrenal, and skin safety evaluations with 
the aim to confirm that the carcinogenicity study findings do not translate into an increased
risk for subjects when treated with the regimens and doses tested in the current studies.
In conclusion, all ongoing clinical studies with vilaprisan will be closed after implementation 
of a structured safety follow-up in all exposed subjects which aims to: 

provide certainty to subjects that they leave the study without any concerning finding,

generate clinical data that will support a thorough analysis of human safety data to 
confirm the hypothesis that the animal findings are of limited relevance to humans.
While closing the current clinical studies for the reasons explained above, the newly collected 
safety data will be thoroughly evaluated in addition to the already collected efficacy data.
Further detailed information and assessment of the carcinogenicity study findings are 
described below and also in the current version (V 11.0 including the associated amendment) 
of the vilaprisan Investigator’s Brochure.
Results from chronic carcinogenicity studies with vilaprisan in rodents (rat and mice)
In preclinical chronic carcinogenicity studies in rats and mice, adenocarcinomas of the 
endometrium were found. Furthermore, in female rats, benign and malignant tumors of the 
adrenal cortex were seen. Such tumors were not seen in male rats or in mice. In addition, skin 
sarcoma (not otherwise specified) were found with increased incidence of statistical 
significance at the high dose of 60 mg/kg in female mice only. This corresponds to about 100 
fold of the daily dose of 2 mg administered in this study. The tumors were derived from 
various cell lineages and were seen at various anatomical locations. The cause and the 
relevance of these skin tumors in mice is unclear but based on the high margin of exposure at 
which these tumors were found, the relevance for humans treated at the intended therapeutic 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  21 of 113
dose is regarded as limited.
Bayer assessment of human relevance of the observed rodent tumors: 
The etiology of the observed endometrial and adrenal tumors is regarded as related to 
vilaprisan’s mode-of-action with species-specific consequences. There was no indication of 
any direct carcinogenic or direct tumor-promoting effect of vilaprisan, which is non-
genotoxic. Male animals did not show any findings and in female animals, effects were 
limited to reproductive and endocrine organs, with the exemption of the skin sarcomas, where 
the high margin of exposure suggested limited human relevance. Reasons why the 
endometrial and adrenal tumors are regarded as of limited relevance in the human setting are 
described in more detail below: 
In the course of these carcinogenicity studies, rats and mice were treated with life-long and 
uninterrupted doses of vilaprisan leading to much higher unbound exposures compared to the 
human dose of 2 mg/day. As a consequence, progesterone action was blocked in these 
animals during their whole life-span. Compatible with this are signs of estrogen dominance 
that were observed in the aging female rats and mice. Such signs have not been found in 
clinical trials of vilaprisan in humans. In the carcinogenicity study rodents entered into 
reproductive senescence during the treatment phase leading to rodent specific endocrine 
changes resulting under continuous blockade of the progesterone receptor in the formation of 
tumors in the endometrium and adrenal cortex. The rodent specific endocrinology does not 
resemble the situation in humans.
Relevant differences between the treatment of humans with vilaprisan and the setting of the 
carcinogenicity studies in rodents are:

Female rodents undergo specific endocrine changes during reproductive senescence 
that do not resemble human menopause, human premenopausal endocrine status or the 
endocrine situation during vilaprisan treatment. 

Prolonged estrous periods with high estradiol levels occur in rodent reproductive 
senescence, or a pseudopregnancy state with moderately high estradiol levels. This 
process takes place due to neurodegeneration on the hypothalamus-pituitary gland and 
in the presence of follicles in the ovaries which are capable of producing hormones. In 
the presence of vilaprisan with its strong antagonistic effect on the progesterone 
receptor this leads to a prolonged, fully unopposed estradiol exposure in the animals. 
Specifically, in rats, life-long vilaprisan treatment seems to promote prolonged estrous 
periods with follicular cysts and reduce states of pseudopregnancy, thus further
enhancing estrogen dominance.

Prolonged phases of unopposed estrogen are a recognized risk factor for development 
of endometrial adenocarcinoma in rodents as well as in humans. However, in contrast 
to the rodents in the pre-clinical carcinogenicity studies, available clinical data for 
vilaprisan do not indicate the occurrence of an unopposed estrogen effect on human 
endometrium. This is supported by the estrogen-lowering effect of vilaprisan shown in 
the Phase 1 and Phase 2 studies as well as by the morphological features of 
endometrial histology in humans under vilaprisan treatment which do not seem to 
indicate a relevant proliferative effect. There was no increased incidence of relevant 
endometrial pathology (hyperplasias, neoplasms) seen in biopsies taken after up to 12 
months of treatment with vilaprisan. 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  22 of 113

Furthermore, vilaprisan is administered in treatment regimens with regular breaks for 
one or two menstrual bleeds, to allow for ovulation, endogenous progesterone 
production, menstruation, and endometrial shedding (versus life-long continuous 
treatment in the rodent carcinogenicity study).
With regards to the development of adrenal tumors, a role of estrogen dominance in adrenal 
stimulation (e.g. hormonal imbalance) is recognized in rodents, whereas in humans adrenal 
functional disorders and adrenal tumors have a different etiology and are not known to be 
influenced in a relevant way by unopposed estrogen. In addition, adrenal tumors under 
vilaprisan treatment occurred only in female rats, but not in mice. Vilaprisan treatment in the 
chronic monkey study also did not result in any hypertrophic or hyperplastic adrenal changes. 
In rats there were likely further species-specific contributing factors like pituitary 
dysregulation and activation of the hypothalamic-pituitary-adrenal (HPA) axis, which was not 
found in the other tested species.
In conclusion, the combination of a hyperestrogenic background status in reproductive 
senescence of female rodents (unopposed estrogen effect) with a continuous blockade of
progesterone action by vilaprisan is a conclusive mechanistic hypothesis to explain the 
endometrial and adrenal tumors observed in the rodent carcinogenicity studies. Based on these 
major differences between rats and humans, the observed findings are most likely to be rodent 
specific with limited relevance to the human situation. 
However, in order to demonstrate endometrial and adrenal safety of repeated intermittent 
treatment with vilaprisan, study subjects will be carefully monitored.

A thorough endometrial monitoring program has been part of the vilaprisan studies 
from the start. 

With the protocol amendment 5 (version 5.0, a robust adrenal safety monitoring 
program is being implemented in this study as well as in all ongoing vilaprisan 
studies, to adequately address this new topic in the clinical program. 
The cause and the relevance of the skin sarcomas observed in the mouse carcinogenicity study 
is unclear but based on the high exposure at which these tumors were found, the relevance for 
humans treated at the intended therapeutic dose is regarded as limited. 
Nevertheless, all study subjects who took at least one dose of vilaprisan in any of the 
currently paused clinical studies will be asked to undergo careful evaluation in order to 
demonstrate skin safety of repeated intermittent treatment with vilaprisan via a thorough skin 
examination by a dermatology expert.
Benefit risk assessment 
The parameters measured in the context of the endometrial, adrenal and skin monitoring have 
been aligned with clinical experts and represent a positive benefit risk balance between their 
ability to detect relevant pathologies and the low procedure related risks associated with them.
These safety measures for subjects participating in the vilaprisan studies intend to ensure that 
potential tumors or diseases of the uterus, the skin or the adrenal glands are detected. If 
detected, it is important to understand that these tumors or diseases are not automatically 
related to the study drug as they can occur in a certain number of women independently of 
participation in a clinical study and independently of whether vilaprisan was taken as a study 
drug or not (“background incidence”). These measures can help to detect such findings,
probably even at an earlier stage than it would have become apparent otherwise. Furthermore, 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  23 of 113
the safety measures will generate important data allowing to examine whether vilaprisan has a 
role in the development of such tumors and diseases.
The safety of short-term treatment with vilaprisan is supported by the available pre-clinical 
and clinical data. Therefore, it is Bayer’s assessment that no acute or long-term risk is 
expected for the subjects who have been treated in any of the clinical studies performed with 
vilaprisan. 
With regards to efficacy vilaprisan has demonstrated in Phase 1 a dose-dependent ovulation 
inhibition and induction of amenorrhea in healthy women. Two Phase 2 studies (15788 –
ASTEROID 1 and 17541 – ASTEROID 2) with a treatment duration of up to 24 weeks were 
conducted in women with uterine fibroids. The results of both studies demonstrated a 
clinically meaningful reduction of symptoms associated with uterine fibroids, especially of 
HMB, improvements of subjects’ health-related quality of life (HRQoL) and a reduction of 
fibroid size.
4.
Study objectives
The primary objective of this study is to show superiority in the treatment of HMB of 
vilaprisan in subjects with uterine fibroids compared to placebo. 
The secondary objectives of this study are to additionally evaluate the efficacy and safety of 
vilaprisan in subjects with uterine fibroids. With the implementation of protocol amendment 5 
(version 5.0), additional focus will be put on safety evaluations of the endometrium, adrenal 
glands and skin.
The other objectives of this study are to evaluate the variability in exposure in relation to the 
efficacy and safety for vilaprisan and to collect patient-reported outcome (PRO) and clinician-
reported outcome (ClinRO) data. 
5.
Study design
This section was changed in Amendment 2, see Section 15.1.1
This is a randomized, parallel-group, double-blind and open-label, placebo-controlled, 
multicenter study. Blinding was applied to Treatment Groups A1, B1, and B2; Treatment 
Group A2 was open-label.
The study is conducted in the US, Bulgaria, Czechia, China, Israel, Malaysia, New Zealand, 
Singapore and South Africa.
Overview of the study design is shown in Figure 5-1.
With the implementation of protocol amendment 5 (version 5.0), this study design is no 
longer valid. No subjects will receive further study drug.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  24 of 113
Figure 5-1  Design overview - amended
Treatment 
Group A1
Screening
up to 120 days
RND
Vilaprisan 2 mg 
12 week
B
Vilaprisan 2 mg 
12 week
Follow-up
Day 7 to 15 of 
the 2nd
menstrual cycle 
after EoT
Treatment 
Group A2
Screening
up to 120 days
RND
Vilaprisan 2 mg
12 week
Vilaprisan 2 mg 12
week
Follow-up
Day 7 to 15 of 
the 2nd
menstrual cycle 
after EoT
Treatment 
Group B1
Screening
up to 120 days
RND
Placebo 
12 week
B
Vilaprisan 2 mg
12 week
Follow-up
Day 7 to 15 of 
the 2nd
menstrual cycle 
after EoT
Treatment 
Group B2
Screening
up to 120 days
RND
Vilaprisan 2 mg 
12 week
B
Placebo
12 week
Follow-up
Day 7 to 15 of 
the 2nd
menstrual cycle 
after EoT
B = bleeding episode; RND = randomization;., EoT = end of treatment
During the screening period, subjects had to demonstrate eligibility including the presence of 
at least 1 uterine fibroid 30 mm and <120 mm in largest diameter based on ultrasound, HMB 
in at least 2 bleeding periods, each with menstrual blood loss (MBL) >80.00 mL, documented 
by the alkaline hematin (AH) method, and endometrial biopsy results without significant 
histological disorder. 
Eligible subjects were randomized in 1:1:1:1 ratio to one of the four treatment groups (Group 
A1, A2, B1, or B2) and stratified by country/region (US, China, and other 
countries).Treatment was started as described in Section 7.1. 
After the end of the final treatment period, subjects were planned to be followed up until day 
7 to 15 of the 2nd menstrual cycle after end of treatment visit. 
The primary efficacy variable is:

Amenorrhea (yes/no), defined as MBL <2 mL during the last 28 days of treatment. 
For the secondary variables, see Sections 10.3.1.2 and 10.3.2.2.
Justification of the design
Placebo control and blinding:
A double-blind placebo-controlled design (Treatment Groups A1, B1, and B2) was
considered necessary to differentiate drug effects from the natural course of disease and 
background findings. To minimize subject burden due to randomization to placebo treatment, 
all subjects were planned to receive active treatment during a part of the study. Treatment 
Group A2 was open-label because the subjects and the investigators knew the treatment 
regimen since there was no break between the treatment periods.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  25 of 113
Study design valid with the implementation of protocol amendment 5 (version 5.0): 
The study was temporarily paused since December 2018. No further subjects will be recruited 
and none of the enrolled subjects will receive further study drug treatment. All subjects who 
were randomized and started treatment before the temporary pause will be asked to have a
comprehensive safety evaluation (with particular focus on endometrial, adrenal and skin
safety) performed. This also applies to subjects who have completed or discontinued the study 
before or during the temporary pause, provided they have taken at least one dose of study 
medication.
Efficacy / pharmacodynamic assessments:
Menstrual bleeding and the impact uterine fibroids symptoms have on the subjects’ daily life 
are determined as efficacy parameters.
Fibroid size and uterus size (by ultrasound), endocrine hormone levels, and bleeding are
determined as pharmacodynamic (PD) parameters.
Safety monitoring:
Safety parameters are regularly and closely monitored throughout the study (eg, questioning 
for adverse events (AEs), measurement of laboratory values, close observation of subjects in 
case of increased liver parameters, a separate liver symptom questionnaire, i.e. the liver 
symptom inquiry, vital signs, endometrial thickness, abnormal menstrual bleeding, and size of 
follicle like structures comprising follicles and functional ovarian cysts). A comprehensive 
screening program for adrenal tumors and a skin examination by a dermatology expert are 
implemented with protocol amendment 5 (version 5.0).
Endometrial monitoring
A careful endometrial safety monitoring assessment was applied in this study from the 
beginning, including regular ultrasound investigations during the treatment period, 
observation of bleeding patterns, and endometrial biopsies at defined time points. Clear 
decision trees are outlined as to when to perform an additional unscheduled endometrial 
biopsy in case of endometrial thickening and/or for the clinical management of endometrial 
thickening/HMB/abnormal menstrual bleeding pattern (see Section 9.7.2). Highly reliable 
diagnosis of any findings in the endometrial biopsies is ensured through the involvement of a 
panel of highly experienced and well renowned expert pathologists who will assess every 
biopsy sample taken from study subjects.
With protocol amendment 5 (version 5.0), additional requirements for endometrial safety 
screening are outlined for subjects who took at least one dose of study medication, see Section 
9.6.3.2.
Liver monitoring
A liver-related safety signal was observed with some selective progesterone receptor 
modulator (PRM) compounds which display differences in molecular structure compared to 
vilaprisan.
Monthly monitoring of liver parameters under treatment was introduced with an earlier 
version of this protocol (protocol amendment 3, version 3.0). With this protocol amendment
(protocol amendment 5, version 5.0), subjects who remained in the study during the 
temporary pause will receive one further laboratory assessment, including liver parameters.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  26 of 113
Adrenal monitoring
A comprehensive adrenal screening program is implemented with amendment 5 (version 5.0). 
This program is described in more detail in Section 9.6.3.8. It encompasses adrenal imaging, 
as well as laboratory tests aimed at identifying overproduction of adrenal hormones in the 
context of tumors of the adrenal cortex. Tumors of the adrenal glands (cortical or medullary in 
origin, benign as well as malignant) are known to occur in a certain frequency (1) in the 
general population, independent of an exposure to the study drug vilaprisan. In case adrenal 
tumors are detected by the screening program in this study, a causal relationship to vilaprisan 
can therefore not be automatically assumed. However, it is expected that all subjects, 
irrespective of their exposure to vilaprisan, will benefit from detection of potential adrenal 
gland disorders through the study monitoring program. All study subjects who took at least 
one dose of study medication in any of the currently paused clinical studies will be asked to 
undergo adrenal monitoring in order to demonstrate adrenal safety of repeated intermittent 
treatment with vilaprisan.
Skin monitoring
In the above-mentioned carcinogenicity studies performed in mice and rats, skin sarcomas 
were found at a dose representing about 100 times the human therapeutic dose of 2 mg. The
tumors were derived from various cell lineages and were seen at various anatomical locations. 
The cause and the relevance of the skin tumors in mice is unclear but based on the high 
exposure at which these tumors were found, the relevance for humans treated at the intended 
therapeutic dose is regarded as limited. 
Nevertheless, all study subjects who took at least one dose of study medication in any of the 
currently paused clinical studies will be asked to undergo a thorough skin examination by a 
dermatology expert in order to demonstrate skin safety of repeated intermittent treatment with 
vilaprisan.
Effects related to study conduct
In addition to drug-related side effects, symptoms caused by the study conduct (eg, due to 
blood sampling, endometrial biopsy) are possible. However, possible risks are regarded as 
acceptable because the planned methods are used routinely in clinical studies, clinical and/or 
gynecological practice.
End of study
The end of the study as a whole will be reached as soon as the last visit of the last subject has 
been reached in all centers in all participating countries (EU and non-EU).
Primary completion
The primary completion event for this study is the last visit of the last subject.
The primary completion date for this study according to the Food and Drug Administration 
(FDA) Amendment Act is specified in a separate document (not part of this study protocol).

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  27 of 113
6.
Study population
Eligibility
No longer valid, since no new subjects will be enrolled in this study with the 
implementation of protocol amendment 5 (version 5.0). Originally the study population 
had to fulfill the following criteria:
Women with symptomatic uterine fibroids meeting all inclusion and presenting none of the 
exclusion criteria will be eligible for enrollment in the study.
Inclusion criteria
6.1
1. Signed and dated informed consent 
2. Women, 18 years or older at the time of Visit 1 
3. Diagnosis of uterine fibroid(s) documented by ultrasound at screening with at least 1 
fibroid with largest diameter ≥30 mm
4. The largest diameter of any uterine fibroid is <120 mm
5. Heavy menstrual bleeding (HMB) in at least 2 bleeding periods during the screening 
period each with blood loss volume of >80.00 mL documented by the alkaline hematin 
(AH) method 
Women who did not suffer from perceived HMB during the 3 months prior to Visit 1 
due to any effective medical treatment (eg, with a hormonal contraceptive) are not 
considered appropriate candidates and should not undergo further screening 
procedures.
Women suffering from perceived HMB despite medical treatment (eg, with a 
hormonal contraceptive) are appropriate candidates for further screening, if rules on 
stopping prior medication (see exclusion criterion 8) are followed.
Heavy menstrual bleeding >80.00 mL should be documented within 10 consecutive 
days.  As guidance, the duration of a bleeding episode should not exceed 12 days.
6. Good general health (except for findings related to uterine fibroids) as proven by 
medical history, physical and gynecological examinations, and laboratory test results. 
7. Normal or clinically insignificant cervical smear not requiring further follow-up.  The 
cervical smear may be waived if a normal result has been documented in the subject’s 
source documents within the previous 6 months.
Human papilloma virus (HPV) testing in subjects with atypical squamous cells of 
undetermined significance (ASCUS) can be used as an adjunctive test.  Subjects with 
ASCUS can be included if they are negative for high-risk HPV strains.
8. An endometrial biopsy performed during the screening period without significant 
histological disorder such as endometrial hyperplasia (including simple hyperplasia) 
or other significant endometrial pathology.  If the sample is inadequate, the biopsy can 
be repeated once within the screening period and must be repeated within 6 weeks 
from the first biopsy in order for the subject to continue.  No further repeated biopsies 
for inadequate samples are permitted. 
9. Use of an acceptable non-hormonal method of contraception (ie, either male condom, 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  28 of 113
cap, diaphragm or sponge, each in combination with spermicide) starting at Visit 1 
until the end of the study.  (Short-acting hormonal contraception [oral, vaginal, or 
transdermal] are allowed up until the start of the menstrual cycle that follows Visit 1.)  
This is not required if contraception is achieved by a permanent method, such as 
bilateral fallopian tube blockage of the subject (including Essure®) or vasectomy of 
the partner(s).
Exclusion criteria
6.2
This section was changed in Amendment 2, see Section 15.1.1
1. Pregnancy or lactation (less than 3 months since delivery, abortion, or lactation before 
start of treatment) 
2. Hypersensitivity to any ingredient of the study drug 
3. Any condition requiring immediate blood transfusion 
4. Laboratory values outside inclusion range 2 before randomization and considered as 
clinically relevant. 
5. Any diseases, conditions, or medications that can compromise the function of the body 
systems and could result in altered absorption, excessive accumulation, impaired 
metabolism, or altered excretion of the study drug including, but not limited to: 

Impaired function of the kidneys (laboratory values outside of inclusion range) 

Abnormal liver parameters (presence of at least one of the following criteria, 
please see also section 9.6.3.1Laboratory evaluations)3: 
-
2 x upper limit of normal (ULN) for glutamic oxaloacetic transaminase 
(GOT) / aspartate aminotransferase (AST) 
-
2 x ULN for glutamic pyruvic transaminase (GPT) / alanine 
aminotransferase (ALT) 
-
2 x ULN for alkaline phosphatase (AP) 
-
Total bilirubin outside the upper limit of normal range4
-
International normalized ratio (INR) outside the upper limit of the 
normal
5

Diagnosis of hepatitis B infection, i.e., Hbs-antigen positive at Visit 1 6

Diagnosis of hepatitis C infection, i.e., hepatitis C-antibodies and HCV-RNA 
positive at Visit 1 7

Chronic bowel diseases, eg, M. Crohn and Colitis ulcerosa 
                                                
2 As specified in the laboratory manual and in the reports from the central laboratory
3 For the liver-related laboratory parameters ALT, AST, and AP the laboratory test also needs to be repeated if 
results of the first test at visit 1 are raised above the ULN, but still < 2x ULN (i.e. still within inclusion range). 
The patient is eligible only if the second test shows a stabilization or decline in those values (see Section 
9.6.3.1).
4 As specified in the laboratory manual and in the reports from the central laboratory.
5 As specified in the laboratory manual and in the reports from the central laboratory.
6 This will be applied only to subjects newly enrolled into the study after protocol version 3.0 has become valid
7 This will be applied only to subjects newly enrolled into the study after protocol version 3.0 has become valid

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  29 of 113

Intake of strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors within 
the last 2 weeks before the randomization visit and during the treatment period 
including antivirals (eg, viekira pak, telaprevir, boceprevir), protease inhibitors 
(eg, ritonavir, lopinavir, indinavir, nelfinavir, saquinavir), antifungals (eg, 
itraconazole, voriconazole, posaconazole), antibiotics (eg, clarithromycin, 
telithromycin), grapefruit and any grapefruit containing food products (eg, 
grapefruit juice). Ketoconazole and other triazole antifungal drugs are allowed 
for topical/local use (including vaginal application). A detailed list is provided 
in Section 16.1.

Intake of strong CYP3A4 inducers (eg, rifampicin, carbamazepine, 
oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, primidone, St John´s 
wort [Hypericum], efavirenz, nevirapine, long term use of ritonavir) within the 
last 2 weeks before the randomization visit and during the treatment period. A 
detailed list is provided in Section 16.2.
6. Any diseases or conditions that might interfere with the conduct of the study or the 
interpretation of the results, including 

Known severe coagulation disorder 

Known anemia for reason other than HMB 

Known hemoglobinopathy 

History of or current uterine, cervical, ovarian, or breast cancer; except cervical 
cancer after curative treatment 

One or more ovarian cysts >30 mm in diameter as measured by ultrasound 
(except endometrioma)

Any ovarian tumors or pelvic masses of unclear etiology requiring further 
diagnostic procedures 

Known or suspected uterine polyp >15 mm 
7. Abuse of alcohol, drugs, or medicines (eg, laxatives) 
8. Use of other treatments that might interfere with the conduct of the study or the 
interpretation of the results including

Short-acting hormonal contraception (oral, vaginal, or transdermal), if not 
stopped at the start of the menstrual cycle that follows Visit 1 

Long-acting hormonal contraception (injectable), if last application was 
performed less than 1 application interval before start of the menstrual cycle 
that follows Visit 1 

Contraceptive devices with or without hormone release (implant, intra-uterine 
device), if not removed at Visit 1 (not applicable in cases of bilateral fallopian 
tube blockage of the subject (including Essure®))

Other hormonal treatments for HMB or fibroids, if not stopped before the start 
of the menstrual cycle that follows Visit 1 (eg, androgens, estrogen receptor 
antagonists, selective estrogen receptor modulators). For progesterone receptor 
modulators see next bullet point

Previous use of ulipristal acetate, if there were not at least two menstruations 
after the last intake before Visit 1

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  30 of 113

Gonadotropin-releasing hormone agonists (GnRHa), if not stopped at least one 
application interval before Visit 1 

Tranexamic acid, traditional Chinese medicine for uterine fibroids or HMB, or 
other treatments for HMB, if not stopped at Visit 1 

Anticoagulants, if not stopped at Visit 1 

Previous use of vilaprisan (≥2 mg) without satisfactory result 
9. Undiagnosed abnormal genital bleeding 
10. Simultaneous participation in another clinical study with investigational medicinal 
product(s). Participation in another clinical trial prior to study entry (before Visit 1)
that might have an impact on the study objectives.  
11. Close affiliation with the investigational site (eg, a close relative of the investigator), 
dependent person (eg, employee or student of investigational site, or sponsor’s staff) 
12. Inability to cooperate with the study procedures for any reason, including the 
following examples: language comprehension, psychiatric illness, inability to get to 
the study site, eDiary compliance 
13. Previous enrollment to the study (ie, rescreening is only allowed as described in 
Section 6.4.1)
Justification of selection criteria
6.3
The exclusion criteria are valid for known or suspected conditions and were chosen to ensure 
that subjects with specific risks for administration of the study drugs and/or subjects with 
conditions that may have an effect on the aims of the study are excluded.
Withdrawal of subjects from study
6.4
6.4.1
Withdrawal
No longer valid, since with the implementation of protocol amendment 5 (version 5.0) no 
subjects will start or continue treatment in this study. Originally, the criteria for 
withdrawal from the study or from the study treatment were the following:  
Withdrawal criteria
Subjects must be withdrawn from the study if any of the following occurs:
At their own request or at the request of their legally acceptable representative. At any 
time during the study and without giving reasons, a subject may decline to participate 
further.  The subject will not suffer any disadvantage as a result. 
At the specific request of the sponsor and in liaison with the investigator (eg, obvious 
non-compliance, safety concerns) 
Pregnancy 
Surgical treatment of uterine fibroids 
Subjects must be withdrawn from study treatment if any of the following occurs:

If, in the investigator's opinion, continuation of the study treatment would be harmful 
to the subject's well-being 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  31 of 113

GPT/ALT or GOT/AST >8 x ULN 

GPT/ALT or GOT/AST >5 x ULN for more than 2 weeks 

GPT/ALT or GOT/AST >3 x ULN and total bilirubin >2 x ULN or international 
normalized ratio (INR) >1.5 

GPT/ALT or GOT/AST >3 x ULN with the appearance of fatigue, nausea, vomiting, 
right upper abdominal quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)

Atypical hyperplasia, endometrial intraepithelial neoplasia (EIN) or malignant 
neoplasm 
Subjects may be withdrawn from study treatment if any of the inclusion criteria are no longer 
fulfilled or if any of the exclusion criteria apply during treatment.
Follow-up of subjects prematurely withdrawing from study treatment or during follow-
up
With the implementation of protocol amendment 5 (version 5.0), subjects who do not consent 
to the updated study design and the additional safety measures will be regarded as “dropouts”.
Screening failure
A subject who, for any reason (eg, failure to satisfy the selection criteria), terminates the study 
before randomization, is regarded a “screening failure”.  
Dropout
A subject who discontinues study participation prematurely for any reason (including subjects 
who do not consent to this protocol amendment which defines safety measures before study 
closure) is defined as a “dropout” if the subject has already been randomized.
Those subjects who were randomized but never started the study medication will not need to 
consent to the safety follow up, but will be handled as drop outs after having been informed 
about the study closure.
Contacting of treated subjects who already left the study
The investigator or designee must make every effort to regain contact with the subject (where 
possible, 3 telephone calls and, if necessary, a certified letter to the subject’s last known 
mailing address or local equivalent methods). These contact attempts should be documented 
in the subject’s source document.
General procedures
In all cases, the reason for withdrawal must be recorded in the electronic Case Report Form 
(eCRF) and in the subject's source documents. 
The subject may object to the generation and processing of post-withdrawal data as specified 
in Section 13.4.
Details for the premature termination of the study as a whole (or components thereof) are 
provided in Section 12.
6.4.2
Replacement
Dropouts will not be replaced. 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  32 of 113
Subject identification
6.5
At screening upon signing the informed consent form and registering the subject in the 
interactive voice/web response system (IVRS/IWRS), each subject was assigned a unique 
multi-digit SID number by the site for unambiguous identification. The SID number was
constructed as follows:

Digits 1 to 2:  unique country code 

Digits 3 to 5:  center code (unique within each country)

Digits 6 to 9:  unique subject code (unique within each center); 6th digit will be “3” for 
this ASTEROID 3 study
Once allocated, the SID number identified the subject throughout the study.
On random assignment to treatment, each subject was assigned a unique randomization 
number.
7.
Treatments
Instructions in Sections 7.1 to 7.4 are no longer valid, since with the implementation of 
protocol amendment 5 (version 5.0) no subjects will start or continue treatment in this 
study. 
Originally, the instructions in Sections 7.1 to 7.4 were the following:
Treatments to be administered
7.1
Eligible subjects will be randomized to one of the following treatment groups: 
A1:  vilaprisan (2 mg), 2 treatment periods of 12 weeks, separated by 1 bleeding episode 
A2: vilaprisan (2 mg), 2 treatment periods of 12 weeks without a break
B1:  placebo, 1 treatment period of 12 weeks, and vilaprisan (2 mg), 1 treatment period of 
12 weeks, separated by 1 bleeding episode
B2:  vilaprisan (2 mg), 1 treatment period of 12 weeks, and placebo, 1 treatment period of 
12 weeks, separated by 1 bleeding episode
Randomization will be 1:1:1:1 and stratified by country/region (US, China, and other 
countries) for Treatment Groups A1, A2, B1, and B2.
Each treatment period will consist of 12 weeks (84 days).  One tablet (oral) will be taken daily 
during the treatment periods.
The tablets should be taken at about the same time every day.  Exceptions to this rule may 
occur before visits with PK blood sampling (see Section 9.5.1).
Start of treatment
Treatment Period 1 for all subjects will start within Days 3 to 7 of the first bleeding episode 
following randomization visit. In case a bleeding episode is ongoing at randomization visit, 
the subject can already start with the intake of study medication during Days 3 to 7 of this 
bleeding episode.  A negative pregnancy test is a prerequisite for starting the study drug
(applies to both treatment periods except the start of Treatment Period 2 in Treatment Group 
A2).

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  33 of 113
In Treatment Groups A1, B1, and B2, Treatment Period 2 will start within Days 3 to 7 of the 
first bleeding episode following the end of the Treatment Period 1. If no bleeding episode 
occurs within 7 weeks after end of the previous treatment period, proceed with the induction 
of bleeding. 
For the start of treatment, subjects will judge based on their experience whether their bleeding 
episode has started. In case of unusual patterns (eg, start with some days of spotting) subjects 
should consult with the investigator.
For the statistical analysis, a bleeding episode is characterized by the following entries in the
Uterine Fibroid Daily Bleeding Diary (UF-DBD):

day(s) with bleeding / spotting of which at least one day is of intensity “mild” or 
higher 

preceded and followed by at least 2 bleed-free days (in case the first bleeding 
episode starts directly after Visit 1, the preceding 2 bleed-free days may not be 
recorded for this first bleeding episode).
Missed intake of study drug
If a subject misses a dose of study drug, she should take the tablet as soon as possible. If the 
dose of study drug was missed by more than 12 hours, she should not take the missed dose 
but simply resume the usual dosing schedule on the following day.
Diet
Subjects will be allowed to eat and drink as usual. However, grapefruit and grapefruit juice 
must be excluded from the subject's diet during treatment because these foods contain 
constituents that inhibit cytochrome P450 3A4.
Identity of study treatment
7.2
The investigational medicinal product vilaprisan and matching placebo are round immediate-
release tablets, 6 mm in diameter and coated with a dark red coat (see Table 7—1).

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  34 of 113
Table 7—1:  Identity of test drug/vilaprisan tablets and matching placebo
Sponsor’s substance code
BAY 1002670 
INN
Vilaprisan
Brand name
Not applicable
Formulation
Film-coated tablet
Tablet strength
2 mg 
Composition
Active ingredient: Vilaprisan micronized
Other ingredients:
Lactose monohydrate, microcrystalline cellulose, croscarmellose 
sodium, hydroxypropyl cellulose, magnesium stearate, dark red 
lacquer (containing hypromellose, macrogol 3350, talc, titanium 
dioxide, and red ferric oxide)
Packaging
28 tablets per package 
Marketing Authorization Holder
Not applicable
Sponsor’s substance code
Placebo (to BAY 1002670)
INN
Not applicable
Brand name
Not applicable
Formulation
Film-coated tablet
Tablet strength
Not applicable 
Composition
Ingredients:
Lactose monohydrate, microcrystalline cellulose, magnesium 
stearate, dark red lacquer (containing hypromellose, 
macrogol 3350, talc, titanium dioxide, and red ferric oxide)
Packaging
28 tablets per package 
Marketing Authorization Holder
Not applicable
INN = International nonproprietary name.
All study drugs will be labeled according to the requirements of local law and legislation.  
Label text will be approved according to the sponsor’s agreed procedures, and a copy of the 
labels will be made available to the study site upon request.
For all study drugs, a system of numbering in accordance with all requirements of Good 
Manufacturing Practice (GMP) will be used, ensuring that each dose of study drug can be 
traced back to the respective bulk batch of the ingredients.  Lists linking all numbering levels 
will be maintained by the sponsor’s clinical supplies QA group. 
A complete record of batch numbers and expiry dates of all study treatment as well as the 
labels will be maintained in the sponsor’s study file.
Study drugs need to be stored in accordance with the label text.
Treatment assignment
7.3
At Visit 3 (randomization), eligible subjects will be randomized via the IVRS/IWRS to one of 
the treatment groups (see Section 7.1).
The site will receive confirmation on the completion of the randomization procedure from the 
IVRS/IWRS.  The confirmation will be considered as source documentation and should be 
maintained in the subject files.  For additional details, refer to the separate IVRS/IWRS
instructions.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  35 of 113
Dosage and administration
7.4
See Section 7.1 for administration details.
Blinding
7.5
Forward looking instructions regarding blinding are no longer valid, since with the 
implementation of protocol amendment 5 (version 5.0) no subjects will start or continue 
treatment in this study. However, for the subjects randomized in this study before the 
temporary pause, the blinding will be maintained until database lock.
7.5.1
Blinding measures
Vilaprisan tablets and respective placebo tablets are identical in appearance (size, shape, 
color).  The packaging and labeling will be designed to maintain the blinding of the 
investigator’s team and the subjects for Treatment Groups A1, B1, and B2. Treatment Group 
A2 is open-label because the subjects and the investigators will know the treatment regimen 
since there is no break between the treatment periods.
The study data will remain blinded in the blinded treatment arms until database lock and 
authorization of data release according to Sponsor’s standard operating procedures.
7.5.2
Unblinding
In compliance with applicable regulations, in the event of a suspected, unexpected serious 
adverse reaction (SUSAR) (see Section 9.6.1.5) related to the blinded treatment, the subject’s 
treatment code will usually be unblinded by the sponsor’s Pharmacovigilance department 
before reporting to the health authorities. Notifications of the ethics committees and 
investigators will be done according to all applicable regulations (see Section 9.6.1.4).
Study responsible PK and bioanalytical personnel will remain unblinded.
7.5.3
Emergency unblinding by the investigator
In case of emergency or any finding that requires unblinding, the investigator can break the 
blind for an individual subject via IVRS/IWRS consistent with the unblinding instructions 
provided.  This will allow breaking the blind for an individual subject without impairing the 
study as a whole, unless safety findings required unblinding.
If it becomes necessary to know the individual treatment during the study and thus to break 
the code for that subject, the date, and reason are to be recorded in the relevant eCRF page.  
The investigator is required to promptly document and explain to the sponsor any premature 
unblinding (eg, unblinding because of a serious adverse event [SAE]) of the study drug. In 
case of unblinding, the subject will not be automatically withdrawn from study treatment.
Drug logistics and accountability
7.6
No longer valid, since with the implementation of protocol amendment 5 (version 5.0) no 
subjects will start or continue treatment in this study and therefore no study medication 
will be newly distributed. All unused study drug should have been returned during the 
temporary pause and this should have been documented in the drug accountability 
section of the eCRF and on the appropriate drug dispensing form by the investigator or 
designee.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  36 of 113
Receipt, distribution, return and destruction (if any) of the study drug must be properly 
documented according to the sponsor’s agreed and specified procedures.
Written instructions on medication destruction will be made available to affected parties as 
applicable.
Treatment compliance
7.7
To monitor compliance, the subjects were required to complete an electronic Diary (eDiary) 
daily throughout the study.  The date of each study drug intake was tracked via the eDiary.  
The eDiary was dispensed at Visit 1 and the completeness of the eDiary data reviewed by the 
investigator or designee regularly between the visits, and together with the subject at every 
visit.
8.
Non-study therapy
Prior and concomitant therapy
8.1
All concomitant medications administered after signing of informed consent until the 
completion of study participation8, including topical (eg, vaginal) preparations and over the 
counter drugs are to be recorded in the eCRF (trade name, dose, unit, frequency, route, start
and stop dates, and indication). This applies with specific focus for medications that could 
interfere with the testing of adrenal parameters. 
Restrictions regarding forbidden concomitant medications were valid before and during the 
treatment phase of this study, but were lifted during the treatment-free safety FUP phase that 
started during the temporary pause and continues with amendment 5 (version 5.0). Please see 
also Section 6.2.
Subjects who withdrew from study drug and subjects who withdrew during FUP were asked 
to not take hormonal treatments before the first menstruation after end of treatment (EoT) was 
completed and the EoT biopsy was performed.
Surgical and interventional treatment for fibroids must be documented in the eCRF if 
performed during the study period (ie, until the last visit of the subject) and should be 
regarded as AE if deemed appropriate by the investigator (see Section 9.6.1.1).
Reasonable efforts should be undertaken to capture such interventions also in subjects who 
had already left the study and are now returning.
8.1.1
Iron supplementation
In subjects with hemoglobin 10.9 g/dL in blood, iron supplementation should be offered in a 
standardized regimen (see Section 9.7.1) consistent with local standards of practice and at the 
investigator’s discretion. Iron supplementation will not be considered a study medication and 
will be documented as concomitant medication.  
                                                
8 In subjects who have completed or discontinued the study before or during the temporary pause, who are asked 
to participate in the safety evaluation, the concomitant medication used during the off study period until re-
consenting to this protocol amendment should also be recorded in the eCRF.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  37 of 113
8.1.2
Progestin therapy for induction of bleeding
If required, subjects were given an appropriate progestin therapy for induction of bleeding. 
Progestin therapy will not be considered as study medication and will be documented as 
concomitant medication.
Post-study therapy
8.2
Before the temporary pause, it was foreseen that subjects completing the treatment periods  
will participate in the post treatment FUP without drug treatment. According to the rules of 
the temporary pause, subjects were required to not start any new treatment period and thereby 
those subjects entered a study drug free FUP phase if they agreed to remain in the study.
Subjects completing the treatment periods will participate in the post-treatment FUP without 
study drug treatment. 
At the individual end of study, the investigator will decide in consultation with each subject 
which treatment is further required and will choose from available treatment options. 
After completion of study the subjects will not be given free access to study drug, since 
alternative treatment options are available.
9.
Procedures and variables
Tabular schedule of evaluations
9.1
No longer valid, since with the implementation of protocol amendment 5 (version 5.0) no 
subjects will be recruited and none of the enrolled subjects will receive further study 
drug treatment. All subjects who were randomized and started treatment before the 
temporary pause will be asked to have the comprehensive safety evaluation (with 
particular focus on endometrial, adrenal and skin safety) performed. This also applies to
subjects who have completed or discontinued the study before or during the temporary 
pause, provided they have taken at least one dose of study medication. All these subjects 
are asked to come to the site for the “Safety closeout visit” which is implemented with 
amendment 5 (version 5.0). The second scheduled visit, the “Safety result reporting 
visit” can be done as a telephone visit.
This “Safety closeout visit” should be performed in all subjects as soon as possible after 
implementation of amendment 5 (version 5.0). The following procedures are to be done:

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  38 of 113
Table 9–1: Schedule of procedures
Visit
Safety closeout visit a
Safety result 
reporting visit
(can be a telephone 
visit)
Timing
After implementation of protocol
amendment 5 (version 5.0)
Once all safety results 
are available
Informed consent
X
Concomitant medications
→
→
AE assessments
→
→
Adrenal disorder signs and symptoms
incl. vital signs b
X
MRI of adrenal glands c
X
Dispense saliva test tubes d
X
Collect saliva test tubes
X
Referral to dermatology expert
X
Physical examination
X
Body weight
X
Gynecological/breast exam e
X
Urine pregnancy test
X
Cervical smear f
X
Ultrasound examination g
X
Endometrial biopsy h
X
Laboratory (blood) i
X
Collection of unused study drug and empty 
drug packs/drug accountability
X
if applicable
Collection of eDiary device and review of 
bleeding data for unusual bleeding pattern
X
if applicable
Deactivation of the subject on the tablet 
computer without selecting a particular visit 
X
Communication of results from safety 
evaluations to the subject
X
a.
In most cases the procedures scheduled for this visit will not take place on the same day
b.
Blood pressure in triplicates and heart rate after 5 minutes of rest in a sitting position
c.
Negative pregnancy test is a prerequisite
d.
Saliva tests should be performed as soon as possible after dispense, to allow for a repeat in case of 
unevaluable results or for review by one of the adrenal experts in case of abnormal results. Saliva test tubes 
should be returned to site on the next day after samples have been taken on two consecutive days.
e.
Only to be performed if subject did not have these performed with normal result after end of treatment
f.
Only to be performed if subject did not have this performed with normal or clinically insignificant result after 
end of treatment
g.
The ultrasound must be done before the biopsy
h.
Negative pregnancy test is a prerequisite. Only to be performed in subjects who did not have a post-
treatment endometrial biopsy (defined as biopsy taken at the earliest 7 days before last study drug intake) 
with a normal result. This is defined as diagnosis of safety read and of all 3 individual components of the 
multiread to be “benign endometrium” in Part II of the evaluation form. In addition, the majority diagnosis 
needs to be “PAEC no” in Part IV of the evaluation form. Furthermore, an endometrial biopsy may also be 
triggered by results of ultrasound examination or bleeding data (see Section 9.6.3.2.8). The biopsy CRF page 
needs to be completed for all subjects, including cases where according to protocol no biopsy is required. For 
subjects with menstrual cycles the endometrial biopsy should be taken between Day 7 to 15 (inclusive) of a 
menstrual cycle.
i.
In subjects who take biotin, the last dose of biotin should be at least 72 hours prior to hormone testing.
AE = adverse event, MRI = magnetic resonance imaging, PAEC = progesterone receptor modulator-associated 
endometrial changes

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  39 of 113
Visit description
9.2
No longer valid, since with the implementation of protocol amendment 5 (version 5.0) all 
subjects will need to come to the site for the safety closeout visit. In most cases the 
procedures scheduled for this visit will not take place on the same day.
The second scheduled visit, the “Safety result reporting visit” can be done as a telephone 
visit. During this visit the subject will be informed about the results of the safety 
investigations. In case follow-up assessments are required, these should be documented as 
unscheduled assessments.
9.2.1
Unscheduled visits
If deemed necessary for an individual subject, the investigator or designee, at his/her 
discretion, may arrange visits in addition to the scheduled study visits. A possible reason for 
unscheduled visits would be the requirement for follow up investigations.
9.2.2
Optional pre-screening phone contact
No longer valid, since with the implementation of protocol amendment 5 (version 5.0) no 
new subjects will be recruited.
9.2.3
Scheduled visits
With the implementation of protocol amendment 5 (version 5.0) all subjects who took at 
least one dose of study medication will need to come to the site for the safety closeout
visit. For details regarding this safety closeout visit please see Section 9.1. The second 
scheduled visit, the “Safety result reporting visit” can be done as a telephone visit.
Population characteristics
9.3
With implementation of protocol amendment 5 (version 5.0) no new subjects will be 
recruited. This section describes the data collection performed in subjects enrolled 
before the temporary pause.
9.3.1
Demographic
Demographic data (eg, year of birth, age at Visit 1, race, ethnic group, educational level) and 
other population characteristics including smoking habits and alcohol consumption were
collected consistent with the original schedule of procedures in protocol amendment 3
(version 3.0).
9.3.2
Medical history
Medical history findings (ie, previous diagnoses, diseases or surgeries) meeting all criteria 
listed below were collected as available to the investigator:

Not pertaining to the study indication

Start before signing of the informed consent 

Considered relevant for the subject’s study eligibility
Any condition that was stabilized by medication at the time of signing the informed consent 
should also be documented in the eCRF.  The medication being used had to be recorded in the 
prior and concomitant medication eCRF.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  40 of 113
All new or worsened findings after signing the informed consent had to be documented on the 
Adverse Event (AE) eCRF.
Detailed instructions on the differentiation between medical history and AEs can be found in 
Section 9.6.1.1.
9.3.3
Reproductive, menstrual, and fibroids history
Reproductive and menstrual history includes information on menarche, births, other 
pregnancies, and inability to conceive.
Fibroids history includes information on family history, onset of symptoms, diagnosis, and 
previous medical treatments and procedures, if applicable.
9.3.4
Heavy menstrual bleeding questions
This set of questions has been developed as a tool to identify women with HMB.  It could 
have been used at Visit 1 and the responses could have been entered directly into electronic 
data capturing system RAVE, which is considered as primary source data. The questionnaire 
could also have been used as a pre-screening tool.  Print outs of the questionnaire were
provided to the sites as needed.
Efficacy
9.4
This section details the procedures for collecting efficacy variables. A concise listing of 
efficacy variables as collected before the temporary pause is given in Section 10.3.1.  The 
complete list of variables to be analyzed for this study will be provided in the Statistical 
Analysis Plan (SAP).
9.4.1
Alkaline hematin method to assess HMB
This section was changed in Amendment 2, see Section 15.1.1
During the duration of the study, subjects were required to use selected types of sanitary 
products provided (pads and/or tampons). During the entire duration of the study, subjects 
were to collect their used sanitary products and return them to the study site as soon as the 
bleeding episode was completed to be sent to the central laboratory for analysis.
The AH method is applied to measure MBL from Screening onwards during the entire study. 
The AH method measures hemoglobin in a fixed amount of alkaline solution with the use of a 
spectrophotometer (2). The fixed amount of solution is taken from the solution pool in which 
the materials (ie, used sanitary protection) to be tested have been macerated for hemoglobin 
extraction.  The blood loss volume was to be reported by day and bleeding episode. This test 
was performed at the central laboratory.  For details refer to the laboratory manual.
9.4.2
Ultrasound (efficacy) to assess uterine fibroids
This section was changed in Amendment 2, see Section 15.1.1
If possible, the same examiner should have conducted all ultrasound examinations of a subject 
throughout the study and the same ultrasound machine (per site) should have been used 
throughout the study.  For each subject, the most appropriate ultrasound method (transvaginal, 
abdominal or transrectal) had to be used depending on fibroid location and this method should 
have been used consistently throughout the study. 
Ultrasound examinations were to be performed consistent with the original schedule of 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  41 of 113
procedures. The 3 largest fibroids were to be identified during the screening period.  The 
largest transverse, longitudinal, and antero-posterior diameters of these 3 fibroids were to be 
documented at each efficacy ultrasound examination for volume calculation.
The dimensions of the uterus were also to be documented at the same time points.  This is of 
particular importance in subjects with multiple small fibroids.
The minimum source documentation included electronic or paper documentation from the 
ultrasound machine showing the 3 largest fibroids. The printouts had to be labeled 
unambiguously, containing at least the study number, SID number, time point, and longest 
diameter of 3 largest fibroids. It is also possible that the site has a CD with the ultrasound 
images available, when in the source the evaluation of the ultrasound images from the CD is 
available as well. The CRA has to be able to review the data on the CD and compare the 
images with the evaluations in the source during the onsite monitoring visits.
Furthermore, if the ultrasound machine is SESAC (Site Electronic Source Assessment
Checklist) conform, ie, GCP conform electronic data storage is possible, then no print out is 
needed.
For safety ultrasound procedures, see Section 9.6.3.6.
Pharmacokinetics / pharmacodynamics
9.5
With the implementation of protocol amendment 5 (version 5.0) no new subjects will be 
recruited and no study medication will be given to the subjects who have been enrolled 
in the study. This section describes processes performed in subjects enrolled before the 
temporary pause.
9.5.1
Drug measurements
Blood samples for measurement of vilaprisan in plasma for PK were to be collected at the 
time points given in the original schedule of procedures. At Visit 5, the PK sample was to be 
taken predose.  At Visit 6, 3 PK samples were to be taken.  The first sample was to be taken
before intake of study drug.  After the predose sample was taken at Visits 5 and 6, the subject 
should have taken her study drug under supervision at the site.  The second sample at Visit 6 
was to be taken 0.5 to 1 hour after drug intake and the third sample was to be taken 2 to 4 
hours after drug intake.  The date and time of the last 2 doses of the study drug prior to the 
first PK sample at Visits 5 and 6, the time of the supervised drug intake at the study site, and 
the time of all blood samples had to be documented in the eCRF.  
If, for any reason, PK samples were taken outside of the pre-specified time window, the exact 
time that the sample was taken have been recorded and not the time of the time window.  
These time deviations were not to be considered as important deviations.
In China, samples were to be collected in some centers only, to achieve a minimum of least 30 
Chinese subjects.
If a subject discontinued study treatment permanently, no blood sampling for PK was
required. Pharmacokinetic analyses are based on a population modeling approach (see 
Section 9.5.2). Blood samples are considered valid for the population PK analysis under the 
following conditions:
1) The dose amount and time of drug intake prior to the blood sample is known
2) The time of the blood sample collection is known.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  42 of 113
The samples were to be collected and processed as described in detail in the respective 
Sample Handling Sheets as a part of a separate Laboratory manual. 
Plasma concentrations of vilaprisan are determined using a validated liquid chromatography-
tandem mass spectrometry (LC-MS/MS). Quality control (QC) and calibration samples are
analyzed concurrently with study samples. The results of calibration samples, QC samples, 
and study samples will be reported in the Bioanalytical Reports, which will be included in the 
Clinical Study Report for this study. A re-opening of the database may become necessary in 
order to include the results of the PK measurements.
The bioanalyst will be unblinded for analysis of study samples. Placebo samples will not be
analyzed.
9.5.2
Population pharmacokinetic analysis of vilaprisan
Based on the plasma concentrations, the variability in vilaprisan PK will be analyzed using
population PK modeling. This analysis might start prior to database lock (eg, at the moment 
that approximately 80% of the expected PK samples have been measured).  Appropriate 
measures will be taken to maintain blinding of the study team (eg, data access will be 
restricted to specific people involved in the analysis and members of the study team will 
neither have access to the randomization list nor to individual data). The measures will be 
described in a Data Operations Plan, which will be provided to the study manager for 
adequate documentation.   
Population or nonlinear mixed effects PK models describe the relationship between dose, 
time, and the vilaprisan plasma drug concentration. A previously developed population PK 
model for vilaprisan based on Phase 1 and 2 data will be applied to all valid PK samples to 
evaluate the relationship between variability in PK and covariates,(ie, intrinsic [eg, body 
weight, race] and extrinsic factors [eg, concomitant medication]) that are of clinical relevance.
If necessary, the population PK model will be adapted to adequately fit the data.  Individual 
PK parameters of vilaprisan will be calculated.  A separate Modeling and Simulation (M&S) 
Plan, providing details of the model development and evaluation will be provided before the 
start of the population PK analysis.  Evaluation of the data will be presented in a separate 
M&S Report.
9.5.3
Pharmacokinetic/pharmacodynamic relationship of vilaprisan
Optionally, a population PK/PD model could be used to describe the effect of vilaprisan 
exposure on PD data related to efficacy and safety such as bleeding intensity and endocrine 
hormone levels. The final population PK model that will be applied to describe the PK of 
vilaprisan in the study population as outlined in Section 9.5.2 will be linked to relevant PD 
parameters (eg, fibroid size, uterus size, endocrine hormone levels, and bleeding) obtained in 
this study to investigate the relationship between vilaprisan exposure and response.  Details of 
the model development and evaluation, if conducted, will be described in a separate M&S 
Analysis Plan and the results reported in a separate M&S Report.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  43 of 113
Safety
9.6
9.6.1
Adverse events
Definitions
9.6.1.1
Definition of AE
This section was changed in Amendment 2, see Section 15.1.1
In a clinical study, an AE is any untoward medical occurrence (ie, any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or 
clinical investigation subject after providing written informed consent for participation in the 
study.  Therefore, an AE may or may not be temporally or causally associated with the use of 
a medicinal (investigational) product. Treatment emergent adverse event (TEAE) is defined as 
any event that occurred after the first study drug intake until the end of FUP.
A surgical procedure that was planned prior to the start of the study by any physician treating 
the subject should not be recorded as an AE (however, the condition for which the surgery is 
required may be an AE).
In the following differentiation between medical history and AEs, the term “condition” may 
include abnormal eg, physical examination findings, symptoms, diseases, and laboratory
findings.

Conditions that started before signing of the initial informed consent and for which no 
symptoms or treatment are present until signing of informed consent are recorded as 
medical history (eg, seasonal allergy without acute complaints).

Conditions that started before signing of the initial informed consent and for which 
symptoms or treatment are present after signing of informed consent, at unchanged 
intensity, are recorded as medical history (eg, allergic pollinosis).

Conditions that started or deteriorated after signing of informed consent will be 
documented as AEs. This includes intercurrent illnesses (eg, increase in occurrences 
and/or severity of symptoms for seasonal allergy or allergic pollinosis).  

In subjects who completed or discontinued before or during the temporary pause and 
now get reconsented conditions that newly occurred or worsened during the off-study 
period should be documented as AEs.
Definition of SAE
An SAE is classified as any untoward medical occurrence that, at any dose, meets any of the 
following criteria (a – f):
a.
Results in death
b. Is life-threatening
The term ‘life-threatening’ in the definition refers to an event in which the subject was 
at risk of death at the time of the event, it does not refer to an event which 
hypothetically might have caused death if it were more severe.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  44 of 113
c.
Requires inpatient hospitalization or prolongation of existing hospitalization 
A hospitalization or prolongation of hospitalization will not be regarded as an SAE if 
at least one of the following exceptions is met:
- The admission results in a hospital stay of less than 12 hours
- The admission is pre-planned (eg, elective or scheduled surgery arranged prior to 
the start of the study)
- The admission is not associated with an AE (eg, social hospitalization for purposes 
of respite care).
However, it should be noted that invasive treatment during any hospitalization may fulfill the 
criterion of ‘medically important’ and as such may be reportable as an SAE dependent on 
clinical judgment.  In addition, where local regulatory authorities specifically require a more 
stringent definition, the local regulation takes precedence. Any fibroid surgery should always 
be reported as SAE, irrespective of associated hospitalization.
d. Results in persistent or significant disability / incapacity
Disability means a substantial disruption of a person’s ability to conduct normal life’s 
functions.
e.
Is a congenital anomaly / birth defect
f.
Is another serious or important medical event as judged by the investigator and/or as 
defined below
All instances of liver parameter testing which meet the criteria for withdrawal defined in the 
original study protocol (see section 6.4.1) of a subject from the study should be reported as 
SAEs.
Endometrial biopsies with a safety read diagnosis of “simple or complex atypical hyperplasia” 
(according to WHO 1994 criteria) or “EIN” (according to WHO 2014 criteria) (3) or with a 
diagnosis of “malignant neoplasm” (“endometrial” or “other”) should be reported as a serious 
adverse event. The subsequent multi-reader assessment should trigger a follow-up report and 
an update of the diagnosis should be considered, if the majority assessment is different from 
the initial safety read diagnosis.
Endometrial biopsies with a majority diagnosis based on the multi-reader assessment of 
“simple or complex atypical hyperplasia” (according to WHO 1994 criteria) or “EIN” 
(according to WHO 2014 criteria) or in a diagnosis of “malignant neoplasm” (“endometrial” 
or “other”) should be reported as a serious adverse event or trigger an update of the respective 
initial SAE report. 
An adrenal tumor needs to be reported as an SAE.
Any dermatology expert´s diagnosis of a malignant skin lesion, including cutaneous sarcoma 
confirmed by biopsy diagnosis, needs to be reported as an SAE.
The following types of events are excluded from SAE reporting:

Elective abortion is considered as an ‘abnormal pregnancy outcome’ but is not 
considered an SAE.  (However, abortions are to be documented as SAEs if they match 
one of the following terms:  spontaneous abortion, missed abortion, infected abortion, 
or abortion induced incomplete.  If no specification for the abortion is available, then 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  45 of 113
one of these categories is assumed to have occurred and the ‘abortion’ is regarded as 
serious and must be recorded as an SAE.)

Hospitalizations for the evaluation or treatment of pre-existing conditions that do not 
worsen in severity or frequency during the subject’s participation in the study.  Such 
conditions must have been present before the subject’s participation in the study and 
reported as such in the corresponding eCRF.

Elective surgery performed for cosmetic reasons or because of pre-existing conditions
as defined in Section 9.3.2.
Important medical event:  Any AE may be considered serious because it may jeopardize the 
subject and may require intervention to prevent another serious condition.  As guidance for
determination of important medical events, refer to the “World Health Organization (WHO) 
Adverse Reaction Terminology – Critical Terms List”.  These terms either refer to or might 
be indicative of a serious disease state.  Such reported events warrant special attention 
because of their possible association with a serious disease state and may lead to more 
decisive action than reports on other terms.
Classifications for AE assessment
9.6.1.2
All AEs will be assessed and documented by the investigator according to the categories 
detailed below.  
9.6.1.2.1
Seriousness
For each AE, the seriousness must be determined according to the criteria given in 
Section 9.6.1.1.
9.6.1.2.2
Intensity
The intensity of an AE is classified according to the following categories:
-
Mild
-
Moderate
- Severe
9.6.1.2.3
Causal relationship 
The assessment of the causal relationship between an AE and the administration of treatment 
is a decision to be made by the investigator, who is a qualified physician, based on all 
information available at the time of the completion of the eCRF.
The assessment is based on the question whether there was a “reasonable causal relationship” 
to the study treatment in question.
Possible answers are “yes” or “no”

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  46 of 113
An assessment of “no” would include:
1. The existence of a highly likely alternative explanation, eg, mechanical bleeding at 
surgical site.
or
2. Non-plausibility, eg, the subject is struck by an automobile when there is no indication 
that the drug caused disorientation that may have caused the event; cancer developing 
a few days after the first drug administration.
An assessment of “yes” indicates that the AE is reasonably associated with the use of the 
study treatment.
Important factors to be considered in assessing the relationship of the AE to study treatment 
include:
- The temporal sequence from drug administration:  The event should occur after the drug 
is given.  The length of time from drug exposure to event should be evaluated in the 
clinical context of the event.
- Recovery on drug discontinuation (de-challenge), recurrence on drug re-introduction 
(re-challenge):  subject’s response after de-challenge or re-challenge should be 
considered in view of the usual clinical course of the event in question.
- Underlying, concomitant, intercurrent diseases:  Each event should be evaluated in the 
context of the natural history and course of the disease being treated and any other 
disease the subject may have.
- Concomitant medication or treatment: The other drugs the subject is taking or the 
treatment the subject receives should be examined to determine whether any of them 
might have caused the event in question.
-
Known response pattern for this class of drug: Clinical/preclinical
- The pharmacology and PK of the study treatment: The PK properties (absorption, 
distribution, metabolism and excretion) of the study treatment, coupled with the 
individual subject’s pharmacodynamics should be considered.
Causal relationship to protocol-required procedure(s)
The assessment of a possible causal relationship between the AE and protocol-required 
procedure(s) is based on the question whether there was a “reasonable causal relationship” to 
protocol-required procedure(s).
Possible answers are “yes” or “no”
9.6.1.2.4
Action taken with study treatment 
Any action on study treatment to resolve the AE is to be documented using the categories 
listed below.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  47 of 113
The study treatment action should be recorded as detailed in the eCRF.
- Drug withdrawn
- Drug interrupted
- Dose not changed
- Not applicable
- Unknown
9.6.1.2.5
Other specific treatment(s) of AEs
- None
- Remedial drug therapy
- Other
9.6.1.2.6
Outcome
The outcome of the AE is to be documented as follows: 
- Recovered/resolved
- Recovering/resolving
- Recovered/resolved with sequelae
- Not recovered/not resolved
- Fatal
- Unknown
Assessments and documentation of AEs
9.6.1.3
Attention is to be paid to the occurrence of AEs at all stages of the examination.  Thus, the 
subject should be closely observed by the investigator.
AEs observed, mentioned on open questioning by a member of the investigator team or 
spontaneously reported by the subject will be documented.  The observation period for AEs 
will start with signing of the informed consent, and will end with the last visit. After the 
Safety result reporting visit there is no requirement to actively collect new AEs.
The outcome of recorded non-serious AEs should be followed up between the signing of the 
informed consent and the end of the FUP phase. For adverse events of special safety interest 
efforts should be made to follow them up until resolution or stabilization (even after the 
Safety result reporting visit, if applicable).
The investigator is responsible for the grading of each category listed in Section 9.6.1.2.  An 
assessment of the seriousness of the event will be made by the investigator using the 
electronic reporting tool in RAVE.  However, SAEs will also be recorded on the AE page of 
the eCRF.
For all SAEs the sponsor has to carry out a separate assessment for expectedness, seriousness 
and causal relationship to study drug.
“Death” should not be recorded as an AE on the AE page.  Instead, “death” is the outcome of 
underlying AE(s).
For details on monitoring algorithms see Section 9.7.2.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  48 of 113
Reporting of SAEs
9.6.1.4
The definition of SAEs is given in Section 9.6.1.1.  Each SAE must be followed up until 
resolution or stabilization by submission of updated reports to the designated recipient.
Investigator’s notification of the sponsor
All investigators will be thoroughly instructed and trained on all relevant aspects of the 
investigator’s reporting obligations for SAEs.  This information, including all relevant contact 
details, is summarized in the investigator site file.  This information will be updated as 
needed.
The investigator must report immediately (within 24 hours of the investigator’s awareness) all 
SAEs occurring during the observation period defined in Section 9.6.1.3 using the electronic 
reporting tool in RAVE (see Section 11) according to the detailed instructions for SAE 
reporting included in the Investigator File. 
SAEs occurring after the protocol-defined observation period will be processed by the 
sponsor according to all applicable regulations.
Notification of the Independent Ethics Committees/Institutional Review Boards
Notification of the Independent Ethics Committees (IECs)/Institutional Review Boards
(IRBs) about all relevant events (eg, SAEs, SUSARs) will be performed by the sponsor and/or 
by the investigator according to all applicable regulations.
Notification of the authorities
The processing and reporting of all relevant events (eg, SAEs, SUSARs) to the authorities 
will be done by the sponsor according to all applicable regulations.
Sponsor’s notification of the investigational site
The sponsor will inform all investigational sites about reported relevant events (eg, SUSARs) 
according to all applicable regulations.
Expected AEs
9.6.1.5
For this study, the applicable reference document is the most current version of the IB.
Overview listings of frequent events that have occurred so far in the clinical development are 
shown in the current IB.  If relevant new safety information is identified, the information will 
be integrated into an update of the IB and distributed to all participating sites.
The expectedness of AEs will be determined by the sponsor according to the applicable 
reference document and according to all local regulations.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  49 of 113
Adverse events of special safety interest
9.6.1.6
The investigators will assess all AEs to determine if they are AEs of special interest (AESIs)
and document this in the eCRF. Adverse events from the following areas should be 
considered for reporting as AESI according to the following guidance: 

HMB (especially after EoT) should be recorded as an AE (and then it 
automatically qualifies as an AESI) only if one or more of the following applies:

Leads to study discontinuation

Leads to diagnostic procedures

Requires any treatment

Shows a clinically significant worsening during the study that, in the judg-
ment of the investigator, is not consistent with the expected clinical course

Meets any seriousness criterion and is to be recorded as an SAE.
HMB will be documented in detail throughout the study (see Section 9.7.3).

Liver disorders:

For all cases which qualified for “close observation” before implementation
of amendment amendment 5 (version 5.0) and/or qualify for “ruling out of 
alternative cause” after approval of amendment 5 (version 5.0) (see Section
9.6.3.9), the underlying event should be recorded as AESI in the AE eCRF.

Endometrial disorders:

Endometrial hyperplasia (all subcategories according to WHO 2014 [and 
WHO 1994] classification), for monitoring and FUP see Section 9.6.3.2

Endometrial thickening >18 mm: If endometrial thickness (double layer) 
18 mm is detected after the start of treatment, the subject should undergo 
immediate evaluation by endometrial biopsy as described in Section 9.7.4.

Skin disorders:

Any dermatology expert´s diagnosis of a pre-cancerous or malignant skin 
lesion, including cutaneous sarcoma confirmed by biopsy diagnosis, qualify 
as an AESI. Malignant skin lesions should be reported as an SAE to ensure 
timely reporting to regulatory agencies.

Adrenal disorders

A robust adrenal safety monitoring program has been implemented in all 
ongoing vilaprisan studies, including MRI of the adrenal glands, laboratory 
parameters, and evaluation of signs and symptoms indicative of adrenal 
disorder. A systematic approach of assessment and evaluation of adrenal 
gland findings will be applied as described in Section 9.6.3.8. Any adrenal 
abnormality assessed as relevant by either the adrenal gland expert or the 
local specialist will need to be documented as an AESI and to be reported 
to the sponsor’s pharmacovigilance department following the same 
standard process (reporting timelines, AE CRF and AE complementary 
pages) as serious AE. Tumors of the adrenal glands (diagnosed by the MRI 
central read, the adrenal gland expert or the local specialist) should in 
addition be reported as SAEs to ensure timely reporting to regulatory 
agencies.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  50 of 113
Progesterone receptor modulator-associated endometrial changes (PAEC) will 
be assessed and documented in a systematic way (see Section 9.6.3.2.5). The 
results of the PAEC assessment will only be reported back to the investigators if 
they trigger the request for a repeat biopsy. Apart from cases where such a repeat 
biopsy is necessary, no clinical action for an individual subject is required based 
on the PAEC assessment results. PAEC assessment results are systematically 
collected for all samples and will be reported in aggregated form at the end of 
the study. They should therefore not be reported as AE for an individual subject.  
A systematic approach of assessment and evaluation will also be applied to HMB (see Section
9.7.3), endometrial hyperplasia and endometrial thickening (see Sections 9.7.2 and 9.7.4), and 
liver parameters.  
9.6.2
Pregnancies
An acceptable nonhormonal contraceptive method has to be used starting at Screening Visit 1 
and continued until the end of the study.  Barrier contraception (eg, condoms with spermicide)
will be dispensed as required by the subject. This is not required if contraception is achieved 
by a permanent method such as bilateral fallopian tube blockage (including Essure) of the 
subject or vasectomy of her partner(s). 
Pregnancy tests were to be performed at site visits and at home before the start of study drug 
in each treatment period.  Home pregnancy tests should also have been performed in case the 
subject was concerned about being pregnant.  All home pregnancy tests were to be 
documented in the eDiary.  In case of a positive pregnancy test, study drug had to be 
discontinued and the investigator had to be informed immediately.
Any planned pregnancy should be postponed until the end of the study. This was to be 
discussed with the subject at screening. If an investigator became aware that a subject wished
to conceive or planned an insemination directly after EoT (thereby deviating from study 
protocol), subject should have been made aware that she is participating in a clinical study 
with a new drug in early clinical development. Therefore she should preferably have 
completed the FUP phase (including endometrial biopsy) or should at least wait for 3 
months/2 menstrual cycles after discontinuation of study drug treatment due to unknown 
effect of the study drug on the human embryo.
In subjects who are currently pregnant or lactating, timing of the safety evaluations required 
in the context of the safety closeout visit should be decided case by case.
Pregnancies occurring during the study
The sponsor will closely monitor the occurrence of unintended pregnancies (based on the 
expedited reporting of pregnancies by the investigators) throughout the study.  If a pregnancy 
was detected before initiation of study drug, the subject was not to be enrolled into the study 
(see Section 6.2).
The investigator must report to the sponsor any pregnancy occurring in a study subject during 
the subject’s participation in this study.  The report should be submitted within the same 
timelines as an SAE (ie, no later than 24 hours of having gained knowledge of the event; see 
Section 9.6.1.4), although a pregnancy per se is not considered an AE or SAE.  The subject 
was instructed to contact the study site immediately if a pregnancy is suspected or detected.  
In such a case, an unscheduled visit should be arranged for the subject as soon as possible and 
the investigator or designee should confirm the pregnancy by a valid method (eg, ultrasound, 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  51 of 113
serum human chorionic gonadotropin [-HCG] test).  If such confirmation cannot be achieved 
within 24 hours of the subject contacting the study center, the investigator must still report 
the pregnancy to the sponsor and then follow-up with information once confirmation has been 
obtained.  A pregnancy will be reported on the forms provided by the sponsor.  The 
investigator is required to document the date of confirmatory testing, whether the pregnancy 
was confirmed, the estimated date of conception, and the location of the pregnancy
implantation at time of diagnosis. 
The investigator is required to provide any additional information (eg, early termination) as 
soon as it becomes available.
All pregnancies occurring during the treatment and follow-up periods will be followed for the 
outcome for both the mother and fetus/child (in case of a life birth) until first birthday of the 
child.  The outcome will be documented on a pregnancy outcome form and a follow-up report 
is requested upon the first birthday of the child.
Any abnormal outcome of the mother or the child should also be reported as an SAE (eg,
spontaneous abortion, preterm birth, elective abortion triggered by medical concern).
For details on elective abortions, refer to Section 9.6.1.1.
For all reports, the forms provided are to be used.  
9.6.3
Further safety
Laboratory evaluations
9.6.3.1
This section was changed in Amendment 2, see Section 15.1.1
Only blood samples analyzed at the central laboratory will be considered for analysis.  The 
name and address for the central lab service provider can be found in the documentation 
supplied by the vendor.  
The following parameters will be assessed at the safety closeout visit in subjects who 
remained in the study during the temporary pause:
Hematology:  leukocytes, erythrocytes, hematocrit, mean corpuscular volume (MCV), mean 
corpuscular hemoglobin (MCH), platelets, neutrophils, eosinophils, basophils, lymphocytes, 
and monocytes.
Hemoglobin (Hb concentration)
Serum chemistry:  creatinine, chloride, potassium, sodium, calcium, total protein, albumin, 
total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) 
cholesterol, triglycerides, ALT, AST, AP, gamma-glutamyl transpeptidase (GT), and total 
bilirubin (in case the result is > 2xULN, conjugated and unconjugated bilirubin will be 
determined). 
See Section 9.6.1.6 for procedure in case of elevated liver parameters.
Biochemistry: glycosylated hemoglobin (HbA1c) and ferritin.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  52 of 113
Additional parameters9: hormones (follicle-stimulating hormone [FSH], luteinizing 
hormone [LH], estradiol [E2], progesterone [P], prolactin, and thyroid-stimulating hormone 
[TSH]), and vitamin D (serum 25-hydroxyvitamin D).
In case of elevated liver enzymes requiring investigation of alternative cause the 
following parameters will have to be determined (in earlier CSP versions this was 
summarized in a particular section “close observation”): Serum chemistry panel (see 
above), A1AT level, conjugated bilirubin, ceruloplasmin, cholinesterase, CK, ferritin, full 
blood count (incl. eosinophilia), hemoglobin, INR, iron, LDH, platelets, PT,  total iron 
binding capacity (TIBC), testing to rule out Hepatitis A-, Hepatitis B-, Hepatitis C, Hepatitis 
E-, Cytomegalo-, Epstein-Barr-, and Herpes simplex virus infection, brucellosis, leptospirosis, 
and toxoplasmosis, ANA/ANCA screening with further tests depending on result and IgA, 
IgG, and IgM, potentially also testing to rule out Hepatitis D.
Parameters measured for adrenal monitoring:

serum cortisol (to be measured between 6 am and 10 am)
o
ACTH will be assessed from the same sampling if the cortisol measurement yields 
an abnormal value.

late night salivary cortisol (to be obtained between 11 PM and midnight)

Serum dehydroepiandrosterone sulfate (DHEA-S)
o
the age-specific DHEA-S ratio (derived by dividing the subject’s DHEA-S value 
by the lower limit of the age-specific reference range) will be calculated. In case of 
an abnormal DHEA-S ratio ACTH will be assessed from the sample taken for 
serum cortisol measurement.

serum total testosterone (tT)

serum glucose measurement under fasting conditions

serum potassium.
The following parameters will be assessed at the safety closeout visit in subjects who 
have completed or discontinued the study before or during the temporary pause:

estradiol

vitamin D (serum 25-hydroxyvitamin D)

Parameters measured for adrenal monitoring:

serum cortisol (to be measured between 6 am and 10 am)
o
ACTH will be assessed from the same sample if the cortisol measurement 
yields an abnormal value.

late night salivary cortisol (to be obtained between 11 PM and midnight)
                                                
9 Blood samples should be taken at least 72 hours after the intake of high doses of biotin, since the laboratory 
results of ferritin, TSH, FSH, LH, estradiol, prolactin, progesterone, cortisol, ACTH and -CTx may be affected, 
if the subject had a biotin intake at a concentration higher than 5 mg per day which occurred less than 72 hours 
before the sample is taken

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  53 of 113

serum dehydroepiandrosterone sulfate (DHEA-S)
o
the age-specific DHEA-S ratio (derived by dividing the patient’s DHEA-S
value by the lower limit of the age-specific reference range) will be calculated.
In case of an abnormal DHEA-S ratio ACTH will be assessed from the sample 
taken for serum cortisol measurement.

serum total testosterone (tT)

serum glucose measurement under fasting conditions

serum potassium

glycosylated hemoglobin (HbA1c).
Endometrial biopsies
9.6.3.2
9.6.3.2.1
Algorithm for endometrial biopsy evaluations
Figure 9–1: Overview of the endometrial safety monitoring algorithm
1 Normal is defined as: Diagnosis of safety read of all 3 individual components of the multiread needs to be 
“benign endometrium” in Part II of the evaluation form. In addition, the majority diagnosis needs to be “PAEC no” 
in Part IV of the evaluation form.
2 Post-treatment is defined as biopsy taken at the earliest 7 days before last study drug intake. For subjects with 
menstrual cycles the endometrial biopsy should be taken between Day 7 to 15 (inclusive) of a menstrual cycle.
PAEC = progesterone receptor modulator-associated endometrial changes, TVU = transvaginal ultrasound

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  54 of 113
9.6.3.2.2
Timing of last endometrial biopsies
Each subject should have an endometrial biopsy with a normal10 result documented from a 
timepoint taken at the earliest 7 days before last study drug intake. For subjects with 
menstrual cycles the endometrial biopsy should be taken between Day 7 to 15 (inclusive) of a 
menstrual cycle.Subject who did not have such a biopsy before or during the temporary pause 
or those who have an abnormality in TVU and/or bleeding pattern are required to undergo an 
endometrial biopsy at the safety closeout visit.
This also applies to subjects who started treatment and have completed or discontinued the 
study before or during the temporary pause. The investigator or designee must make every 
effort to regain contact with the subject (where possible, 3 telephone calls and, if necessary, a 
certified letter to the subject’s last known mailing address or local equivalent methods). These 
contact attempts should be documented in the subject’s source document.
The biopsy CRF page should be filled out for every subject at the safety closeout visit. This 
also applies to subjects who do not require a new biopsy according to the guidance above. The 
CRF page allows to capture the reason why a biopsy was not done.
Depending on the result of this last biopsy repeat unscheduled endometrial biopsies should be 
performed in addition. See Sections 9.6.3.2.1 and 9.6.3.2.8 for details.
9.6.3.2.3
Sampling of endometrial biopsies
All endometrial biopsies must be collected by a gynecologically well experienced physician.
A negative pregnancy test is a prerequisite for performing an endometrial biopsy.  In addition, 
an ultrasound should be performed before each biopsy.
If a cervical smear sample is collected at the same visit, those procedures have to be 
performed before performing the biopsy.
The sterilized, disposable device Pipelle de Cornier will be used – a flexible and transparent 
polypropylene sheath with an internal plunger for aspiration. This device allows for gentle 
tissue sampling, without hysteroscopy, and generally requires no local anesthesia or cervical 
dilatation. 
The following contraindications have to be strictly adhered to: pregnancy (ie, positive urine 
pregnancy test), and local inflammation (eg, vaginitis, cervicitis).
Any procedure-related complaints will be documented as AEs. If necessary for pain 
prophylaxis or relief relating to the endometrial biopsy procedure, the use of an analgesic is 
permitted and will be documented as concomitant medication (investigator’s choice; however, 
no intake of acetylsalicylic acid or any other medication substantially influencing bleeding). 
9.6.3.2.4
Assessment of endometrial biopsies
Blinding and distribution of biopsy samples will be organized by the central laboratory.
Central assessment of endometrial biopsies will be performed in 2 steps, i.e. safety assessment 
                                                
10 Normal is defined as: Diagnosis of safety read of all 3 individual components of the multiread needs to be 
“benign endometrium” in Part II of the evaluation form. In addition, the majority diagnosis needs to be “PAEC 
no” in Part IV of the evaluation form.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  55 of 113
and multi-reader assessment. In cases where an abnormality, e.g. atypia or malignancy, cannot 
be ruled out, readers will select the most severe diagnosis:
Safety assessment
The safety assessment will be performed by one pathologist who will be blinded regarding 
treatment group. The results of the safety assessment need to be available in time to 
document:

Any relevant pathology that requires further diagnostic or therapeutic measures 
according to local medical practice

Absence of clinically relevant endometrial pathology before the subject leaves the 
study 

A repeat endometrial biopsy will be requested, if sample is inadequate for evaluation 
in the safety assessment.

For follow-up of biopsies with abnormalities see Section 9.6.3.2.5.
Multi-reader assessment
The multi-reader assessment will be performed by a panel of pathologists who will be blinded 
regarding treatment group and time point of sample.
A majority consensus diagnosis of the multi-reader assessment is derived from the individual 
diagnoses of the pathologist panel (single-reader diagnoses), according to pre-specified rules.
In the absence of a majority consensus, the most severe diagnosis is used. The derived 
diagnosis resulting from these rules will be used for primary analysis of endometrial biopsy 
data. The individual diagnoses of each reader will be captured in addition.  
Starting with Protocol Amendment 5 (version 5.0), the majority diagnosis of the multi-reader 
assessment including the single reader assessments (part II of the evaluation form, i.e. the 
diagnosis of either benign endometrium, endometrial hyperplasia or malignant neoplasm) will 
be communicated to the study sites once the majority consensus diagnosis is available. 
A repeat endometrial biopsy will be requested, if sample is inadequate for evaluation in the 
majority multi-reader assessment.
For follow-up of biopsies with abnormalities see Section 9.6.3.2.5.
Besides standard safety criteria (e.g., proliferative/secretory/atrophic endometrium, 
endometrial hyperplasia, malignant neoplasm) the pathologists will document the presence of 
PAEC (see Section 9.6.3.2.6). The results of the PAEC assessment are not  reported back to 
the investigators except if in the last biopsy within the study, PAEC is still present and further 
biopsy sampling is needed.
The main study analysis will be based on the majority diagnosis of the multi-reader 
assessment. An analysis of single-reader diagnoses that is more severe than the majority 
diagnosis will be provided in the Study Report. 
While the relevant diagnosis for study purposes is the majority result of the multi-reader 
assessment, any single reader diagnosis that is more severe than the majority diagnosis, 
should be evaluated by the investigator (or by a gynecologist in case the investigator or sub-
investigator is not specifically trained in gynecology) for the necessity of therapeutic 
interventions. The minimal diagnostic requirement for those cases is a follow up biopsy. For 
all follow-up examinations and/or therapeutic interventions all efforts should be taken that 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  56 of 113
these examinations are conducted according to the standards of this protocol (e.g. biopsies 
should undergo multi-reader assessment) and are documented within the study framework.
9.6.3.2.5
Follow-up of endometrial biopsies with abnormalities
Endometrial biopsies with a safety-reader diagnosis (Part II of the evaluation form) other than 
“benign endometrium” (i.e. “Malignant neoplasm”, “Endometrial Hyperplasia” with or 
without atypia) should undergo an expedited multi-reader assessment. If an expedited multi-
reader assessment is not possible (e.g. due to sample export regulations), follow-up 
procedures will be decided based on the safety-reader diagnosis.
Endometrial biopsies with a multi-reader majority diagnosis (Part II of the evaluation form) 
other than “benign endometrium” (i.e. “Malignant neoplasm”, “Endometrial Hyperplasia” 
with or without atypia) should be followed-up according to investigator11 assessment, i.e., 
either by performing endometrial biopsies until resolution (i.e. until a follow-up biopsy shows 
a majority diagnosis of “Benign endometrium”) and/or by performing a therapeutic 
intervention as per local standard of care.
The timing of follow-up biopsies and/or possible therapeutic interventions according to local 
standard of care will be determined by the investigator (or by a gynecologist in case the 
investigator or sub-investigator is not specifically trained in gynecology) according to the 
observed abnormality. Typically, at least one endometrial shedding should have occurred 
before a follow-up biopsy is performed.
The follow-up biopsies should be performed within the study framework and analyzed by 
blinded multi-reader assessment. In case follow-up biopsies and/or other interventions are 
conducted at non-study sites, all efforts should be taken that results are obtained and 
documented appropriately.
For FUP of a majority diagnosis of “Benign endometrium – PAEC yes” please see Section 
9.6.3.2.6.
For reporting of abnormal biopsy results as adverse event of special interest or SAE, please 
see Sections 9.6.1.1 and 9.6.1.6.
9.6.3.2.6
Follow-up of PAEC
Besides standard diagnostic criteria (i.e., proliferative/secretory/atrophic endometrium, 
endometrial hyperplasia) presence of PAEC will be analyzed in all endometrial biopsy 
samples as part of the multi-reader assessment. The diagnosis of PAEC is based on a 
constellation of histologic features that, taken together, are characteristic. None of the features 
is unique, and to some extent any may be seen in subjects who have not been treated with 
PRMs. The common histologic features are endometrial glands showing cystic dilatation and 
an irregular architecture lined by inactive gland cells and compact, nondecidualized stroma. 
If PAECs have been detected in the biopsy at the last visit before leaving the study according 
to the majority diagnosis resulting from the multi-reader assessment, the site will be informed 
and an additional biopsy should be scheduled. In case PAEC findings are still present, the 
study site will be informed and an additional biopsy is to be taken to evaluate resolution, with 
the timepoint of this additional biopsy to be determined case-by-case. If needed, more than 
                                                
11 or by a gynecologist in case the investigator or sub-investigator is not specifically trained in gynecology.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  57 of 113
one repeated biopsy may be taken and analyzed, except for cases with PAEC already present 
in the pre-treatment biopsy.
9.6.3.2.7
Heavy menstrual bleeding / suspicious bleeding pattern
The study drug was administered in a study population with symptomatic heavy menstrual 
bleeding. The study drug itself leads to changes in bleeding pattern, mostly amenorrhea 
during treatment, but can also be associated with intermittent spotting or mild intermittent 
bleeding of short duration. Heavy menstrual bleeding is expected to return in the FUP phase 
after cessation of treatment.
Because unusual bleeding patterns or unusually heavy menstrual bleeding can also be a sign 
of endometrial pathology, the subject should be instructed to report changes in bleeding 
pattern or bleeding volume that seem unusual to her (and does not resemble the subject´s 
natural cycle or bleeding pattern). In case such unusual bleeding events are reported or are 
detected from the AH, MP or UF-DBD the subject should undergo immediate evaluation by 
the investigator.
Standard criteria for subjects with unusual HMB or bleeding pattern identified from 
review of bleeding data or reports by the subject during the temporary pause
As guidance the following occurrences should be considered for further evaluation in the 
context of unusual bleeding: 

Prolonged bleeding:
Evaluation should be initiated if

Prolonged bleeding is reported by the subject and/or

the subject entered more than 10 consecutive days of bleeding in the e-diary 
(intensity of “mild” or more) with a maximum of 2 non-bleeding days in between.

Continuous spotting:
Evaluation should be initiated if

Continuous spotting is reported by the subject and/or

the subject entered more than 10 consecutive days of spotting in the e-diary with a 
maximum of 2 non-spotting days in between.

Unusual heavy bleeding:
Evaluation should be initiated if

Unusually heavy bleeding is reported by the subject and/or

If blood loss per bleeding episode is more than 50% higher than the subject´s 
baseline blood loss (when observed via the menstrual pictogram or alkaline 
hematin method). 
Evaluation plan for subjects with unusual HMB or new onset bleeding pattern
The evaluation should include the following assessments:
o
Comparison of subject’s subjective report with documented bleeding pattern and 
amount of blood loss (UF-DBD, MP, and/or AH method, if available from the months 
preceding the safety closeout visit).
o
Unscheduled ultrasound 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  58 of 113
o
In case of HMB or prolonged bleeding, unscheduled blood sample to assess for 
anemia 
o
Possible contributing factors (eg, new concomitant medication, variability of disease, 
perception of increased HMB after period of amenorrhea)
An unscheduled endometrial biopsy should be conducted in case of
o
Endometrial thickness (double layer) > 18 mm and/or
o
Clinical suspicion of relevant endometrial pathology
Further follow-up measures will be determined by the outcome of the endometrial biopsy (see 
Section 9.6.3.2.5).
HMB should be recorded as an AE only as specified in Section 9.6.1.6. If HMB fulfills the 
criteria of an SAE (see Section 9.6.1.1), if needed, an appropriate treatment as per local 
standard of care (eg, curettage) is to be performed.
9.6.3.2.8
Unscheduled endometrial biopsy
Unscheduled endometrial biopsies can result from the requirement to follow-up on abnormal 
results of a previous biopsy, see Section 9.6.3.2.5. In addition, also the following two findings 
trigger unscheduled biopsies:

In case of increased endometrial thickness (18 mm) 

Work up of suspicious bleeding pattern as described.
For unscheduled biopsies triggered by increased endometrial thickness or unusual bleeding 
events, the following procedure applies, depending on the result of the unscheduled 
endometrial biopsy:

Normal result of the endometrial biopsy: unscheduled ultrasound examination after 
about 4 weeks and close follow up of bleeding pattern. If endometrial thickness 
remains above 18 mm and/or unusually heavy bleeding occurs further procedures 
should be performed according to local medical practice and as defined in Section 
9.6.3.2.7.

For procedures in case of an abnormal result of the unscheduled biopsy, please see 
Section 9.6.3.2.5.
Cervical smear
9.6.3.3
This section was changed in Amendment 2, see Section 15.1.1
The cervical smear should be obtained with the gynecological examination at the safety 
closeout visit in subjects who did not have this performed with normal result after end of 
treatment. As a guidance, a cervical smear should only be repeated once in case of insufficient 
material.
Physical and gynecological examinations
9.6.3.4
Complete physical examinations will be done in all subjects. Gynecological examinations, 
including breast palpation, will be performed in subjects who did not have this performed 
with normal result after end of treatment. In case of any suspicious finding, further diagnostic 
investigations will be performed at the discretion of the investigator.
Abnormal physical examination findings are recorded either as medical history or as adverse 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  59 of 113
events (see Section 9.6.1.1).
Vital signs, weight, and height
9.6.3.5
Vital signs (blood pressure in triplicates and heart rate) should be documented at the safety 
closeout visit. Blood pressure should be measured in triplicates after 5 minutes of rest, while 
the subject is sitting. Measurements should be made at least 1 minute apart using the same 
arm at each visit and should be recorded on the eCRF. Body weight will be determined once 
again at the safety closeout visit.
Ultrasound (safety)
9.6.3.6
If possible, the same examiner should conduct all ultrasound examinations of a subject 
throughout the study and the same ultrasound machine (per site) should be used throughout 
the study.  Preferably the safety evaluation should be performed by transvaginal ultrasound
(TVU). However, if deemed appropriate, transabdominal or transrectal ultrasound
examinations can be performed instead. The chosen method should be used consistently 
throughout the study.
The following safety parameters will be documented at the safety closeout visit: endometrial 
thickness (double layer), evaluation of ovaries, and any pathology detected during the 
examination. Endometrial thickness will be measured in the medio-sagittal section as double-
layer in millimeters.
If endometrial thickness (double layer) 18 mm is detected after start of treatment, the subject 
should undergo immediate evaluation by endometrial biopsy as described in Section 9.7.4.
If cyst like structures >30 mm without suspicious appearance (ie, functional cysts) are 
visualized in the ovaries, unscheduled ultrasound examinations to document 
regression/outcome of these findings should be performed as described in Section 9.7.5.
In case of any suspicious finding, further diagnostic investigations will be performed at the 
discretion of the investigator.
The minimum documentation at the site will include printouts from the ultrasound machine
showing the endometrium in sagittal section and both ovaries. The printouts have to be 
labeled unambiguously, containing at least the study number, SID number, time point, 
endometrial thickness, and side (left/right) for ovaries.
For efficacy ultrasound procedures, see Section 9.4.2. 
Contraception and pregnancy test
9.6.3.7
With the implementation of protocol amendment 5 (version 5.0) no further restrictions apply 
to the use of contraception. New placement of intrauterine devices should only happen once it 
is clear that no further biopsies are needed. At safety closeout visit a urine pregnancy test will 
be performed at the study site.  A pregnancy test must also be performed in case of any further 
repeat of an endometrial biopsy. 
Any pregnancies during the study and during the off study period in subjects who return for 
the safety closeout visit must be reported as detailed in Section 9.6.2.
Adrenal monitoring
9.6.3.8
A robust adrenal safety monitoring program is implemented in all ongoing vilaprisan studies 
with this protocol amendment.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  60 of 113
A plan for subjects showing adrenal neoplasms or hormonal abnormalities has been 
developed with the input of external endocrinology experts, see Adrenal monitoring algorithm 
below. 
A panel of three external clinical adrenal gland experts has been set up, that will support and 
guide further evaluations and/or referral to local specialists in case an abnormality is detected 
in a study subject. The assessment by the experts will be performed in 2 steps: 

A safety assessment of cases showing abnormalities will be performed by one of these 
experts. The results of this assessment will be available in time to document

Any relevant finding that requires further diagnostic or therapeutic 
measures according to local medical practice

Absence of clinically relevant adrenal findings before the subject 
discontinues from the study.
In case of a local specialist consult, the work-up and results will be captured in a dedicated 
CRF page.

In addition, the expert panel will perform a central evaluation of all cases after the 
outcome of the local specialist referral or other evaluations is available. The panel will 
meet once a sufficient number of cases is available to perform a comprehensive data 
analysis by using uniform diagnostic standards and classifications (see also Adrenal 
Monitoring Manual).
The further details of adrenal monitoring are described in the Adrenal Monitoring Manual.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  61 of 113
Figure 9–2: Adrenal monitoring algorithm
MRI = magnetic resonance imaging

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  62 of 113
9.6.3.8.1
Timing of adrenal monitoring
Subjects will undergo scheduled adrenal monitoring at the safety closeout visit.
Signs and symptoms possibly related to hypercortisolism (such as Cushing’s syndrome, and 
hirsutism/virilization) or hyperaldosteronism will be documented on a dedicated CRF page 
(see Section 9.6.3.8.4).
Adrenal monitoring also needs to be performed in subjects who started treatment and have 
completed or discontinued the study before or during the temporary pause. After re-
consenting, data related to adrenal monitoring and their results are to be documented in the 
CRFs, and if applicable, same applies to any related AEs and respective concomitant 
medications. The investigator or designee must make every effort to regain contact with the 
subject (where possible, 3 telephone calls and, if necessary, a certified letter to the subject’s 
last known mailing address or local equivalent methods). These contact attempts should be 
documented in the subject’s source document.
9.6.3.8.2
Adrenal MRI
Non-contrast-enhanced (native) MRI will be implemented as the standard adrenal imaging 
modality. Due to the associated radiation exposure, non-contrast-enhanced (native) CT scan is 
permitted as an alternative option only if an MRI is not feasible, e.g., due to a subject having a 
contraindication to MRI or a site has no access to MRI. Further details on the procedures of 
the image acquisition and reading process will be provided in a separate Imaging Manual. 
The images will be evaluated by two central readers with an established adjudication process 
in case of discrepant results. Abnormalities indicative of an adrenal tumor or of any other 
relevant adrenal disorder need to be further evaluated (for details see Section 9.6.3.8 and 
Adrenal monitoring algorithm above). During the central review process, the independent 
reader may detect clinically significant pathological imaging findings that are not part of the 
primary review purpose, i.e., evaluating the adrenal glands. If deemed relevant, these 
incidental findings will be reported to GCIS at the discretion of the readers. GCIS will 
forward the incidental finding report to the study team, who will then inform the principal 
investigator.
Any procedure-related complaints will be documented as AEs. 
9.6.3.8.3
Laboratory testing
Adrenal monitoring: 

Serum cortisol, to be measured between 6 am and 10 am
o
ACTH will be assessed from the same sample if the cortisol measurement yields 
an abnormal value. 

Late night salivary cortisol (to be obtained between 11 PM and midnight)
Subjects will be instructed to use the specifically provided saliva test tubes on two 
consecutive evenings for separate sampling. The time of sampling needs to be 
documented on the test tube / requisition form. Subjects will be asked to return 
samples to the site to ensure standardized transport and processing at the central 
laboratory (please see algorithm above). 

Serum glucose measurements under fasting conditions

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  63 of 113

Serum DHEA-s (Dehydroepiandrosterone sulfate) and total testosterone (tT)
Furthermore, the age-specific DHEA-s ratio (derived by dividing the subject’s 
DHEA-s value by the lower limit of the age-specific reference range) will be 
calculated12.
9.6.3.8.4
Adrenal signs and symptom inquiry
Vital signs (blood pressure in triplicates and heart rate) will be documented at the safety 
closeout visit. Blood pressure should be measured in triplicates after 5 minutes of rest, while 
the subject is sitting. Measurements should be made at least 1 minute apart using the same 
arm at each visit and should be recorded on the eCRF13. 
During the visit the subject should also be evaluated for clinical signs and symptoms of 
adrenal disorders, such as Cushing’s syndrome, and hirsutism/virilization. A dedicated CRF 
page has been implemented to document those, if applicable.
Liver symptom inquiry
9.6.3.9
Investigators, subjects and their family members should be alert for non-specific symptoms 
which may be associated with liver dysfunction including anorexia, nausea, fatigue, right 
upper abdominal discomfort, vomiting, malaise, jaundice, fever, and rash. 
Before the implementation of protocol amendment 5 (version 5.0), investigators were asked to 
regularly inquire about symptoms that according to their medical judgement may indicate 
liver disturbance and document the result of this inquiry in the respective eCRF page. This 
structured inquiry was used to determine withdrawal criteria and is therefore not needed at the 
safety closeout visit.
Liver monitoring
9.6.3.10
In the past, investigators, subjects and their family members were instructed to be alert for 
non-specific symptoms which may be associated with liver dysfunction. In addition, the liver 
inquiry had to be completed at regular intervals. Based on the long interval between 
implementation of protocol amendment 5 (version 5.0) and last intake of study drug this is no 
longer needed on a routine basis.
Investigation of potential causes (which replaces the close observation procedures applied 
before this protocol amendment) has to be initiated and recorded in the dedicated liver case 
report form if at least one of the options below applies: 

GPT/ALT or GOT/AST value increases to 3 x ULN
or
                                                
12 High levels of tT and/or DHEA-s may be indicators of an androgen-producing adrenal cortical tumor and are 
measured in this study in conjunction with adrenal imaging to support their early detection. Therefore, despite 
the fact that many confounders are present in the female study population (e.g., PCOS, influence of Vilaprisan 
or other concomitant medications on hormone levels), tT and DHEA-s concentrations will be measured to 
screen for androgen-producing tumors. Highly abnormal values of one or both parameters, i.e., tT >240 ng/dL 
and/or DHEA-s > 600 µg/dL, will trigger an assessment by one of the external adrenal panel experts.
132018 Draft Guidance for Industry: Assessment of Pressor Effects of Drugs 
(https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinforma tion/guidances/ucm609185.pdf

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  64 of 113

GPT/ALT or GOT/AST value 2-fold increases above the lowest baseline value for 
subjects with elevated values before drug exposure
or

AP (alkaline phosphatase) value increases to > 2x ULN and irrespective of the level of 
transaminase (GPT/ALT or GOT/AST) values
o
in cases with baseline showing normal AP
o
in cases of at least 2 times the baseline values if slightly above the upper 
limit of normal at baseline
In those cases, a search for underlying causes should be performed including:

Repeating a serum chemistry panel (including liver parameters and bilirubin).

Obtaining a more detailed history of the symptoms and prior or concurrent diseases.

Obtaining a history of concomitant drug use (including nonprescription medications 
and herbal and dietary supplement preparations), alcohol use, recreational drug use, 
and special diets.

Ruling out acute viral hepatitis; autoimmune or alcoholic hepatitis; non-alcoholic 
steatohepatitis (NASH); hypoxic/ischemic hepatopathy; and biliary tract disease. This 
may require performing additional procedures, e.g. ultrasound examinations.

Obtaining a history of exposure to environmental chemical agents. 

Obtaining additional tests to evaluate liver function as appropriate, (eg, international 
normalized ratio [INR], total bilirubin measurements). 

Referral for a liver ultrasound.
Any of these additional findings is to be recorded on the corresponding eCRF pages in 
RAVE.
Skin monitoring
9.6.3.11
All subjects who have taken at least one dose of the study medication will undergo a thorough
skin examination by a dermatology expert.
The outcome of the dermatology expert’s examinations will be reported in the CRF. Any 
dermatology expert´s diagnosis of a pre-cancerous or malignant skin lesion, including 
cutaneous sarcoma confirmed by biopsy diagnosis, qualify as an AESI. Any dermatology 
expert´s diagnosis of a malignant skin lesion, including cutaneous sarcoma confirmed by 
biopsy diagnosis, needs to be reported as an SAE to ensure timely reporting to regulatory 
agencies (see Section 9.6.1.6).
Subjects who were randomized, started treatment, and have completed or discontinued the 
study before or during the temporary pause should be contacted by the site and asked to have 
the skin monitoring performed. After re-consenting, data related to the skin exam by a 
dermatology expert and the results are to be captured and if applicable any related AEs and 
respective concomitant medications. 
The investigator or designee must make every effort to regain contact with the subject (where 
possible, 3 telephone calls and, if necessary, a certified letter to the subject’s last known 
mailing address or local equivalent methods). These contact attempts should be documented 
in the subject’s source document.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  65 of 113
Other procedures and variables
9.7
9.7.1
Iron supplementation
This section was changed in Amendment 2, see Section 15.1.1
Subjects in whom causes for anemia unrelated to HMB are suspected should not have been
enrolled. 
Moderate anemia is defined as hemoglobin 10.9 g/dL (4). Iron supplementation should be 
offered to subjects with hemoglobin 10.9 g/dL consistent with local standards of practice 
and at the investigator’s discretion. Iron supplementation will not be considered as study drug 
and should be documented as concomitant medication.  
9.7.2
Algorithm for monitoring of endometrial safety
See Section 9.6.3.2.1.
9.7.3
Heavy menstrual bleeding / suspicious bleeding pattern
See Section 9.6.3.2.7.
9.7.4
Unscheduled endometrial biopsy
See Section 9.6.3.2.8.
9.7.5
Monitoring of ovarian cysts
If cyst like structures >30 mm without suspicious appearance (ie, functional ovarian cysts) are 
visualized in the ovaries, unscheduled ultrasound examinations should be performed every 
4 weeks or more frequently, if required due to symptoms, to document the regression/
outcome.
If the subject demonstrates menstrual cyclicity, the ultrasound should be performed after 
menstruation as soon as possible, preferably in the early follicular phase. The monitoring will 
be continued until resolution, ie, until cyst can no longer be distinguished from functional 
follicles. If the cysts persist after 3 months or grow, decision on further treatment should be 
made according to local medical practice.
In the event of cyst like structures with suspicious appearance, further procedures should be 
performed according to local medical practice.
Appropriateness of procedures / measurements
9.8
All efficacy and safety parameters, as well as the methods to measure them, are standard 
variables/methods in clinical studies and/or clinical/gynecological practice.  They are widely 
used and generally recognized as reliable, accurate, and relevant.
10.
Statistical methods and determination of sample size
General considerations
10.1
Statistical analyses will be conducted by or under the supervision of the sponsor’s study 
statistician, except for the analysis of PK/PD data, which will be performed and reported 
under the supervision of the sponsor´s pharmacometrics group.  
Statistical analyses will be performed using Statistical Analysis Software (SAS Institute Inc., 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  66 of 113
Cary, North Carolina, US). The SAS version and further details on the statistical analyses 
will be provided in the SAP that will be approved before database release.
All target variables will be described according to their type using descriptive statistics 
frequencies or mean, standard deviation (SD), minimum, maximum, median, first and third
quartiles.  Where appropriate, the individual change from baseline to end of treatment will 
also be analyzed.  
Analysis sets
10.2
The documentation of important deviations from the protocol and validity findings and the 
assignment of subjects to analysis sets will be performed according to the sponsor’s 
applicable Standard Operating Procedures and/or Instruction Manuals.  The definition for
important deviations and validity findings will be provided in the Specification of assessment 
criteria and identification requirements before unblinding the data.
The following statistical analysis sets will be defined:
Full analysis set (FAS): All randomized subjects, excluding randomized subjects who did 
not start Treatment Period 1 due to the study being temporarily on hold. Subjects will be 
analyzed as randomized. 
Per protocol set (PPS):  All subjects in the FAS without any validity findings impacting the 
primary efficacy variable in Treatment Period 1.
Safety analysis set (SAF):  All subjects who took at least 1 dose of study drug. Subjects will 
be analyzed as treated.
The primary efficacy variable will be analyzed on the FAS and PPS, where the analysis on the 
FAS is considered to be the primary one. Safety analyses will be performed on the SAF. The 
FAS will be used for the display of all other variables.
Variables and planned statistical analyses
10.3
10.3.1
Variables
This section was changed in Amendment 2, see Section 15.1.1
The primary efficacy variable and secondary efficacy variables will be calculated based on the 
alkaline hematin method (unless otherwise specified). Other efficacy variables related to 
menstrual blood loss will be calculated based on the two methods, the alkaline hematin 
method and the menstrual pictogram.
Primary efficacy variable
10.3.1.1
This section was changed in Amendment 2, see Section 15.1.1
The primary efficacy variable is amenorrhea (yes/no), defined as MBL <2 mL during the last 
28 days of treatment. 
If an endometrial biopsy was conducted during this time period, bleeding on the day of biopsy 
and the 3 days thereafter will not be considered in this evaluation.
For the primary analysis, the amenorrhea rates at the end of Treatment Period 1 of Treatment 
Groups A1, B1, and B2 will be used.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  67 of 113
Subjects who discontinue treatment prior to completion of treatment Week 8 of the respective 
treatment period will be considered not having amenorrhea.
Secondary efficacy variables
10.3.1.2
This section was changed in Amendment 2, see Section 15.1.1
The secondary efficacy variables are:

HMB response defined as blood loss <80.00 mL during the last 28 days of treatment 
and >50% reduction compared to baseline

Time to onset of amenorrhea. Onset of amenorrhea is defined by the first day for which 
the menstrual blood loss for all subsequent 28-day periods up to the end of the 
treatment period is <2 mL.

Time to onset of controlled bleeding.  Onset of controlled bleeding is defined by the 
first day for which the menstrual blood loss for all subsequent 28-day periods up to the 
end of the treatment period is <80.00 mL.

Absence of bleeding (spotting allowed) during the last 28 days of the treatment; based 
on the UF-DBD
Other efficacy variables
10.3.1.3
This section was changed in Amendment 2, see Section 15.1.1
Other efficacy variables are:

Treatment success rate defined as percentage of subjects who fulfill the criteria of 
HMB response (<80.00 mL, >50% reduction in menstrual blood loss as compared to 
baseline) and who have not been withdrawn from the study due to AEs, due to non-
fulfillment of selection criteria (related to fibroid size or HMB at baseline) or due to 
fibroid surgery having been performed during the study.

Amenorrhea (yes/no), defined as MBL < 2 mL per 28 days of treatment (for treatment 
time/method not considered as primary variable) 

HMB response defined as blood loss <80.00 mL and >50% reduction compared to 
baseline per 28 days of treatment (for treatment time/method not considered as 
secondary variable)

Time to onset of amenorrhea. Onset of amenorrhea is defined by the first day for which 
the menstrual blood loss for all subsequent 28-day periods up to the end of the 
treatment period is <2 mL (for treatment time/method not considered as secondary
variable)

Time to onset of controlled bleeding.  Onset of controlled bleeding is defined by the 
first day for which the menstrual blood loss for all subsequent 28-day periods up to the 
end of the treatment period is <80.00 mL (for treatment time/method not considered as 
secondary variable)

Volume of menstrual blood loss per 28 days 

Volume of menstrual blood loss per bleeding episode for the first, second, and if 
applicable third bleeding episode after the EoT 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  68 of 113

Volume of menstrual blood loss per bleeding episode within the treatment break (not
applicable for Treatment Groups A2). All days of the bleeding episodes will be used 
even if some days of the episode lie outside the treatment break.  

Percentage of subjects with ≥50% reduction in menstrual bleeding per 28 days 
compared to baseline 

Time to start of bleeding after last study drug intake (assessed by the UF-DBD in 
addition to the other two measurement methods). If bleeding has to be induced, the 
subject´s data will be censored at that time point for the induction. 

Percent change in volume of 3 largest fibroids compared to baseline (measured by 
ultrasound) 

Percent change in volume of uterus compared to baseline (measured by ultrasound) 

Percentage of subjects with a volume reduction of ≥25% of the 3 largest fibroids 
(measured by ultrasound) 

Percentage of subjects with a reduction of ≥25% of uterine volume (measured by 
ultrasound) 

Percentage of subjects undergoing surgical treatment for uterine fibroids

Change in UF-DSD individual items compared to baseline 

Change in UFS-QoL scores compared to baseline 

Change in SF-36v2 scores compared to baseline 

PGI-C assessments 

Change in CGI-I/PGI-S scores compared to baseline 

Subject satisfaction assessed by the TSQM-9 at the 12 week and at end of treatment 
visit

Change from baseline in hemoglobin, hematocrit, and ferritin

Percentage of subjects with normal hemoglobin >12 g/dL and normal hematocrit >36% 
Pharmacokinetics (PK)
10.3.1.4
For details, see Section 9.5.2 and 9.5.3 and the separate M&S Analysis plan.  
Secondary safety variables
10.3.1.5

Endometrial histology (eg, benign endometrium, presence or absence of hyperplasia or 
malignancy)

Endometrial thickness 
Other safety variables
10.3.1.6
This section was changed in Amendment 2, see Section 15.1.1

Endometrial histology (diagnosis of PAEC, individual features of PAEC) 

Ovarian cysts (number, size) 

Laboratory parameters

AEs 

Cervical smear

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  69 of 113

Vital signs 

Percentage of subjects with moderate to severe anemia (ie, hemoglobin 10.9 g/dL)

Findings resulting from liver monitoring

Findings resulting from adrenal monitoring

Findings resulting from skin monitoring
10.3.2
Statistical and analytical plans
Demographic and other baseline characteristics
10.3.2.1
Demographic variables and baseline characteristics will be summarized overall by means of 
descriptive statistics and/or frequency tables as appropriate.
Medical history findings and AEs will be coded by Medical Dictionary for Regulatory 
Activities (MedDRA) codes and medications by Anatomical Therapeutic Chemical (ATC) 
codes (World Health Organization Drug Dictionary [WHO-DD]).
Efficacy analysis
10.3.2.2
This section was changed in Amendment 2, see Section 15.1.1
For the confirmatory efficacy analysis, a hierarchical testing approach will be applied, 
involving the primary efficacy variable amenorrhea (yes/no) and the first three secondary 
efficacy variables HMB response, time to onset of amenorrhea and time to onset of controlled 
bleeding. These tests always include a comparison of vilaprisan 2 mg versus placebo:
After 12 weeks of treatment in Treatment Period 1: 
Comparison of vilaprisan 2 mg in pooled Treatment Groups A1 and B2 (as the 
treatments are the same and pooling increases the power) vs. placebo in Treatment 
Group B1
In total, four tests will be carried out each to an alpha level of 0.05: First, the test for the
primary efficacy variable amenorrhea (yes/no) will be carried out, followed by the test for 
HMB response (yes/no), the test for time to onset of amenorrhea, and finally, the test for onset 
of controlled bleeding. As the hierarchical testing procedure follows a fixed sequence, it stops 
as soon as any of these tests cannot be rejected to an alpha level of 0.05 and all further tests 
after failing to reject one null hypothesis in the testing sequence will be considered 
exploratory. This fixed sequence procedure accounts for the multiplicity created by carrying 
out multiple tests. 
Amenorrhea (yes/no), defined as MBL <2 mL during the last 28 days of treatment
The primary efficacy variable amenorrhea (yes/no) will be analyzed by means of a two-sided 
Cochran-Mantel-Haenszel test stratified by region/country at a local 0.05 significance level.
The number of subjects with amenorrhea (yes/no) is assumed to be binomial distributed. 
Thus, the Cochran-Mantel-Haenszel test is applied to test the null hypothesis  that the 
amenorrhea rates in the vilaprisan 2 mg group () and in the placebo group () in Treatment 
Period 1 are equal versus the alternative hypothesis 	 that they are not:
:  =    vs.   	:  ≠.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  70 of 113
HMB response defined as blood loss <80.00 mL during the last 28 days and >50% 
reduction compared to baseline
The first secondary efficacy variable HMB response (yes/no) will be analyzed analogously to 
the primary efficacy variable amenorrhea. 
Time to onset of amenorrhea 
Onset of amenorrhea is defined by the first day for which the menstrual blood loss for all 
subsequent 28-day periods up to the end of the Treatment Period 1 is <2 mL. Subjects are 
treated as censored if they did not experience an onset of amenorrhea during Treatment Period
1. Censoring rules will be described in more detail in the SAP.
In order to investigate the null hypothesis that there is no difference in time to onset of 
amenorrhea between vilaprisan 2 mg and placebo versus the alternative hypothesis that there 
is a difference, a logrank test stratified by region/country is conducted at a local 0.05 
significance level. 
Time to onset of controlled bleeding
Onset of controlled bleeding is defined by the first day for which the menstrual blood loss for 
all subsequent 28-day periods up to the end of Treatment Period 1 is <80.00 mL. Subjects are 
treated as censored if they did not experience an onset of controlled bleeding during
Treatment Period 1. Censoring rules will be described in more detail in the SAP.
Time to onset of controlled bleeding will be analyzed analogously to the secondary efficacy 
variable time to onset of amenorrhea.
The study will be considered successful if at least superiority of vilaprisan 2 mg vs. placebo 
after Treatment Period 1 based on the primary variable could be demonstrated. 
Sensitivity analyses will be conducted for the primary efficacy variable and the first three 
secondary efficacy variables as applicable. These will be described in the SAP.
All primary and secondary efficacy variables will also be analyzed descriptively in frequency 
tables by treatment period within each treatment group, except for time to event variables 
which will be analyzed by treatment group using the Kaplan-Meier estimates.
Other efficacy variables will be evaluated and presented by means of descriptive statistics.
Pharmacokinetic analysis
10.3.2.3
For details, see Sections 9.5.1 and 9.5.3 and the separate M&S Analysis Plan.  Results will be 
reported in a separate M&S Report, if applicable.
Safety analysis
10.3.2.4
Safety analyses will be performed on the SAF. AEs and other safety variables will be 
summarized descriptively by treatment group.
The incidence of treatment-emergent AEs and drug-related AEs will be summarized using 
MedDRA preferred term and the primary system organ class.  
Subgroup analysis
10.3.2.5
This section was changed in Amendment 2, see Section 15.1.1
Subgroup analyses are planned using descriptive statistics for the primary and secondary 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  71 of 113
efficacy variables separately for each country (China and the US), race and ethnicity. Further 
subgroup analyses will be described in the SAP.
10.3.3
Missing data/drop outs
This section was changed in Amendment 2, see Section 15.1.1
For the primary efficacy variable and secondary efficacy variables included in the testing 
strategy described in Section 10.3.2.2 it is assumed that data measured with the AH method 
will be only available on days when vaginal bleeding occurred. To differentiate missing AH 
data and days without vaginal bleeding the bleeding intensity collected in the UF-DBD will 
be used. 
Missing bleeding data in the subject diaries will be imputed. For the UF-DBD, the worst case 
approach will be used for missing bleeding intensity for the single or two consecutive missing 
days (ie, the maximum of the bleeding intensities of the day before and the day after the 
missing day[s] will be assumed).
If an endometrial biopsy was conducted during the time period under treatment, bleeding on 
the day of biopsy and the 3 days thereafter will not be considered as day(s) with 
bleeding/spotting and the AH value will be set to 0 mL. For the primary efficacy variable
amenorrhea and the secondary efficacy variable HMB response, subjects will be defined as 
not having amenorrhea/ not being a HMB responder if they did not complete at least 8 weeks 
of treatment. Generally, in case a daily bleeding intensity is recorded with the UF-DBD as 
“no vaginal bleeding” or “spotting”, the missing AH value for this day will be set to 0 mL. 
For days with bleeding intensity of “mild” or higher in the UF-DBD, missing AH values will 
be replaced by the mean value of AH values of the days with the same bleeding intensity. In 
case there are no AH values with the same bleeding intensity, the mean of the AH values of 
next higher intensity will be used. In case there is no intensity higher than the bleeding 
intensity of the missing AH values available, either, no replacement for the missing AH 
values will be done for such days; but if there at least one such day occurs within the 
respective 28 days of treatment for a subject, the subject will be considered as not having 
amenorrhea/ not being a HMB responder.
Furthermore, the last days under treatment with at least 28 days with non-missing bleeding 
intensity/AH values under treatment until the initial bleeding episode when the treatment 
started (after the imputations above) (without missing information: Days 57 to 84 under 
treatment) will be used to calculate the primary efficacy variable and the secondary efficacy 
variable HMB response. After these imputations a subject will be considered as not having 
amenorrhea in the presence of missing AH values if the sum of all non-missing AH values is 
not lower than 2 mL or if for missing AH values the bleeding intensity in the UF-DBD is 
“mild” or higher, otherwise the subject will be considered as having amenorrhea. An 
equivalent approach as described for the amenorrhea rate will be applied for the secondary 
variable HMB response, ie, after the imputations as described above a subject will be 
considered as not being a HMB responder in the presence of missing AH values if the sum of 
all non-missing AH values is ≥80.00 mL or the reduction of blood loss is ≤50% as compared 
to baseline or if for missing AH values the bleeding intensity in the UF-DBD is “mild” or 
higher, otherwise the subject will be considered as a HMB responder.
For the secondary variables onset of amenorrhea and onset of controlled bleeding the first 28 
days with non-missing bleeding/AH values until the last 28 days with non-missing

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  72 of 113
bleeding/AH values under treatment will be considered. An analogous approach as described 
above for the primary efficacy variable and the secondary efficacy variable HMB response 
will be applied to assess the bleeding status for each of these 28-day windows in terms of 
amenorrhea and controlled bleeding. If a subject does not achieve amenorrhea or controlled 
bleeding until end of treatment the subject will be considered as censored for the respective
endpoint. 
Sensitivity analyses will be conducted to evaluate the impact of missing data. These will be 
described in the SAP.
Determination of sample size
10.4
This section was changed in Amendment 2, see Section 15.1.1
No longer applicable as with the implementation of protocol amendment 5 (version 5.0)
no new subjects will be recruited and no study medication will be given to the subjects 
who have been enrolled in the study. This section describes the original sample size 
planning prior to the decision to temporarily pause the study. The originally planned
sample size has not been reached. 
Assumptions for sample size calculations were based on the ASTEROID 1 study (Study 
15788) and the ASTEROID 2 study (Study 17541) with treatment durations of 12 and 24 
weeks. 
In ASTEROID 1, amenorrhea rates (defined as MBL <2 mL during last 28 days of treatment) 
of about 0.7, 0.9, and 0.9 for vilaprisan 2 mg and of about 0.2, 0.0, and 0.1 for placebo for the 
regions US/Japan/European Union and Canada, respectively, were observed with differences 
between vilaprisan 2 mg and placebo of about 0.5 to 0.9. In ASTEROID 2, similar 
amenorrhea rates were observed with numerical variation between the treatment periods. 
HMB response rates in the last 28 days amounted to percentages above 90% for vilaprisan 2 
mg and 33% or lower for placebo. Median onset of amenorrhea was reached on day 6 after 
start of treatment for vilaprisan 2 mg. Due to the low number of subjects achieving
amenorrhea until the end of placebo treatment, no median onset of amenorrhea could be 
calculated for placebo. Onset of controlled bleeding was reached on day 2 after start of 
treatment for vilaprisan 2 mg. Again, as for onset of amenorrhea, no median onset of 
controlled bleeding could be calculated for placebo due to the low number of subjects 
achieving controlled bleeding until the end of placebo treatment. At the end of treatment 
controlled bleeding was reported for about 97% of subjects for vilaprisan 2 mg and for 49% 
of subjects for placebo, respectively.
Taking these aspects into account, a difference in amenorrhea rates of at least 0.4 between 
vilaprisan 2 mg and placebo is assumed after 12 weeks and 24 weeks. Sample size calculation 
was further based on a balanced randomization scheme of 1:1:1:1 (A1:A2:B1:B2), an overall
power of 0.9 for the study (ie, higher for each individual test), and the application of the two-
sided Cochran-Mantel-Haenszel test for the primary variable and the secondary variable HMB 
response as well as the logrank test for the secondary variables onset of amenorrhea and onset 
of controlled bleeding (stratified by region/country), each to a local 0.05 significance level.
Assuming a dropout rate of about 20%, the number of subjects to be randomized into the 
study was planned to be 260; 65 subjects in each treatment group.
Approximately 50% of subjects were planned to be enrolled from the US (based on feedback 
from the FDA).

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  73 of 113
Based upon the anticipated screen failures rates (60% in the US and 50% in China and in the 
other countries), about 585 subjects were planned to be enrolled to achieve the planned 
number of randomized subjects.
PASS version 13.0.11 was used for sample size calculation.
Planned interim analyses
10.5
With the implementation of protocol amendment 5 (version 5.0) a safety and efficacy analysis 
is planned after all subjects have completed their treatment period. Data of the follow-up 
period available at that time point will also be included in the analysis. Remaining data of the 
follow-up phase will be analyzed after all subjects have completed the follow-up period. For 
all other data this safety and efficacy analysis is considered the final analysis.
11.
Data handling and quality assurance
Data recording
11.1
The data collection tool for this study is a validated, internet-based, electronic data capture 
(EDC) software system called RAVE.  Subject data necessary for analysis and reporting will 
be entered/transmitted into a validated database or data system (Clinical Information 
Environment).  
RAVE, which Bayer has licensed from Medidata Solutions Worldwide, has been validated by 
Medidata Solutions Worldwide and Bayer for use in its clinical studies.  RAVE allows for the 
application of software logic to set-up data entry screens and data checks to ensure the 
completeness and accuracy of the data entered by the site personnel.  Bayer extensively 
applies the logic to ensure data are complete and reflect the clinical data requirements of the 
study.  Data queries resulting from the application of the software logic are resolved by the 
site personnel.  The data are stored at a secure host facility maintained by Medidata Solutions 
Worldwide and transferred on a periodic basis to Bayer's internal computer system via a 
secure Virtual Private Network.
Access to RAVE is through a password-protected security system that is part of the RAVE 
software.  All Bayer and investigator site personnel must be trained before they are granted 
access.  Training records will be maintained.
All personnel with access to RAVE are supported by a Service Desk staffed with trained 
personnel to answer questions and ensure access is maintained so data entry can proceed in a 
timely manner.
RAVE contains a system-generated audit trail that captures any changes made to a data field, 
including who made the change, why the change was made, and the date and time it was 
made.  This information is available both at the investigator’s site and at Bayer.  Data entries 
made in the RAVE EDC screens are supported by source documents maintained for all 
subjects enrolled in this study.
Source documentation
The site must implement processes to ensure availability of all required source 
documentation.  A source document checklist (not part of this protocol) will be used at the 
site to identify the source data for key data points collected and the monitor will work with the 
site to complete this.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  74 of 113
It is the expectation of the sponsor that all data have source documentation available at the 
site except for the data entered directly into the eCRF (eg, HMB questions, ClinRO) and 
ePRO data; these data will be the source and no additional source documentation will be 
available.  The data entered directly into the eCRF/ePRO are not needed for the subject’s 
routine medical care. 
Data recorded from screening failures (screening failure confirmed at Visit 1)
At a minimum, the following data should have been recorded in the eCRF, which will be 
transferred to the respective database:

Demographic information (SID number, year of birth, age, race, ethnicity)

Date of informed consent

Date of Visit 1

Relevant inclusion/exclusion criteria

Reason for screening failure

Date of last visit.
For all subjects continuing after Visit 1, all data had to be reported until screen failure was 
declared or randomization occurred.  Additionally, to the above mentioned data these include:

All available data from Visit 1, Visit 2, and Visit 3 including visit independent folder 
data, if applicable (AE, concomitant medication, and medical history data)

Endometrial biopsy results (if done before screen failure was declared)

Reason for premature discontinuation, if applicable
For screening failures with an SAE or a pregnancy all information related to the 
SAE/pregnancy should be recorded in the eCRF (eg, the SAE, concomitant medication, 
medical history, other information needed for SAE/pregnancy complementary page).
Monitoring
11.2
In accordance with applicable regulations, GCP, and sponsor’s/CRO’s procedures, monitors 
contacted the site prior to the start of the study to review with the site staff the protocol, study 
requirements, and their responsibilities to satisfy regulatory, ethical, and sponsor’s 
requirements.  When reviewing data collection procedures, the discussion also included
identification and documentation of source data items.
The sponsor/designee is monitoring the site activity to verify that the:

Data are authentic, accurate and complete

Safety and rights of subjects are being protected

Study is conducted in accordance with the currently approved protocol (including 
study treatment being used in accordance with the protocol)

Any other study agreements, GCP, and all applicable regulatory requirements are met.
The investigator and the head of the medical institution (where applicable) agrees to allow the 
monitor direct access to all relevant documents.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  75 of 113
Data processing
11.3
Data management is performed consistent with applicable sponsor’s standards and data 
cleaning procedures.  This is applicable for data recorded in the eCRF as well as for data from 
other sources (eg, IVRS/IWRS, laboratory, ePRO).
For data coding (eg, AEs, medication), internationally recognized and accepted dictionaries 
are used.  MedDRA is used for AEs and medical history and WHO Drug Dictionary for prior 
and concomitant medication.
The results of endometrial biopsies taken after the FUP visit will be entered into the clinical 
database at a pre-planned database re-opening, if needed. These results will not be part of the 
clinical study report, but will be reported in a separate addendum to the report after all the 
relevant data are available if applicable. Also, a re-opening of the database may become 
necessary in order to include the results of the PK measurements.
Missing data 
11.4
Most important is to avoid missing data (eg, by monitoring in time for completeness; see 
Section 11.2) and by training the investigators, especially instructing them to motivate 
subjects to be compliant with the study protocol. Study site personnel has been trained to
monitor the completeness of the eDiary data using the web portal, and the importance of the 
regular checks throughout the study for all subjects were emphasized in the training and by 
the Clinical Research Associate during the study. The subjects were informed on use of the 
dispensed sanitary products, and the reasons for adhering to these practices were emphasized 
at the beginning of the study and reviewed with them during the site visits.
Audit and inspection
11.5
To ensure compliance with GCP and regulatory requirements, a member of the sponsor’s (or a 
designated CRO’s) quality assurance unit may arrange to conduct an audit to assess the 
performance of the study at the study site and of the study documents originating there.  The 
investigator/institution will be informed of the audit outcome.
In addition, inspections by regulatory health authority representatives and IEC(s)/IRB(s) are 
possible.  The investigator should notify the sponsor immediately of any such inspection.
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to 
discuss findings and any issues.  Audits and inspections may occur at any time during or after
completion of the study.
Archiving
11.6
Essential documents shall be archived safely and securely in such a way that ensures that they 
are readily available upon authorities’ request.
Subject (hospital) files will be archived according to local regulations and in accordance with 
the maximum period of time permitted by the hospital, institution or private practice.  Where 
the archiving procedures do not meet the minimum timelines required by the sponsor, 
alternative arrangements must be made to ensure the availability of the source documents for 
the required period.
The investigator/institution notifies the sponsor if the archival arrangements change (eg, 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  76 of 113
relocation or transfer of ownership).
The investigator site file is not to be destroyed without the sponsor’s approval.
The contract with the investigator/institution will contain all regulations relevant for the study 
center.
12.
Premature termination of the study
The sponsor has the right to close this study (or, if applicable, individual segments thereof 
[eg, treatment arms; dose steps; centers]) at any time, which may be due but not limited to the 
following reasons: 

If risk-benefit ratio becomes unacceptable owing to, for example,

Safety findings from this study (eg, SAEs)

Results of parallel clinical studies

Results of parallel animal studies (on eg, toxicity, teratogenicity, 
carcinogenicity or reproduction toxicity).

If the study conduct (eg, recruitment rate; drop-out rate; data quality; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time 
frame.
The investigator has the right to close his/her center at any time.
For any of the above closures, the following applies:

Closures should occur only after consultation between involved parties.  Final decision 
on the closure must be in writing.

All affected institutions (eg, IECs/IRBs; competent authority[ies]; study center; head 
of study center) must be informed as applicable according to local law.

All study materials (except documentation that has to remain stored at site) must be 
returned to the sponsor.  The investigator will retain all other documents until 
notification is given by the sponsor for destruction.

In the event of a partial study closure, ongoing subjects, including those in post study 
follow-up, must be taken care of in an ethical manner.
Details for individual subject's withdrawal can be found in Section 6.4.1.
13.
Ethical and legal aspects
Investigators and other study personnel
13.1
Study Medical Expert is identified on the Title Page of this protocol (see Section 1). From 
among the participating investigators, the Global Clinical Leader will select the coordinating 
investigator, who will be responsible for signing the clinical study report.  All other study 
personnel not included in this section are identified in a separate personnel list (not part of this 
clinical study protocol) as appropriate. This list will be updated as needed; an abbreviated 
version with personnel relevant for the centers will be available in each center’s investigator 
site file.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  77 of 113
Whenever the term ‘investigator’ is noted in the protocol text, it may refer to either the 
principal investigator at the site, or an appropriately qualified, trained and delegated 
individual of the investigational site.
The principal investigator of each center must sign the protocol signature page and must 
receive all required external approvals (eg, health authority, ethics committee, sponsor) before 
subject recruitment may start at the respective center.  Likewise, all amendments to the 
protocol must be signed by the principal investigator and must have received all required 
external approvals before coming into effect at the respective center.
A complete list of all participating centers and their investigators, as well as all required 
signature documents, will be maintained in the sponsor’s study file.
The global sponsor of this study is identified on the title page of this protocol.  If required by 
local law, local co-sponsors will be nominated; they will be identified on the respective 
country-specific signature pages.
Funding and financial disclosure
13.2
Funding
This study will be funded by its sponsor.
Financial disclosure 
Each investigator (including principal and/or any sub investigators) who is directly involved 
in the treatment or evaluation of research subjects has to provide a financial disclosure 
according to all applicable legal requirements.  All relevant documentation will be filed in the 
trial master file.
Ethical and legal conduct of the study
13.3
The procedures set out in this protocol, pertaining to the conduct, evaluation, and 
documentation of this study, are designed to ensure that the sponsor and investigator abide by 
GCP guidelines and the guiding principles detailed in the Declaration of Helsinki.  The study 
will also be carried out in keeping with applicable local law(s) and regulation(s).
Documented approval from appropriate IECs/IRBs will be obtained for all participating 
centers/countries before start of the study, according to GCP, local laws, regulations and 
organizations.  When necessary, an extension, amendment or renewal of the IEC/IRB 
approval must be obtained and also forwarded to the sponsor.  The responsible unit (eg,
IEC/IRB, head of the study center/medical institution) must supply to the sponsor, upon 
request, a list of the IEC/IRB members involved in the vote and a statement to confirm that 
the IEC/IRB is organized and operates according to GCP and applicable laws and regulations.
Strict adherence to all specifications laid down in this protocol is required for all aspects of 
study conduct; the investigator may not modify or alter the procedures described in this 
protocol.  
Modifications to the study protocol will not be implemented by either the sponsor or the 
investigator without agreement by both parties.  However, the investigator or the sponsor may 
implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) 
to the trial subjects without prior IEC/IRB/sponsor approval/favorable opinion.  As soon as 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  78 of 113
possible, the implemented deviation or change, the reasons for it and if appropriate the 
proposed protocol amendment should be submitted to the IEC/IRB/head of medical 
institution/sponsor.  Any deviations from the protocol must be explained and documented by 
the investigator.
Details on discontinuation of the entire study or parts thereof can be found in Section 12.
Subject information and consent
13.4
All relevant information on the study will be summarized in an integrated subject information 
sheet and informed consent provided by the sponsor or the study center.  A sample subject 
information and informed consent is provided as a document separate to this protocol.
Based on this subject information sheet, the investigator or designee will explain all relevant 
aspects of the study to each subject, prior to her entry into the study (ie, before any 
examinations and procedures associated with the selection for the study are performed or any 
study-specific data is recorded on study-specific forms).
The investigator will also mention that written approval of the IRB/IEC has been obtained.
Each subject will be informed about the following aspects of premature withdrawal:
Each subject has the right to withdraw from the study at any time without any 
disadvantage and without having to provide reasons for this decision.  
The subject’s consent covers end-of-study examinations as specified in the protocol 
amendment 3 (version 3.0) to be conducted after withdrawal of consent.  
The subject’s data that have been collected until the time of withdrawal will be retained 
and statistically analyzed in accordance with the SAP
Subject-specific data on the basis of material obtained before withdrawal may be 
generated after withdrawal (eg, image reading, analysis of biological specimen such as 
blood, urine or tissues); these data would also be retained and statistically analyzed in 
accordance with the SAP.  The subject has the right to object to the generation and 
processing of this post-withdrawal data. The subject’s oral objection may be documented 
in the subject’s source data.
Each subject will have ample time and opportunity to ask questions and will be informed 
about the right to withdraw from the study at any time without any disadvantage and without 
having to provide reasons for this decision.
Only if the subject voluntarily agrees to sign the informed consent and has done so, may she 
enter the study.  Additionally, the investigator will personally sign and date the form.  The 
subject will receive a copy of the signed and dated form.
The signed informed consent is to remain in the investigator site file or, if locally required, in 
the subject’s note/file of the medical institution. 
If the informed consent is obtained on the date that baseline study procedures are performed, 
the study record or subject´s clinical record must clearly show that informed consent was 
obtained prior to these procedures.
The informed consent and any other written information provided to subjects will be revised 
whenever important new information becomes available that may be relevant to the subject’s 
consent, or there is an amendment to the protocol that necessitates a change to the content of 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  79 of 113
the subject information and/or the written informed consent.  The investigator will inform the 
subject of changes in a timely manner and will ask the subject to confirm her participation in 
the study by signing the revised informed consent.  Any revised informed consent text and 
other information must receive the IEC/IRB’s approval/favorable opinion in advance of use.
Publication policy and use of data
13.5
All relevant aspects regarding publication will be part of the contract between the sponsor and 
the investigator/institution.
The sponsor has made the information regarding the study protocol publicly available on the 
internet at www.clinicaltrials.gov. 
All data and results and all intellectual property rights in the data and results derived from the 
study will be the property of the sponsor who may utilize them in various ways, such as for 
submission to government regulatory authorities or disclosure to other investigators.
Regarding public disclosure of study results, the sponsor will fulfill its obligations according 
to all applicable laws and regulations.  The sponsor is interested in the publication of the 
results of every study it performs.  
The sponsor recognizes the right of the investigator to publish the results upon completion of 
the study.  However, the investigator, whilst free to utilize study data derived from his/her 
center for scientific purposes, must obtain written consent of the sponsor on the intended 
publication manuscript before its submission.  To this end, the investigator must send a draft 
of the publication manuscript to the sponsor within a time period specified in the contract.  
The sponsor will review the manuscript promptly and will discuss its content with the 
investigator to reach a mutually agreeable final manuscript.  
Compensation for health damage of subjects / insurance
13.6
The sponsor maintains clinical trial insurance coverage for this study in accordance with the 
laws and regulations of the country in which the study is performed.
Confidentiality
13.7
All records identifying the subject will be kept confidential and, to the extent permitted by the 
applicable laws and/or regulations, will not be made publicly available.
Subject names will not be supplied to the sponsor.  Only the SID number will be recorded in 
the eCRF, and if the subject name appears on any other document (eg, pathologist report), it 
must be obliterated before a copy of the document is supplied to the sponsor.  Study findings 
stored on a computer will be stored in accordance with local data protection laws.  As part of 
the informed consent process, the subjects will be informed in writing that representatives of 
the sponsor, IEC/IRB, or regulatory authorities may inspect their source documents to verify 
the information collected, and that all personal information made available for inspection will 
be handled in strictest confidence and in accordance with local data protection laws.
If the results of the study are published, the subject’s identity will remain confidential.
The investigator will maintain a list to enable subjects to be identified.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  80 of 113
14.
Reference list 
1.
Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered 
adrenal masses. Endocr Rev. 1995;16(4):460-84.
2.
Hallberg L, Nilsson L. Determination of Menstrual Blood Loss. Scand J Clin Lab 
Invest. 1964;16:244-8.
3.
Emons G, Beckmann MW, Schmidt D, Mallmann P, for the Uterus commission of the 
Gynecological Oncology Working G. New WHO Classification of Endometrial 
Hyperplasias. GebFra - DGGG-Gesellschaftsausgaben. 2015(01):135-6.
4.
WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of 
severity (WHO/NMH/NHD/MNM/11.1). Available from: 
http://who.int/vmnis/indicators/haemoglobin.pdf, accessed 26 Jan 2016. 2011.
15.
Protocol amendments
Amendment 2 – Dated 15 NOV 2017
15.1
Amendment 2 is the first global amendment. The following is an overview of the changes 
made to the original protocol Version 1.0.
15.1.1
Overview of the changes to the study
The protocol was amended to maintain consistency across Vilaprisan Phase 3 studies and to 
modify the collection period of the sanitary products.
Change 1: Modification of the collection periods of sanitary products
15.1.1.1
The collection period for sanitary products was extended to cover the entire study.
Rationale
Currently, the alkaline hematin method is the only validated method to collect information on 
menstrual blood loss volume accepted by the FDA. In order not to jeopardize the data 
collection in the two pivotal studies, Asteroid 3 and 4, by using a non-validated method, ie, 
the menstrual pictogram, the decision was made to use both, AH and MP, throughout the 
entire study.
Affected sections:

Section 9.2.3 Scheduled visits

Section 9.2.3.1 Visit 1 Screening

Section 9.2.3.2 Visit 2 Screening

Section 9.2.3.3 Visit 3 Randomization

Section 9.2.3.4 Visits 4, 5, and 6

Section 9.2.3.5 EoT visit

Section 9.4.3 Alkaline hematin method to assess HMB

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  81 of 113
Change 2: Changes in the statistical analysis
15.1.1.2
Statistical sections of the protocol were updated.
Rationale:
In order to consider feedback from Authorities and to support label claims on the endpoints 
HMB response, time to onset of amenorrhea and time to onset of controlled bleeding, time to 
onset of amenorrhea was elevated to a secondary endpoint and all of these above-mentioned 
endpoints were included in the hierarchical testing strategy. Description of analyses and 
missing data considerations were added for these endpoints and the rationale for the study 
sample size was modified with respect to these changes in the testing strategy. Furthermore, 
the calculation of the primary efficacy variable was adapted and further efficacy variables 
were added to ‘other’ efficacy variables. 
Affected sections:

Section 9.6.3.1 Laboratory evaluations

Section 10.3.1 Variables

Section 10.3.1.1 Primary efficacy variable

Section 10.3.1.2 Secondary efficacy variables

Section 10.3.1.3 Other efficacy variables

Section 10.3.1.6 Other safety variables

Section 10.3.2.2 Efficacy analysis, Section 10.3.2.3 Secondary efficacy analysis and 
Section 10.3.2.4 other efficacy

Section 10.3.2.5 Subgroup analysis

Section 10.3.3 Missing data/drop-outs

Section 10.4 Determination of sample size
Change 3: Modifications of the tabular schedule of evaluations
15.1.1.3
Footnotes were modified.
Rationale:
Footnotes were revised to reflect the actual requirements correctly.
Affected sections:

Section 9.1 Tabular schedule of evaluations
Change 4: Minor clarifications for consistency
15.1.1.4
Clarifications were made throughout the document to ensure readability, logic and 
consistency of the protocol and across studies.
Affected sections:

Section 2 Synopsis

Section 5 Study design

Section 6.2 Exclusion criteria

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  82 of 113

Section 9.1 Tabular schedule of evaluations

Section 9.2.2 Optional pre-screening phone contact

Section 9.4.4 Ultrasound (efficacy) to assess uterine fibroids

Section 9.6.1.1 Definitions

Section 9.6.3.3 Cervical smear

Section 9.7.1 Iron supplementation

Section 9.7.3 Heavy menstrual bleeding / suspicious bleeding pattern
15.1.2
Changes to the protocol text
In this section, all changes are detailed by presenting the “old text” and the “new text”, and 
the sequence of the sections follows the structure of the protocol. Deletions are crossed out 
and additions are underlined. Corrections of typos or omissions, as well as automatic update 
of referenced numbers and changes in the list of abbreviations, are not highlighted.
Section 2 Synopsis
15.1.2.1
Old text:
[…]
Methodology
Subjects will document the intensity of their daily menstrual bleeding in the 
Uterine Fibroid Daily Bleeding Diary (UF-DBD) and assess the intensity of 
their menstrual blood loss daily using a visual scoring system (MP) in an 
electronic diary (eDiary).  Subjects will collect the sanitary products used 
during specified periods of the study to analyze the volume of blood loss 
using the AH method.
[…]
[…]
Plan for statistical analysis
The primary efficacy will be assessed by testing the amenorrhea rates of 
vilaprisan after 12 weeks of treatment in Treatment Period 1 and after 
24 weeks of treatment in Treatment Period 2 (with and without a break) 
versus placebo after 12 weeks of treatment using two-sided Cochran-
Mantel-Haenszel test at a 0.05 significance level. A hierarchical (fixed 
sequence) testing procedure will be used.
In addition, efficacy and safety variables will be summarized by descriptive 
statistics.
New text:
[…]
[…]

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  83 of 113
Methodology
Subjects will document the intensity of their daily menstrual bleeding in the 
Uterine Fibroid Daily Bleeding Diary (UF-DBD) and assess the intensity of 
their menstrual blood loss daily using a visual scoring system (MP) in an 
electronic diary (eDiary). Subjects will collect the sanitary products used 
during the study to analyze the volume of blood loss using the AH method.
[…]
[…]
Plan for statistical analysis
The primary efficacy will be assessed by testing the amenorrhea rates of 
vilaprisan after 12 weeks of treatment in Treatment Period 1 and after 
24 weeks of treatment in Treatment Period 2 (with and without a break) 
versus placebo after 12 weeks of treatment using two-sided Cochran-
Mantel-Haenszel test at a 0.05 significance level. A hierarchical (fixed 
sequence) testing procedure will be used, involving the primary efficacy 
variable amenorrhea and key secondary efficacy variables HMB response, 
time to onset of amenorrhea and time to onset of controlled bleeding.
In addition, efficacy and safety variables will be summarized by descriptive 
statistics.
Section 5 Study design
15.1.2.2
Old text:
[…]
Overview of the study design is shown in Figure 5–1.
Figure 5–1  Design overview
Treatment 
Group A1
Screening
about 120 days
RND
Vilaprisan 2 mg 
12 week
B
Vilaprisan 2 mg 
12 week
12-week
follow-up
Treatment 
Group A2
Screening
about 120 days
RND
Vilaprisan 2 mg
12 week
Vilaprisan 2 mg 
12 week
12-week 
follow-up
Treatment 
Group B1
Screening
about 120 days
RND
Placebo 
12 week
B
Vilaprisan 2 mg
12 week
12-week 
follow-up
Treatment 
Group B2
Screening
about 120 days
RND
Vilaprisan 2 mg 
12 week
B
Placebo
12 week
12-week 
follow-up
B = bleeding episode; RND = randomization.
During the screening period, subjects will have to demonstrate eligibility including the 
presence of at least 1 uterine fibroid 30 mm and <120 mm in largest diameter based on 
ultrasound, HMB in at least 2 bleeding periods, each with menstrual blood loss (MBL) 
>80.00 mL, documented by the alkaline hematin (AH) method, and endometrial biopsy 
results without significant histological disorder.  The duration of the screening period should 
be kept to a minimum (about 120 days).  In the event that the screening endometrial biopsy 
yielded an inadequate sample and needs to be repeated before randomization, the screening 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  84 of 113
period interval is allowed to be extended in order to accommodate the endometrial sample 
analysis.  In this case, the randomization visit (Visit 3) should take place:  1) after the biopsy 
results are available, 2) when all the eligibility criteria are confirmed, and 3) as close to the 
screening period interval as possible.
[…]
After the end of the final treatment period, subjects will be followed up for 12 weeks.
[…]
Dose and regimen:
Nine Phase 1 studies with vilaprisan have been completed.  Vilaprisan has been tested at a 
maximum oral dose of 30 mg for up to 28 days (Study 14721, Report A52153) in 
postmenopausal women and at oral doses of 0.1, 0.5, 1.0, 2.0 and 5.0 mg for up to 12 weeks 
(Study 14723, Report A56310) in healthy young women.
[…]
New text:
[…]
Overview of the study design is shown in Figure 5–1.
Figure 5–1  Design overview 
Treatment 
Group A1
Screening
up to 120 days
RND
Vilaprisan 2 mg 
12 week
B
Vilaprisan 2 mg 
12 week
Follow-up Day 
7 to 15 of the 2nd
menstrual cycle 
after EoT
Treatment 
Group A2
Screening
up to 120 days
RND
Vilaprisan 2 mg
12 week
Vilaprisan 2 mg 12 
week
Follow-up Day 
7 to 15 of the 
2nd menstrual 
cycle after EoT
Treatment 
Group B1
Screening
up to 120 days
RND
Placebo 
12 week
B
Vilaprisan 2 mg
12 week
Follow-up Day 
7 to 15 of the 2nd
menstrual cycle 
after EoT
Treatment 
Group B2
Screening
up to 120 days
RND
Vilaprisan 2 mg 
12 week
B
Placebo
12 week
Follow-up Day 
7 to 15 of the 2nd
menstrual cycle 
after EoT
B = bleeding episode; RND = randomization.
During the screening period, subjects will have to demonstrate eligibility including the 
presence of at least 1 uterine fibroid 30 mm and <120 mm in largest diameter based on 
ultrasound, HMB in at least 2 bleeding periods, each with menstrual blood loss (MBL) 
>80.00 mL, documented by the alkaline hematin (AH) method, and endometrial biopsy 
results without significant histological disorder.  The duration of the screening period should 
be kept to a minimum (maximum up to 120 days).  In the event that the screening endometrial 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  85 of 113
biopsy yielded an inadequate sample and needs to be repeated before randomization, the 
screening period interval is allowed to be extended in order to accommodate the endometrial 
sample analysis.  In this case, the randomization visit (Visit 3) should take place:  1) after the 
biopsy results are available, 2) when all the eligibility criteria are confirmed, and 3) as close 
to the screening period interval as possible.
[…]
After the end of the final treatment period, subjects will be followed up until day 7 to 15 of 
the 2nd menstrual cycle after end of treatment visit.
[…]
Dose and regimen:
Ten Phase 1 studies with vilaprisan have been completed.  Vilaprisan has been tested at a 
maximum oral dose of 30 mg for up to 28 days (Study 14721, Report A52153) in 
postmenopausal women and at oral doses of 0.1, 0.5, 1.0, 2.0 and 5.0 mg for up to 12 weeks 
(Study 14723, Report A56310) in healthy young women.
[…]
Section 6.2 Exclusion criteria
15.1.2.3
Old text:
[…]
8. Use of other treatments that might interfere with the conduct of the study or the 
interpretation of the results including
[…]

Contraceptive devices with or without hormone release (implant, intra-uterine 
device), if not removed at Visit 
[…]
New text:
[…]
8. Use of other treatments that might interfere with the conduct of the study or the 
interpretation of the results including
[…]

Contraceptive devices with or without hormone release (implant, intra-uterine 
device), if not removed at Visit 1 (not applicable in cases of bilateral fallopian 
tube blockage of the subject (including Essure®))
[…]
Section 9.1 Tabular schedule of evaluations
15.1.2.4
Old text:
[…]

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  86 of 113
Table 9—1: Schedule of procedures
Study Phase
Screening
TP 1 a
TP 2 b
FUP 
Visit 
1
2
3
4 c
5
6 d
EoT
Visit e
FUP
Visit f
Timing
Day 7-15 
(inclusive) of the 
1st or 2nd 
menstrual cycle 
after Visit 1
RND
Day 22-42/ 
Wk 4-6 
after start 
of TP1
Day 78-
84/ Wk 
12 after 
start of 
TP1
Day 22-42/
Wk 4-6 
after start 
of TP2
Day 78-
84/ Wk 
12 after 
start of 
TP2
Day 7-15 
(inclusive) 
of the 2nd 
menstrual 
cycle 
after EoT
Informed consent
X
In-/exclusion criteria
X
X
X
Demographics/smoking/alcohol 
consumption
X
Medical/reproductive/menstrual/fi
broids histories
X
HMB questions
X
Prior/ concomitant medications
X
X
X
X
X
X
X
X
AE assessments
X
X
X
X
X
X
X
X
Physical examination
X
X
X
Vital signs g/body 
weight/BMI/height at Visit 1 only
X
X
X
X
Gynecological/breast exam
X
X
Urine pregnancy test h
X
X
X
X
X
X
X
X
Cervical smear
X i
X
Ultrasound examination j
X
X k
X
X
X
X
X
X b
Instruct subject to call site at start 
of next menstrual bleed
X
X
X at the 
2nd bleed
Endometrial biopsy l
X m
X n
X b
Laboratory (blood) o
X
X
X
X
PK sampling p
X
X
Supervised study drug intake at 
site
X
X
Urinalysis
X
Barrier contraception/sanitary 
protection/home pregnancy test 
dispensed
X
X
X
X
X
X
X
Alkaline hematin kit dispensed
(as needed)
X
X
X
X
X
X
Collect pads and tampons (as 
needed)
→
→
→
→
→
→
Randomization
X
Study drug dispensed
X
X
X
X
Unused study drug and empty 
drug packs collected/drug 
accountability
X
X
X
X
X if 
applicable
Return unused study drug to 
subject
X
X q
X
X q
Assess subject’s study drug 
compliance
→
→
→
→
→ if 
applicable
eDiary dispensed/collected
X
X
eDiary checked via web-report
→
→
→
→
→
→
→
→
PRO (eDiary/hand held device) r:
UF-DSD
→
→
→
→
→
→
→
→
UF-DBD s
→
→
→
→
→
→
→
→
Menstrual pictogram
→
→
→
→
→
→
→
→
PRO (tablet computer) – completed at the site t:
UFS-QoL
X
X
X
X
PGI-S
X
X
X
PGI-C
X
X
SF-36v2
X
X
X
X
TSQM-9
X
X
ClinRO (RAVE): CGI_I
X
X
X
Treatment Day 1 is defined as the first day of study drug intake (ie, start of treatment).

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  87 of 113
a
If no bleeding episode occurs within 7 weeks after the end of the TP, an ultrasound will be performed after which 
bleeding will be induced (Treatment Groups A1, B1, and B2).
b
If spontaneous menstrual bleeding does not occur within 7 weeks after the EoT, the scheduled ultrasound will be 
performed as planned after which bleeding will be induced.  The scheduled endometrial biopsy (ie, at FUP visit) will 
be performed thereafter at Day 7-15 (inclusive) of the first menstrual cycle after the induced bleeding episode.  
Ultrasound and pregnancy test will be performed before the endometrial biopsy as described in Section 9.6.3.2.
c
Remind subjects randomized to Treatment Groups A1, B1 and B2 to start collecting sanitary items on Day 50 of the 
TP1.
d
Remind all subjects to start collecting sanitary items on Day 50 of the TP2; for subjects randomized to Treatment 
Group A2; this is Day 134 of treatment.
e
EoT visit is also to be performed if a subject is prematurely withdrawn from the study during treatment phase.
f
FUP visit is also to be performed, if a subject is prematurely withdrawn from the study during FUP phase.
g
Vital signs after 5 minutes of rest in a sitting position.
h
Instruct the subject to perform a home pregnancy test before the start of study drug treatment (all groups at TP 1, 
and all but Group A2 at TP 2), document it in the eDiary and only start study drug if the test is negative.
i
The cervical smear may be waived if a normal result has been documented in the subject’s source documents 
within the previous 6 months.
j
If endometrial thickness (double layer) >18 mm is detected after the start of treatment, the subject should undergo 
immediate evaluation by endometrial biopsy as described in Section 9.6.3.2.  If cyst like structures >30 mm without 
suspicious appearance (ie, functional cysts) are visualized in the ovaries, unscheduled ultrasound examinations to 
document regression/outcome of these finding should be performed every 4 weeks or more frequently, if required 
due to symptoms.
k
Ultrasound for safety only.
l
For scheduling the visits, consider for subjects with menstrual cycles that biopsies should be taken between Day 7-
15 (inclusive) of a menstrual cycle, which may require scheduling an additional visit. The EoT biopsy should be 
taken while under treatment; this biopsy may require to be scheduled before the EoT visit. A pregnancy test and 
ultrasound have to be performed before an endometrial biopsy is taken.  See Section 9.6.3.2 for details.
m
Check laboratory results prior to the biopsy at Visit 2 to ensure subject is still eligible for the study.
n
For subjects with amenorrhea, biopsies are to be taken without considering any day in a cycle.
o
Coagulation parameters will be determined at Visit 1 only.
p
PK sampling. At Visit 5, one sample is to be taken pre-dose.  At Visit 6, 1 sample is to be taken pre-dose, and 2 
samples are to be taken after supervised study drug intake at the site (one between 0.5-1 hour after, and one 
between 2-4 hours after study drug intake).  Document the following in the eCRF: the date and time of the last 2 
study drug doses prior to the first PK sample at each visit, the time of the supervised drug intake at the study site 
(Visits 5 and 6), and the time of all blood samples.  For China, a minimum of 30 subjects with two PK samples is 
required from some centers.  See Section 9.5.1.
q
For subjects who have completed the TP, collect unused study drug and empty packaging.  For subjects who have 
not completed TP, collect empty packaging and provide unused study drug back to the subject.  Instruct the subject 
to complete the treatment period.
r
PROs on the eDiary/electronic hand-held device will be responded by the subjects until the next visit at home as 
required.
s
Check for any suspicious bleeding pattern and/or HMB at each visit except Visit 1.
t
PROs on the tablet computer will be responded by the subjects at scheduled visits under standardized conditions in 
the same visit-relevant sequence and prior to other activities and evaluations.
= continuous collection of data (eg, daily or weekly questionnaire) or collection of data in a schedule different to 
the visit time point; AE = adverse event; BMI = body mass index; CGI_I = Clinical Global Impression -
Investigator; ClinRO= Clinician-reported outcome; EoT = end of treatment; FUP = follow-up; HMB = heavy 
menstrual bleeding; PGI-C = Patient Global Impression of Change; PGI-S = Patient Global Impression of 
Severity; PK = pharmacokinetics; PRO = patient-reported outcome; RND = randomization; SF-36v2 = Short Form 
36 Health Survey Version 2; TP = Treatment Period; TSQM-9 = Treatment Satisfaction Questionnaire for 
Medication (9 items); UF-DBD = Uterine Fibroid Daily Bleeding Diary; UF-DSD = Uterine Fibroid Daily Symptom 
Diary; UFS-QoL = Uterine Fibroid Symptom and Quality of Life questionnaire; Wk = week.
New text:
[…]

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  88 of 113
Table 9—1:  Schedule of procedures
Study Phase
Screening
TP 1 a
TP 2 b
FUP 
Visit 
1
2
3
4
5
6
EoT
Visit c
FUP
Visit d
Timing
Day 7-15 
(inclusive) of the 
1st or 2nd 
menstrual cycle 
after Visit 1
RND
Day 22-42/ 
Wk 4-6 
after start 
of TP1
Day 78-
84/ Wk 
12 after 
start of 
TP1
Day 22-42/
Wk 4-6 
after start 
of TP2
Day 78-
84/ Wk 
12 after 
start of 
TP2
Day 7-15 
(inclusive) 
of the 2nd 
menstrual 
cycle 
after EoT
Informed consent
X
In-/exclusion criteria
X
X
X
Demographics/smoking/alcohol 
consumption
X
Medical/reproductive/menstrual/fi
broids histories
X
HMB questions
X
Prior/ concomitant medications
X
X
X
X
X
X
X
X
AE assessments
X
X
X
X
X
X
X
X
Physical examination
X
X
X
Vital signs e/body 
weight/BMI/height at Visit 1 only
X
X
X
X
Gynecological/breast exam
X
X
Urine pregnancy test f
X
X
X
X
X
X
X
X
Cervical smear
X g
X
Ultrasound examination h
X
X i
X
X
X
X
X
X b
Instruct subject to contact site at 
start of next menstrual bleed
X
X at the 
2nd bleed
Endometrial biopsy j
X k
X l
X b
Laboratory (blood) m
X
X
X
X
PK sampling n
X
X
Supervised study drug intake at 
site
X
X
Urinalysis
X
Barrier contraception/sanitary 
protection/home pregnancy test 
dispensed
X
X
X
X
X
X
X
Alkaline hematin kit dispensed
(as needed)
X
X
X
X
X
X
X
Collect pads and tampons (as 
needed)
→
→
→
→
→
→
→
Randomization
X
Study drug dispensed
X
X
X
X
Unused study drug and empty 
drug packs collected/drug 
accountability
X
X
X
X
X if 
applicable
Return unused study drug to 
subject
X
X o
X
X o
Assess subject’s study drug 
compliance
→
→
→
→
→ if 
applicable
eDiary dispensed/collected
X
X
eDiary checked via web-report
→
→
→
→
→
→
→
→
PRO (eDiary/hand held device) p:
UF-DSD
→
→
→
→
→
→
→
→
UF-DBD q
→
→
→
→
→
→
→
→
Menstrual pictogram
→
→
→
→
→
→
→
→
PRO (tablet computer) – completed at the site r:
UFS-QoL
X
X
X
X
PGI-S
X
X
X
PGI-C
X
X
SF-36v2
X
X
X
X
TSQM-9
X
X
ClinRO (RAVE): CGI_I
X
X
X
Treatment Day 1 is defined as the first day of study drug intake (ie, start of treatment).

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  89 of 113
a
If no bleeding episode occurs within 7 weeks after the end of the TP, an ultrasound will be performed after which 
bleeding will be induced (Treatment Groups A1, B1, and B2).
b
If spontaneous menstrual bleeding does not occur within 7 weeks after the EoT, the scheduled ultrasound will be 
performed as planned after which bleeding will be induced.  The scheduled endometrial biopsy (ie, at FUP visit) will 
be performed thereafter at Day 7-15 (inclusive) of the first menstrual cycle after the induced bleeding episode.  
Ultrasound and pregnancy test will be performed before the endometrial biopsy as described in Section 9.6.3.2.
c
EoT visit is also to be performed if a subject is prematurely withdrawn from the study during treatment phase.
d
FUP visit is also to be performed, if a subject is prematurely withdrawn from the study during FUP phase.
e
Vital signs after 5 minutes of rest in a sitting position.
f
Instruct the subject to perform a home pregnancy test before the start of study drug treatment (all groups at TP 1, 
and all but Group A2 at TP 2), document it in the eDiary and only start study drug if the test is negative. 
g
The cervical smear may be waived if a normal result has been documented in the subject’s source documents 
within the previous 6 months.
h
1. Ultrasound measurements do not have to be done on the same day as other assessment on that visit, but have 
to be performed as close to the specified visit as possible. On visits where a biopsy will be taken, the ultrasound 
must be done before the biopsy.
2. If endometrial thickness (double layer) >18 mm is detected after the start of treatment, the subject should 
undergo immediate evaluation by endometrial biopsy as described in Section 9.6.3.2.  If cyst like structures >30 mm 
without suspicious appearance (ie, functional cysts) are visualized in the ovaries, unscheduled ultrasound
examinations to document regression/outcome of these finding should be performed every 4 weeks or more 
frequently, if required due to symptoms.
i
Ultrasound for safety only.
j
For scheduling the visits, consider for subjects with menstrual cycles that biopsies should be taken between Day 7-
15 (inclusive) of a menstrual cycle, which may require scheduling an additional visit. The EoT biopsy should be 
taken while under treatment; this biopsy may require to be scheduled before the EoT visit.  A pregnancy test and 
ultrasound have to be performed before an endometrial biopsy is taken.  See Section 9.6.3.2 for details.
k
Check laboratory results prior to the biopsy at Visit 2 to ensure subject is still eligible for the study. 
l
For subjects with amenorrhea, biopsies are to be taken without considering any day in a cycle.
m
Coagulation parameters will be determined at Visit 1 only.
n
PK sampling. At Visit 5, one sample is to be taken pre-dose.  At Visit 6, 1 sample is to be taken pre-dose, and 2 
samples are to be taken after supervised study drug intake at the site (one between 0.5-1 hour after, and one 
between 2-4 hours after study drug intake).  Document the following in the eCRF: the date and time of the last 2 
study drug doses prior to the first PK sample at each visit, the time of the supervised drug intake at the study site 
(Visits 5 and 6), and the time of all blood samples.  For China, a minimum of 30 subjects with PK samples from V5 
and V6 are required from some centers.  See Section 9.5.1.
o
For subjects who have completed the TP, collect unused study drug and empty packaging.  For subjects who have 
not completed TP, collect empty packaging and provide unused study drug back to the subject.  Instruct the subject 
to complete the treatment period.
p
PROs on the eDiary/electronic hand-held device will be responded by the subjects until the next visit at home as 
required.
q
Check for any suspicious bleeding pattern and/or HMB at each visit except Visit 1.
r
PROs on the tablet computer will be responded by the subjects at scheduled visits under standardized conditions in 
the same visit-relevant sequence and prior to other activities and evaluations.
= continuous collection of used sanitary products (pads or tampons), data (eg, daily or weekly questionnaire) or 
collection of data and used sanitary products in a schedule different to the visit time point; 
AE = adverse event; BMI = body mass index; CGI_I = Clinical Global Impression - Investigator; ClinRO= 
Clinician-reported outcome; EoT = end of treatment; FUP = follow-up; HMB = heavy menstrual bleeding; PGI-C = 
Patient Global Impression of Change; PGI-S = Patient Global Impression of Severity; PK = pharmacokinetics; 
PRO = patient-reported outcome; RND = randomization; SF-36v2 = Short Form 36 Health Survey Version 2; TP = 
Treatment Period; TSQM-9 = Treatment Satisfaction Questionnaire for Medication (9 items); UF-DBD = Uterine 
Fibroid Daily Bleeding Diary; UF-DSD = Uterine Fibroid Daily Symptom Diary; UFS-QoL = Uterine Fibroid 
Symptom and Quality of Life questionnaire; Wk = week.
Section 9.2.2 Optional pre-screening phone contact
15.1.2.5
Old text:
[…]
After the telephone discussion, the patient information and informed consent form may be 
sent to the subject for further information.  Regardless of whether the patient information and 
informed consent form is sent to the subject, it must be thoroughly discussed and reviewed 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  90 of 113
with her at the Screening Visit 1 before obtaining the signed informed consent form.
[…]
New text:
[…]
After the telephone discussion, the patient information and informed consent form may be 
sent to the subject for further information.  Regardless of whether the patient information and 
informed consent form is sent to the subject, it must be thoroughly discussed and reviewed 
with her in person before obtaining the signed informed consent form.
[…]
Section 9.2.3 Scheduled visits
15.1.2.6
Old text:
For timing of the visits see Table 9—1.  Site personnel will determine the start of each 
treatment period from the eDiary provider web portal. Subjects must be contacted (eg, via 
phone call) after the first dose is taken in each treatment period to schedule the subsequent 
visits.
New text:
For timing of the visits see Table 9—1.  Site personnel will determine the start of each 
treatment period from the eDiary provider web portal. For Scheduling Visit 6 and the EoT 
visit in Treatment Group A2, the Day 1 of the TP2 is the next day after Day 84 of TP1.
Subjects must be contacted (eg, via phone call) after the first dose is taken in each treatment 
period to schedule the subsequent visits.
Section 9.2.3.1 Visit 1 Screening
15.1.2.7
Old text:
[…]

Dispense AH kit

Dispense sanitary protection.  Explain procedure for collection of sanitary protection 
items for measurement of menstrual blood loss.

Remind the subject to return all used sanitary protection items as soon as the bleeding 
episode has been completed. 
[…]
New text:
[…]
[…]

Dispense AH kit and sanitary protection. Explain procedure for collection of sanitary 
protection items for measurement of menstrual blood loss

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  91 of 113

Remind the subject to return all used sanitary protection items as soon as the bleeding 
episode has been completed (but no later than 12 days from the start of the collection 
of the first item)
[…]
Section 9.2.3.2 Visit 2 Screening
15.1.2.8
Old text:
[…]

Dispense AH kit

Dispense sanitary protection
[…]

Remind the subject to return all used sanitary protection items as soon as a bleeding 
episode has been completed
[...]
New text:
[…]

Dispense AH kit and sanitary protection. Explain procedure for collection of sanitary 
protection items for measurement of menstrual blood loss.
[…]

Remind the subject to return all used sanitary protection items as soon as a bleeding 
episode has been completed, (but no later than 12 days from the start of the collection 
of the first item).
[…]
Section 9.2.3.3 Visit 3 Randomization
15.1.2.9
Old text:
[…]

Dispense sanitary protection
[…]

Complete ClinRO (RAVE):  CGI_I (see Section 9.4.2)
New text:
[…]

Dispense AH kit and sanitary protection. Explain procedure for collection of sanitary 
protection items for measurement of menstrual blood loss
[…]

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  92 of 113

Remind the subject to return all used sanitary protection items as soon as a bleeding 
episode has been completed (but no later than 12 days from the start of the collection 
of the first item).

Complete ClinRO (RAVE):  CGI_I (see Section 9.4.2)
Section 9.2.3.4 Visits 4, 5, and 6
15.1.2.10
Old text:
[…]

Dispense AH kit

Dispense sanitary protection

Visit 4: Remind subjects randomized to Treatment Groups A1, B1, and B2 to start 
collecting sanitary items on day 50 of the TP1; collection to be continued until the end 
of this TP. 
Remind the subject to return all used sanitary protection items as soon as the bleeding 
episode has been completed.

Visit 5: Collect used sanitary protection items, if they have not yet been provided to 
the site. If a subject is continuing her treatment after the visit, remind her to continue 
collecting the used sanitary items until the end of their treatment and advise the 
subject to return them to the site as soon as bleeding episode has been completed.

Visit 6: Remind all subjects to start collecting sanitary items on Day 50 of the TP2; for 
subjects randomized to Treatment Group A2; this is Day 134 of their treatment. ; 
Collection is to be continued until the end of this TP. 
Remind the subject to return all used sanitary protection items as soon as the bleeding 
episode has been completed.
[…]

Remind the subject to complete eDiary-based questionnaires until the next visit as 
required (UF-DSD, UF-DBD, and MP) (see Sections 9.4.1.1 and 9.4.1.2.2)

Check of eDiary entries via web; check for suspicious bleeding pattern and HMB (see 
Section 9.7.3)
[…]
New text:
[…]

Dispense AH kit and sanitary protection. Explain procedure for collection of sanitary 
protection items for measurement of menstrual blood loss

Collect used sanitary protection items, if they have not yet been provided to the site.
[…]

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  93 of 113

Remind the subject to complete eDiary-based questionnaires until the next visit as 
required (UF-DSD, UF-DBD, and MP) (see Sections 9.4.1.1 and 9.4.1.2.2)

Remind the subject to return all used sanitary protection items as soon as a bleeding 
episode has been completed, (but no later than 12 days from the start of the collection 
of the first item).

Check of eDiary entries via web; check for suspicious bleeding pattern and HMB (see 
Section 9.7.3)
[…]
Section 9.2.3.5 EoT visit
15.1.2.11
Old text:
[…]

Collect used sanitary protection items, if they have not yet been provided to the site. If 
a subject is continuing her treatment after the visit, remind her to continue collecting 
the used sanitary items until the end of her treatment and remind the subject to return 
them to the site as soon as bleeding episode has been completed.

Remind the subject to return all used sanitary protection items as soon as a bleeding 
episode has been completed

Endometrial biopsy (see Section 9.6.3.2)

Laboratory evaluations excluding coagulation parameters and urinalysis (see Section 
9.6.3.1)

Dispense barrier contraception (eg, condoms with spermicide) (see Section 9.6.3.7)

Dispense AH kit

Dispense sanitary protection
[…]
New text:
[…]

Collect used sanitary protection items, if they have not yet been provided to the site. 

Remind the subject to continue collecting the used sanitary products during the 
follow-up.

Remind the subject to return all used sanitary protection items as soon as a bleeding 
episode has been completed, (but no later than 12 days from the start of the collection 
of the first item).

Endometrial biopsy (see Section 9.6.3.2)

Laboratory evaluations excluding coagulation parameters and urinalysis (see Section 
9.6.3.1)

Dispense barrier contraception (eg, condoms with spermicide) (see Section 9.6.3.7)

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  94 of 113

Dispense AH kit and sanitary protection. Explain procedure for collection of sanitary 
protection items for measurement of menstrual blood loss.
[…]
Section 9.4.3 Alkaline hematin method to assess HMB
15.1.2.12
Old text:
During the duration of the study, subjects will be required to use selected types of sanitary 
products provided (pads and/or tampons). During specified periods of the study, subjects need 
to collect their used sanitary products and return them to the study site as soon as the episode 
is completed to be sent to the central laboratory for analysis. 
The AH method will be applied to measure MBL during Screening and during the last 35 
days of each treatment period. Collection for 35 days at the end of each treatment period is 
chosen to avoid missing data for calculation of the primary endpoint (last 28 days of 
treatment) in cases where subjects stop treatment prematurely.
[…]
New text:
During the duration of the study, subjects will be required to use selected types of sanitary 
products provided (pads and/or tampons). During the entire duration of the study, subjects 
need to collect their used sanitary products and return them to the study site as soon as the 
bleeding episode is completed to be sent to the central laboratory for analysis. 
The AH method will be applied to measure MBL from Screening onwards during the entire 
study.
[…]
Section 9.4.4 Ultrasound (efficacy) to assess uterine fibroids
15.1.2.13
Old text:
[…]
The minimum source documentation will include printouts from the ultrasound machine 
showing the 3 largest fibroids.  The printouts have to be labeled unambiguously, containing at 
least the study number, SID number, time point, and longest diameter of 3 largest fibroids.
For safety ultrasound procedures, see Section 9.6.3.6.
New text:
[…]
The minimum source documentation will include printouts from the ultrasound machine 
showing the 3 largest fibroids.  The printouts have to be labeled unambiguously, containing at 
least the study number, SID number, time point, and longest diameter of 3 largest fibroids. It 
is also possible that the site has a CD with the ultrasound images available, when in the source 
the evaluation of the US images from the CD is available as well. The CRA should be able to 
review the data on the CD and compare the images with the evaluations in the source during 
the onsite monitoring visits.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  95 of 113
Furthermore, if the US machine is SESAC (Site Electronic Source Assessment Checklist) 
conform, ie, GCP conform electronic data storage is possible, then no print out is needed
For safety ultrasound procedures, see Section 9.6.3.6.
Section 9.6.1.1 Definitions
15.1.2.14
Old text:
In a clinical study, an AE is any untoward medical occurrence (ie, any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or 
clinical investigation subject after providing written informed consent for participation in the 
study.  Therefore, an AE may or may not be temporally or causally associated with the use of 
a medicinal (investigational) product.
[…]
New text:
In a clinical study, an AE is any untoward medical occurrence (ie, any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or 
clinical investigation subject after providing written informed consent for participation in the 
study.  Therefore, an AE may or may not be temporally or causally associated with the use of 
a medicinal (investigational) product. Treatment emergent adverse event (TEAE) is defined as 
any event that occurred after the first study drug intake until the end of FUP.
[…]
Section 9.6.3.1 Laboratory evaluations
15.1.2.15
A footnote was added to Laboratory evaluations of hematocrit, hemoglobin, and ferritin 
stating that hemoglobin, hematocrit and ferritin are also efficacy variables.
Section 9.6.3.3 Cervical smear
15.1.2.16
Old text:
The cervical smear should be obtained with the gynecological examination at the visits shown 
in Table 9—1. It may be repeated once during the screening period if the results are abnormal 
(this repeat is not considered rescreening).  If the cervical smear is repeated at Visit 2 
(screening), it should be performed before the endometrial biopsy.  The cervical smear at 
screening may be waived if a normal result has been documented in the subject’s source 
documents within the previous 6 months.  Subjects with ASCUS can be included in the study 
if they have an HPV deoxyribonucleic acid test that is negative for high-risk HPV.
New text:
The cervical smear should be obtained with the gynecological examination at the visits shown 
in Table 9—1. It may be repeated once during the screening period if the results are abnormal 
(this repeat is not considered rescreening).  If the cervical smear is repeated at Visit 2 
(screening), it should be performed before the endometrial biopsy.  The cervical smear at 
screening may be waived if a normal result has been documented in the subject’s source 
documents within the previous 6 months.  Subjects with ASCUS can be included in the study 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  96 of 113
if they have an HPV deoxyribonucleic acid test that is negative for high-risk HPV. As a 
guidance, a cervical smear should only be repeated once in case of insufficient material.
Section 9.7.1 Iron supplementation
15.1.2.17
Old text:
If causes for anemia unrelated to HMB are suspected these subjects should not be enrolled. 
Moderate anemia is defined as hemoglobin 10.9 g/dL (12). Iron supplementation should be 
offered to subjects with hemoglobin 10.9 g/dL consistent with local standards of practice 
and the Centers for Disease Control and Prevention recommendation, ie, 50 to 60 mg of oral 
elemental iron (the approximate amount of elemental iron in one 325 mg tablet of ferrous 
sulfate) twice daily for 3 months for the treatment of iron deficiency anemia.  Iron 
supplementation will not be considered as study drug and should be documented as 
concomitant medication.
New text:
If causes for anemia unrelated to HMB are suspected these subjects should not be enrolled. 
Moderate anemia is defined as hemoglobin 10.9 g/dL (12). Iron supplementation should be 
offered to subjects with hemoglobin 10.9 g/dL consistent with local standards of practice 
and at the investigator’s discretion.  Iron supplementation will not be considered as study drug 
and should be documented as concomitant medication.
Section 9.7.3 Heavy menstrual bleeding / suspicious bleeding pattern
15.1.2.18
Old text:
[…]
In case of suspicious bleeding pattern (eg, continuous spotting, unusually heavy bleeding) 
after the start of treatment, which does not resemble the subject’s natural cycle or bleeding 
pattern, detected from the MP or UF-DBD, the subject should undergo immediate evaluation 
by the investigator. 
Especially if during intake of the study drug and after the initial reduction of bleeding and/or 
onset of amenorrhea, any recording in the MP, or bleeding of an intensity of “mild” or worse 
occurs continuously for 10 days or more the subject should be instructed to contact the site for 
immediate evaluation.
[…]
New text:
[…]
In case of suspicious bleeding pattern (eg, continuous spotting, unusually heavy bleeding) 
after the start of treatment, which does not resemble the subject’s natural cycle or bleeding 
pattern, detected from the AH, MP or UF-DBD, the subject should undergo immediate 
evaluation by the investigator. 
Especially if during intake of the study drug and after the initial reduction of bleeding and/or 
onset of amenorrhea, any recording in the MP, worsened bleeding detected from the AH 
analysis, or bleeding of an intensity of “mild” or worse occurs continuously for 10 days or 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  97 of 113
more the subject should be instructed to contact the site for immediate evaluation.
[…]
Section 10.3.1 Variables
15.1.2.19
Old text:
The primary efficacy variable will be calculated based on the alkaline hematin method. 
Secondary and other variables related to menstrual blood loss will be calculated based on the 
two methods, the alkaline hematin method and the menstrual pictogram, depending on the 
planned application of the methods.
New text:
The primary efficacy variable and secondary efficacy variables will be calculated based on the 
alkaline hematin method (unless otherwise specified). Other efficacy variables related to 
menstrual blood loss will be calculated based on the two methods, the alkaline hematin 
method and the menstrual pictogram.
Section 10.3.1.1 Primary efficacy variable
15.1.2.20
Old text:
[…]
Subjects who discontinue treatment due to lack of efficacy, AEs, or prior to completion of 
treatment Week 8 of the respective treatment period will be considered not having 
amenorrhea.
Further, based on scientific advice by FDA, subjects who did not adequately fulfill selection 
criteria or require fibroid surgery during study participation will be considered not having 
amenorrhea.
New text:
[…]
Subjects who discontinue treatment prior to completion of treatment Week 8 of the respective 
treatment period will be considered not having amenorrhea.
Section 10.3.1.2 Secondary efficacy variables
15.1.2.21
Old text:
The secondary efficacy variables are:

Absence of bleeding (spotting allowed) during the last 28 days of the treatment; based 
on the UF-DBD

Time to onset of controlled bleeding.  Onset of controlled bleeding is defined by the 
first day, for which the menstrual blood loss for all subsequent 28-day periods up to the 
end of the treatment period is <80.00 mL

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  98 of 113

HMB responder rate (percentage of subjects with blood loss <80.00 mL per 28 days 
and 50% reduction compared to baseline)
[…]
New text:
The secondary efficacy variables are:

HMB response defined as blood loss <80.00 mL during the last 28 days of treatment 
and >50% reduction compared to baseline

Time to onset of amenorrhea. Onset of amenorrhea is defined by the first day for which 
the menstrual blood loss for all subsequent 28-day periods up to the end of the 
treatment period is <2 mL.

Time to onset of controlled bleeding.  Onset of controlled bleeding is defined by the 
first day for which the menstrual blood loss for all subsequent 28-day periods up to the 
end of the treatment period is <80.00 mL.

Absence of bleeding (spotting allowed) during the last 28 days of the treatment; based 
on the UF-DBD
Section 10.3.1.3 Other efficacy variables
15.1.2.22
Old text:
Other efficacy variables are:

Amenorrhea (yes/no), defined as MBL < 2 mL during the last 28 days of treatment 
(for treatment time/method not considered as primary variable) 

Volume of menstrual blood loss per 28 days 

Volume of menstrual blood loss per bleeding episode for the first, second, and if 
applicable third bleeding episode after the EoT 

Percentage of subjects with 50% reduction in menstrual bleeding per 28 days 
compared to baseline 

Time to onset of amenorrhea. Onset of amenorrhea is defined by the first day for 
which the menstrual blood loss for all subsequent 28-day periods up to the end of the 
treatment period is <2 mL.

Time to start of bleeding after last study drug intake (assessed by the UF-DBD).  If 
bleeding has to be induced, the subject´s data will be censored at that time point for 
the induction. 
[…]

Patient satisfaction

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  99 of 113
New text:
Other efficacy variables are:

Treatment success rate defined as percentage of subjects  who fulfill the criteria of 
HMB response (<80.00 mL, >50% reduction in menstrual blood loss as compared to 
baseline) and who have not been withdrawn from the study due to AEs, due to non-
fulfillment of selection criteria (related to fibroid size or HMB at baseline) or due to 
fibroid surgery having been performed during the study.

Amenorrhea (yes/no), defined as MBL < 2 mL per 28 days of treatment (for treatment 
time/method not considered as primary variable) 

HMB response defined as blood loss <80.00 mL and >50% reduction compared to 
baseline per 28 days of treatment (for treatment time/method not considered as 
secondary variable)

Time to onset of amenorrhea. Onset of amenorrhea is defined by the first day for 
which the menstrual blood loss for all subsequent 28-day periods up to the end of the 
treatment period is <2 mL (for treatment time/method not considered as secondary 
variable)

Time to onset of controlled bleeding.  Onset of controlled bleeding is defined by the 
first day for which the menstrual blood loss for all subsequent 28-day periods up to the 
end of the treatment period is <80.00 mL (for treatment time/method not considered as 
secondary variable)

Volume of menstrual blood loss per 28 days 

Volume of menstrual blood loss per bleeding episode for the first, second, and if 
applicable third bleeding episode after the EoT 

Volume of menstrual blood loss per bleeding episode within the treatment break (not 
applicable for Treatment Groups A2). All days of the bleeding episodes will be used 
even if some days of the episode lie outside the treatment break.  

Percentage of subjects with 50% reduction in menstrual bleeding per 28 days 
compared to baseline 

Time to start of bleeding after last study drug intake (assessed by the UF-DBD in 
addition to the other two measurement methods).  If bleeding has to be induced, the 
subject´s data will be censored at that time point for the induction. 
[…]

Patient satisfaction assessed by the TSQM-9 at the 12 week and at end of treatment 
visit

Change from baseline in hemoglobin, hematocrit, and ferritin

Percentage of subjects with normal hemoglobin >12 g/dL and normal hematocrit 
>36% 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  100 of 113
Section 10.3.1.6 Other safety variables
15.1.2.23
Old text:
[…]

Vital signs 

Change from baseline in hemoglobin, hematocrit, and ferritin 

Percentage of subjects with normal hemoglobin >12 g/dL and normal hematocrit >36% 

Percentage of subjects with moderate to severe anemia (ie, hemoglobin 10.9 g/dL)
New text:
[…]

Vital signs 

Percentage of subjects with moderate to severe anemia (ie, hemoglobin 10.9 g/dL)
Section 10.3.2.2 Efficacy analysis, Section 10.3.2.3 Secondary efficacy 
15.1.2.24
analysis and Section 10.3.2.4 other efficacy
Old text:
10.3.2.2 Primary efficacy analysis
The primary efficacy will be assessed by testing the amenorrhea (yes/no) for superiority of 
vilaprisan 2 mg after 12 weeks of treatment in Treatment Period 1 and after 24 weeks of 
treatment in Treatment Period 2 (with and without a break) versus placebo after 12 weeks of 
treatment using two-sided Cochran-Mantel-Haenszel test stratified by region/country at a 0.05 
significance level.  
The number of subjects with amenorrhea (yes/no) is assumed to be binomial distributed. 
In order to adjust for the multiplicity created by the testing of 3 hypotheses a fixed sequence
procedure is applied: 
1. ,		: 		, = 		, vs. 	,		: 		, ≠		,
2. ,	: 	, = 	, vs. 	,	: 	, ≠	,
3. ,	: 	, = 	, vs. 	,	: 	, ≠	,
where 		, and 		, are the amenorrhea rate during the last 28 days of vilaprisan 
treatment after 12 weeks of treatment (in pooled Treatment Groups A1 and B2, as the 
treatments are the same and pooling increases the power) and the amenorrhea rate during the 
last 28 days of placebo treatment after 12 weeks of treatment (in Treatment Group B1), 
respectively. Similarly, 	, and 	, represent the amenorrhea rate during the last 28 
days of vilaprisan treatment after 2x12 weeks of treatment (in Treatment Group A1) and the 
amenorrhea rate during the last 28 days of placebo treatment after 2x12 weeks of treatment (in 
Treatment Group B2). The term 	, stands for the amenorrhea rate during the last 28 days 
of vilaprisan treatment after 24 weeks of treatment (in Treatment Group A2). 
First ,		 is tested to the significance level of 0.05. If ,		 is rejected, the procedure 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  101 of 113
moves on to test the second hypothesis ,	 to the same alpha level, otherwise the 
procedure stops at ,		.  If ,	 is rejected, the procedure moves on to test the third 
hypothesis ,	 to the same alpha level, otherwise the procedure stops at ,	. 
10.3.2.3 Secondary efficacy analysis
The secondary efficacy variables will be analyzed descriptively in frequency tables by 
treatment period within each treatment group, except for time to event variables which will be 
analyzed by treatment group using the Kaplan-Meier estimates. 
10.3.2.4 Other efficacy 
Other variables will be evaluated and presented by means of descriptive statistics.
New text:
10.3.2.2  Efficacy analysis
For the confirmatory efficacy analysis, a hierarchical testing approach will be applied, 
involving the primary efficacy variable amenorrhea (yes/no) and the first three secondary 
efficacy variables HMB response, time to onset of amenorrhea and time to onset of controlled 
bleeding. These tests always include a comparison of vilaprisan 2 mg versus placebo and can 
be applied in three different situations:
1
After 12 weeks of treatment in Treatment Period 1: 
Comparison of vilaprisan 2 mg in pooled Treatment Groups A1 and B2 (as the 
treatments are the same and pooling increases the power) vs. placebo in 
Treatment Group B1
2
After 12 weeks of treatment in Treatment Period 2:
Comparison of vilaprisan 2 mg in Treatment Group A1 vs. placebo in 
Treatment Group B2
3
After 24 weeks of treatment:
Comparison of vilaprisan 2 mg in Treatment Group A2 vs. placebo in 
Treatment Period 2 of Treatment Group B2
In total, ten tests will be carried out each to an alpha level of 0.05: First, the tests for the 
primary efficacy variable amenorrhea (yes/no) will be carried out in scenarios 1, 2 and 3 in 
this order, followed by the tests for HMB response (yes/no) in scenarios 1, 2 and 3, the tests 
for time to onset of amenorrhea in scenarios 1 and 2, and finally, the tests for onset of 
controlled bleeding in scenarios 1 and 2. As the hierarchical testing procedure follows a fixed 
sequence, it stops as soon as any of these tests cannot be rejected to an alpha level of 0.05 and 
all further tests after failing to reject one null hypothesis in the testing sequence will be 
considered exploratory. This fixed sequence procedure accounts for the multiplicity created 
by carrying out multiple tests. 
Amenorrhea (yes/no), defined as MBL <2 mL during the last 28 days of treatment
The primary efficacy variable amenorrhea (yes/no) will be analyzed by means of a two-sided 
Cochran-Mantel-Haenszel test stratified by region/country at a local 0.05 significance level.  
The number of subjects with amenorrhea (yes/no) is assumed to be binomial distributed. 
Thus, the Cochran-Mantel-Haenszel test is applied to test the null hypothesis , that the 
amenorrhea rates in the vilaprisan 2 mg group (,) and in the placebo group (,) in the 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  102 of 113
respective situations  =1, 2 or 3 are equal versus the alternative hypothesis 	, that they are 
not:
,: , = ,   vs.   	,: , ≠,.
__________________________________________________________________________________________________________________
HMB response defined as blood loss <80.00 mL during the last 28 days and >50% 
reduction compared to baseline
The first secondary efficacy variable HMB response (yes/no) will be analyzed analogously to 
the primary efficacy variable amenorrhea. 
Time to onset of amenorrhea 
Onset of amenorrhea is defined by the first day for which the menstrual blood loss for all 
subsequent 28-day periods up to the end of the treatment period is <2 mL. Subjects are treated 
as censored if they did not experience an onset of amenorrhea during the respective treatment 
period. Censoring rules will be described in more detail in the SAP.
In order to investigate the null hypothesis that there is no difference in time to onset of 
amenorrhea between vilaprisan 2mg and placebo versus the alternative hypothesis that there is 
a difference, a logrank test stratified by region/country is conducted at a local 0.05 
significance level. 
Time to onset of controlled bleeding
Onset of controlled bleeding is defined by the first day for which the menstrual blood loss for 
all subsequent 28-day periods up to the end of the treatment period is <80.00 mL. Subjects are 
treated as censored if they did not experience an onset of controlled bleeding during the 
respective treatment period. Censoring rules will be described in more detail in the SAP.
Time to onset of controlled bleeding will be analyzed analogously to the secondary efficacy 
variable time to onset of amenorrhea.
The study will be considered successful if at least superiority of vilaprisan 2 mg vs. placebo 
after Treatment Period 1 based on the primary variable could be demonstrated. 
Sensitivity analyses will be conducted for the primary efficacy variable and the first three 
secondary efficacy variables as applicable. These will be described in the SAP.
All primary and secondary efficacy variables will also be analyzed descriptively in frequency 
tables by treatment period within each treatment group, except for time to event variables 
which will be analyzed by treatment group using the Kaplan-Meier estimates. 
Other efficacy variables will be evaluated and presented by means of descriptive statistics.
Sections 10.3.2.3 (Secondary efficacy analysis) and 10.3.2.4 (Other efficacy) have been 
incorporated into Section 10.3.2.2 Efficacy analysis. Due to this section numbering of 
sections 10.3.2.3 Pharmacokinetic analysis, 10.3.2.4 Safety analysis and 10.3.2.5
Subgroup analysis have changed.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  103 of 113
Section 10.3.2.5 Subgroup analysis
15.1.2.25
Old text:
Subgroup analyses are planned using descriptive statistics for the primary and secondary 
efficacy variables separately for each country (China and the US), race and ethnicity.
New text:
Subgroup analyses are planned using descriptive statistics for the primary and secondary 
efficacy variables separately for each country (China and the US), race and ethnicity. Further 
subgroup analyses will be described in the SAP.
Section 10.3.3 Missing data/drop-outs
15.1.2.26
Old text:
For the primary efficacy variable it is planned to collect the AH data only on days when 
vaginal bleeding occurred.  To differentiate missing AH data and days without vaginal 
bleeding the bleeding intensity collected in the UF-DBD will be used. 
Missing bleeding data in the subject diaries will be imputed.  For the UF-DBD, the worst case 
approach will be used for missing bleeding intensity for the single or two consecutive missing 
days (ie, the maximum of the bleeding intensities of the day before and the day after the 
missing day[s] will be assumed).
If an endometrial biopsy was conducted during the time period under treatment, bleeding on 
the day of biopsy and the 3 days thereafter will not be considered as day(s) with 
bleeding/spotting and AH value will be set to 0 mL.  For the primary efficacy analysis, 
subjects will be defined as not having amenorrhea if they did not complete at least 8 weeks of 
treatment.  Generally, in case a daily bleeding intensity is recorded as “no vaginal bleeding” 
or “spotting”, the missing AH value for this day will be set to 0 mL. 
For days with bleeding intensity of light bleeding or higher in the UF-DBD, missing AH 
values will be replaced by the mean value of AH values of the days with the same bleeding 
intensity.  In case there are no AH values with the same bleeding intensity, the mean of the 
AH values of next higher intensity will be used.  In case there is no intensity higher than 
bleeding intensity of the missing AH values available, either, no replacement for the missing 
AH values will be done for such days; but if there at least one such day occurs within the 
respective 28 days of treatment for a subject, the subject will be considered as not having 
amenorrhea.
Furthermore, the last days under treatment with at least 28 days with non-missing bleeding 
intensity/AH values under treatment until the initial bleeding episode when the treatment 
started (after the imputations above) (without missing information:  Days 57 to 84 under 
treatment) will be used to calculate the primary variable.  After these imputations a subject 
will be considered as not having amenorrhea in the presence of missing AH values if the sum 
of all non-missing AH values is not lower than 2 mL or if for missing AH values the bleeding 
intensity in the UF-DBD is light or higher, otherwise the subject will be considered as having 
amenorrhea. Sensitivity analyses will be conducted to evaluate the impact of missing data. 
These will be described in the SAP.
New text:
For the primary efficacy variable and secondary efficacy variables included in the testing 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  104 of 113
strategy described in section 10.3.2.2 it is assumed that data measured with the AH method 
will be only available on days when vaginal bleeding occurred.  To differentiate missing AH 
data and days without vaginal bleeding the bleeding intensity collected in the UF-DBD will 
be used. 
Missing bleeding data in the subject diaries will be imputed.  For the UF-DBD, the worst case 
approach will be used for missing bleeding intensity for the single or two consecutive missing 
days (ie, the maximum of the bleeding intensities of the day before and the day after the 
missing day[s] will be assumed).
If an endometrial biopsy was conducted during the time period under treatment, bleeding on 
the day of biopsy and the 3 days thereafter will not be considered as day(s) with 
bleeding/spotting and the AH value will be set to 0 mL.  For the primary efficacy variable 
amenorrhea and the secondary efficacy variable HMB response, subjects will be defined as 
not having amenorrhea/ not being a HMB responder if they did not complete at least 8 weeks 
of treatment.  Generally, in case a daily bleeding intensity is recorded with the UF-DBD as 
“no vaginal bleeding” or “spotting”, the missing AH value for this day will be set to 0 mL. 
For days with bleeding intensity of light bleeding or higher in the UF-DBD, missing AH 
values will be replaced by the mean value of AH values of the days with the same bleeding 
intensity.  In case there are no AH values with the same bleeding intensity, the mean of the 
AH values of next higher intensity will be used.  In case there is no intensity higher than the 
bleeding intensity of the missing AH values available, either, no replacement for the missing 
AH values will be done for such days; but if there at least one such day occurs within the 
respective 28 days of treatment for a subject, the subject will be considered as not having 
amenorrhea/ not being a HMB responder.
Furthermore, the last days under treatment with at least 28 days with non-missing bleeding 
intensity/AH values under treatment until the initial bleeding episode when the treatment 
started (after the imputations above) (without missing information:  Days 57 to 84 under 
treatment) will be used to calculate the primary efficacy variable and the secondary efficacy 
variable HMB response.  After these imputations a subject will be considered as not having 
amenorrhea in the presence of missing AH values if the sum of all non-missing AH values is 
not lower than 2 mL or if for missing AH values the bleeding intensity in the UF-DBD is light 
or higher, otherwise the subject will be considered as having amenorrhea. An equivalent 
approach as described for the amenorrhea rate will be applied for the secondary variable 
HMB response, ie, after the imputations as described above a subject will be considered as not 
being a HMB responder in the presence of missing AH values if the sum of all non-missing 
AH values is ≥80.00 mL or the reduction of blood loss is ≤50% as compared to baseline or if 
for missing AH values the bleeding intensity in the UF-DBD is light or higher, otherwise the 
subject will be considered as a HMB responder.
For the secondary variables onset of amenorrhea and onset of controlled bleeding the first 28 
days with non-missing bleeding/AH values until the last 28 days with non-missing 
bleeding/AH values under treatment will be considered. An analogous approach as described 
above for the primary efficacy variable and the secondary efficacy variable HMB response 
will be applied to assess the bleeding status for each of these 28-day windows in terms of 
amenorrhea and controlled bleeding. If a subject does not achieve amenorrhea or controlled 
bleeding until end of treatment the subject will be considered as censored for the respective 
endpoint.    

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  105 of 113
Sensitivity analyses will be conducted to evaluate the impact of missing data. These will be 
described in the SAP.
Section 10.4 Determination of sample size
15.1.2.27
Old text:
Assumptions for sample size calculations are based on the ASTEROID 1 study (Study 15788) 
with treatment duration of 12 weeks and take into account scientific advice from Health 
Authorities. 
In ASTEROID 1, amenorrhea rates (defined as MBL <2 mL during last 28 days of treatment) 
of about 0.7, 0.9, and 0.9 for vilaprisan 2 mg and of about 0.2, 0.0, and 0.1 for placebo for the 
regions US/Japan/European Union and Canada were observed with differences between 
vilaprisan 2 mg and placebo of about 0.5 to 0.9. 
Based on scientific advice by FDA an analysis will be required in which certain groups of 
patients are counted as treatment failures (patients who did not adequately fulfill selection 
criteria; patients who require fibroid surgery during study participation).
Taking these aspects into account, a difference of at least 0.4 between vilaprisan and placebo 
is assumed after 12 weeks and 24 weeks. Sample size calculation is further based on a 
balanced randomization scheme of 1:1:1:1 (A1:A2:B1:B2), a power of 0.9 for the study (ie,
higher for each individual test), and the application of the two-sided Cochran-Mantel-
Haenszel test (stratified by region/country) to a 0.05 significance level.
Assuming a dropout rate of about 20%, the number of subjects to be randomized into the 
study is planned to be 260; 65 subjects in each treatment group.
Approximately 50% of subjects are planned to be enrolled from the US.
Based upon the anticipated screen failures rates (60% in the US and 50% in China and in the 
other countries), about 585 subjects will be enrolled to achieve the planned number of 
randomized subjects.
PASS version 13.0.11 was used for sample size calculation.
New text:
Assumptions for sample size calculations are based on the ASTEROID 1 study (Study 15788) 
and the ASTEROID 2 study (Study 17541) with treatment durations of 12 and 24 weeks. 
In ASTEROID 1, amenorrhea rates (defined as MBL <2 mL during last 28 days of treatment) 
of about 0.7, 0.9, and 0.9 for vilaprisan 2 mg and of about 0.2, 0.0, and 0.1 for placebo for the 
regions US/Japan/European Union and Canada, respectively, were observed with differences 
between vilaprisan 2 mg and placebo of about 0.5 to 0.9. In ASTEROID 2, similar 
amenorrhea rates were observed with numerical variation between the treatment periods. 
HMB response rates in the last 28 days amounted to percentages above 90% for vilaprisan 2 
mg and 33% or lower for placebo. Median onset of amenorrhea was reached on day 6 after 
start of treatment for vilaprisan 2 mg. Due to the low number of subjects achieving 
amenorrhea until the end of placebo treatment, no median onset of amenorrhea could be 
calculated for placebo. Onset of controlled bleeding was reached on day 2 after start of 
treatment for vilaprisan 2 mg. Again, as for onset of amenorrhea, no median onset of 
controlled bleeding could be calculated for placebo due to the low number of subjects 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  106 of 113
achieving controlled bleeding until the end of placebo treatment. At the end of treatment 
controlled bleeding was reported for about 97% of subjects for vilaprisan 2 mg and for 49% 
of subjects for placebo, respectively. 
Taking these aspects into account, a difference in amenorrhea rates of at least 0.4 between
vilaprisan 2 mg and placebo is assumed after 12 weeks and 24 weeks. Sample size calculation 
is further based on a balanced randomization scheme of 1:1:1:1 (A1:A2:B1:B2), an overall
power of 0.9 for the study (ie, higher for each individual test), and the application of the two-
sided Cochran-Mantel-Haenszel test for the primary variable and the secondary variable HMB 
response as well as the logrank test for the secondary variables onset of amenorrhea and onset 
of controlled bleeding (stratified by region/country), each to a local 0.05 significance level.
Assuming a dropout rate of about 20%, the number of subjects to be randomized into the 
study is planned to be 260; 65 subjects in each treatment group.
Approximately 50% of subjects are planned to be enrolled from the US (based on feedback 
from the FDA).
Based upon the anticipated screen failures rates (60% in the US and 50% in China and in the 
other countries), about 585 subjects will be enrolled to achieve the planned number of 
randomized subjects.
PASS version 13.0.11 was used for sample size calculation.
Amendment 3
15.2
Amendment 3 (04 JUL 2018)
Overall Rationale for the Amendment:
This amendment is based on recommendations provided for ulipristal acetate on 18 May 2018 
from the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines 
Agency (EMA) and guidance from Health Authorities regarding hepatic monitoring to 
provide a robust data base for evaluation of hepatic safety of vilaprisan. In addition to health 
authority triggered changes additional updates had to be performed, which are listed below, 
together with the respective reasons for the updates.
Section # and 
Name
Description of Major Changes
Brief Rationale
3 Introduction
1) Text added describing hepatic safety signal 
with Esmya® (ulipristal acetate), a compound 
that belongs to the compound group of 
selective PRMs, and the result of the respective 
PRAC review procedure including risk 
minimization measures. 
2) Provided rationale that vilaprisan is 
structurally different from other selective 
PRMs.
1) EMA Pharmacovigilance 
Risk Assessment 
Committee (PRAC) review 
procedure concluded in 
May 2018
2) For clarification
5. Study design
1) Description of increased frequency of liver 
monitoring and its background in subsection 
1) FDA feedback in January 
and May 2018; FDA 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  107 of 113
Section # and 
Name
Description of Major Changes
Brief Rationale
“safety monitoring”
2) Creation of a separate section on Benefit 
Risk Assessment 
Guidance for Industry 
Drug-Induced Liver Injury 
(July 2009)
2) Feedback received from 
health authorities in the 
initial submission of 
Asteroid protocols
6.2 Exclusion 
criteria
1) The criterion about abnormal liver 
parameters was revised.
2) The diagnosis of chronic hepatitis B / C 
infection was added to exclusion criteria.
3) The criterion about intake of strong CYP 
inducer was updated; correcting information 
about metronidazole. 
4) A clarification that endometrioma are 
exempt was added to the criterion regarding 
ovarian cysts.
1) + 2) To address FDA’ 
requirement on more robust 
liver safety data and to 
closely align with specific 
feedback received in Jan 
and May 2018 and the 2009 
FDA DILI guideline.
3) correction
4) clarification
9.1 Tabular 
schedule of 
evaluations
9.2.3 Scheduled 
visits
Added additional visits (e. Visits 4.1, 5.1 and 
6.1); added liver symptom inquiry for all visits
To address FDA 
requirement on more robust 
liver safety data, and to 
closely align with specific 
feedback received in Jan 
and May, 2018 and the 
2009 FDA DILI guideline
9.6.1.1 
Definition
Newly included sentences “Any fibroid surgery 
should always be reported as serious adverse 
event (SAE), irrespective of associated 
hospitalization” and “All instances of liver 
parameter testing which meet criteria for 
withdrawal of a subject from the study 
treatment should be reported as SAE.”
To address FDA 
recommendation in 
response to SPA for 
Asteroid 3 received in Jul 
2017 and to align with FDA 
2009 DILI guidance
9.6.1.3 
Assessments and 
documentation of 
adverse events
Added details about follow up of AEs of 
special safety interest.
For clarity
9.6.1.6 AEs of 
special interest
Added more detailed instructions for the 
monitoring of liver parameters and liver 
disorders and for close observation in cases 
with increased liver parameters and liver 
disorders; added a flow chart aiding the 
understanding of the intended processes for 
FDA feedback in Jan and 
May 2018 regarding 
improved liver monitoring 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  108 of 113
Section # and 
Name
Description of Major Changes
Brief Rationale
liver function monitoring
9.6.3.1 
Laboratory 
evaluations
Added more details on laboratory parameters 
including liver related parameters, screening 
tests for hepatitis A, B, and C, hemoglobin, and 
additional parameters.  Added parameters 
measured under close observation in cases of 
increased liver parameters after start of 
treatment
To address FDA’ 
requirement on more robust 
liver safety data received in 
Jan and May 2018
9.6.3.2 Further 
safety
Added description for liver symptom inquiry.
To address FDA require-
ment on more robust liver 
safety data received in Jan  
and May 2018 
9.7.4 
Unscheduled 
endometrial 
biopsy
Following procedures regarding the case of a 
diagnosis that does not fall into the categories 
that require immediate stop of study drug (e.g. 
simple hyperplasia) were added.
For clarity
8.1.1 Iron 
supplementation
Addition of “consistent with local standards of 
practice and at the investigator’s discretion”
Clarification needed 
because of regional 
differences in medical 
practice
9.1 Tabular 
schedule of 
evaluations, 9.2.3 
Scheduled visits, 
9.3.4 HMB 
questions
Addition of “not mandatory” for HMB- related 
pre-screening questions
For clarity, to avoid 
unnecessary burden to 
investigators and subjects
10.3.1.6 Other 
safety variables
Details for laboratory parameters were added
To address FDA re-
quirement on more robust 
liver safety data received in 
Jan and May 2018
16.1 Strong 
CYP3A4 
inhibitors
Added delavirdine and troleandomycin to the 
listing of strong CYP3A4 inhibitors
New compounds which 
need to be added to the list 
of excluded concomitant 
medications

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  109 of 113
Amendment 4
15.3
Stand-alone global amendment 4 was not integrated into the integrated version of the protocol 
as it explained why Bayer decided to temporarily pause enrollment and randomization, and to 
temporarily withdraw study treatment in already randomized patients after completion of the 
ongoing treatment period. This global amendment provided background, justification, as well 
as a detailed description of the transient temporary measures to be taken. 
Amendment 5
15.4
The rationale for changes in this amendment 5 and all affected sections are provided in the 
below‘Protocol Amendment Summary of Changes Table’ 
Section # and 
Name
Description of Major Changes
Brief Rationale
3 Introduction
Information on carcinogenicity studies with 
vilaprisan in rodents as well as details 
regarding the additional safety measures were 
added to the section, included adrenal skin, and 
endometrial evaluation, added the new benefit-
risk assessment 
Provision of comprehensive 
information about recent 
events
To re-assess benefits/risks, 
including the findings from 
the carcinogenicity studies 
into consideration and 
address the newly 
introduced monitoring
4. Study 
objectives
Added additional focus on safety evaluations of 
the endometrium, adrenal glands and skin
To address FDA requests
5. Study design
Updated study design; information deleted that 
is no longer relevant
To address FDA requests 
With the implementation of 
protocol amendment 5 
(version 5.0) no new 
subjects will be recruited 
and no study medication 
will be given to the subjects 
who have been enrolled in 
the study
6 Study 
population
7. Treatments
8. Non-study 
therapy
9.3 Population 
characteristics
9.4 Efficacy
9.5 
Updated based on new study design; 
information deleted that is no longer relevant
To address FDA requests

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  110 of 113
Section # and 
Name
Description of Major Changes
Brief Rationale
Pharmacokinetic
s/pharmacodyna
mics
11. Data 
handling and 
quality assurance
9.1 Tabular 
schedule of 
evaluations
9.2 Visit 
description
Information deleted that is no longer relevant; 
added “Safety closeout visit” and “Safety result 
reporting visit” 
To depict the procedures of 
the “Safety closeout 
visit”and the “Safety result 
reporting visit”.
9.6.1.1 
Definition
New criteria for SAE reporting for endometrial 
biopsies, adrenal tumors, and malignant skin 
tumors
To address FDA requests 
9.6.1.6 AEs of 
special interest
New AESIs added for adrenal and skin 
disorders.
To address FDA requests
9.6.3.1 
Laboratory 
evaluations
Added more details on laboratory parameters 
associated with adrenal disorders. Added 
requirement for Vit D measurement
To address FDA requests 
on adrenal monitoring; Vit 
D measurement for 
harmonization of data 
across all studies
9.6.3 Further 
safety
Deleted “In addition, the subjects should be 
reminded regularly to contact the study site 
immediately, if they are concerned about such 
symptoms and testing for unscheduled liver 
parameters should be considered.”
No longer required as no 
further treatment will be 
administered
9.6.3.3 
Endometrial 
biopsies
Added more details on endometrial biopsies
To address FDA requests
9.6.3.4 Cervical 
smear
9.6.3.5 Physical 
and 
gynecological 
examinations
9.6.3.6 Vital 
signs, weight, 
and height
9.6.3.7 
Revised to reflect the collection of the 
parameters at the safety closeout visit.
Update necessary due to 
new visit structure

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  111 of 113
Section # and 
Name
Description of Major Changes
Brief Rationale
Ultrasound 
(safety)
9.6.3.8 
Contraception 
and pregnancy 
test
9.6.3.9 Adrenal 
monitoring
Added description for adrenal monitoring 
(MRI, laboratory investigations and inquiry)
To address FDA requests 
9.6.3.10 Liver 
monitoring
Content shifted from previous Section 9.6.1.6 
and added alkaline phosphatase (AP) value 
increasing to > 2x ULN in cases with normal 
baseline AP as a close observation criterion
To address FDA requests
9.6.3.11 Skin 
monitoring
New section added on skin monitoring
To address FDA requests
9.7.2 Algorithm 
for monitoring of 
endometrial 
safety
9.7.3 Heavy 
menstrual 
bleeding / 
suspicious 
bleeding pattern
9.7.4 
Unscheduled 
endometrial 
biopsy
Content shifted to Sections 9.6.3.3.1, 9.6.3.3.7, 
and 9.6.3.3.8
To address FDA requests
10.2 Analysis 
sets
Adapted FAS and PPS definitions
FAS needed to be newly 
defined to take the handling 
of subjects into account 
who were not allowed to 
start TP1 due to the clinical 
hold. 
PPS needed to be newly 
defined in order to account 
for the changed analysis 
(only evaluation of 
Treatment Period 1).
10.3.1.1 Primary 
Changed text since primary efficacy analysis 
Data for Treatment Period 2 
is not sufficient to draw 

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  112 of 113
Section # and 
Name
Description of Major Changes
Brief Rationale
efficacy variable
will only be performed for Treatment Period 1
valid conclusions.
10.3.1.6 Other 
safety variables
Added adrenal monitoring and skin safety
To address FDA requests
10.3.2.2 Efficacy 
analysis
Changed text and hypothesis since primary 
efficacy analysis will only be performed for 
Treatment Period 1.
Comparison of vilaprisan 2 mg against placebo 
after 24 weeks dropped (treatment arm A2).
Data for Treatment Period 2 
is not sufficient to draw 
valid conclusions.
Due to dropping A2 arm, 
analysis after 24 weeks of 
treatment is not valid 
anymore
10.4 
Determination of 
sample size
Added text to clarify that the sample size 
calculation described is not valid anymore.
No new subjects will be 
included in the study. 
10.5 Planned 
interim analyses
Added text on additional analysis planned 
before the end of the study.
Added to reflect new 
analysis strategy
Amendment 6
15.5
The rationale for the HA requested changes in this amendment and all affected sections are 
provided in the ‘Protocol Amendment Summary of Changes Table’ directly before the Table 
of Contents in this document. A separate file with tracked changes as against the last 
integrated protocol version is available upon request.

Integrated Clinical Study Protocol
BAY 1002670 / 15787
Version 6.0
Page:  113 of 113
16.
Appendices
Strong CYP3A4 inhibitors
16.1
Table 16—1:  Strong CYP3A4 inhibitors
Substance name
Inhibitor strength
Boceprevir
Strong
Clarithromycin
Strong
Cobicistat
Strong
Conivaptan
Strong
Delavirdine
Strong
Grapefruit juice
Depending on dose: Moderate or strong
Idelalisib
Strong
Indinavir
Strong
Itraconazole
Strong
Ketoconazole
Strong
Lopinavir
Strong
Mibefradil
Strong
Miconazole
Strong
Nefazodone
Strong
Nelfinavir
Strong
Posaconazole
Strong
Ritonavir
Strong
Saquinavir
Strong
Telaprevir
Strong
Telithromycin
Strong
Tipranavir
Strong
Troleandomycin
Strong
Voriconazole
Strong
Strong CYP3A4 inducers
16.2
Table 16—2: Strong CYP3A4 inducers
Substance name
Inducer strength
Phenobarbital
Strong
Avasimibe
Strong
Carbamazepine
Strong
Enzalutamide
Strong
St. John’s Wort (Hypericum)
Strong
Lumacaftor
Strong
Methylphenobarbital
Strong
Mitotane
Strong
Phenytoin
Strong
Rifampicin
Strong
Rifamycin
Strong